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Abstract 
 
 
Actionable research, at a doctoral level, allows personnel to utilize personal experiences within 
the organization to explore the possibility to manifest change through collaborative efforts of 
internal and external stakeholders within the industry (Coghlan and Brannick, 2010).   
Background: 
The practice-based problem for this actionable research is as follows: In the United States, 
branded medications used to treat type II diabetes are more expensive than generic medications.  
The literature lacks sufficient evidence to support the healthcare provider’s decision to order a 
more expensive product to treat this chronic disease, type II diabetes as opposed to a less 
expensive product.   
Aim / Objectives:   
The process of action learning addressed the aim and objectives for this study.  To begin with, 
the survey conducted in this study was to address the  prevalence and impact of type II diabetes 
in the state of Georgia, USA via uncovering the direct and indirect costs associated with this 
chronic disease.  Using this demographical and geographical diverse population in the state of 
Georgia, inferences about the health benefits and cost-savings of diabetes medications used to 
treat type II diabetes created the aim of the study by properly characterizing the type II diabetes 
population in Georgia.  
The objective of the study was to utilize the actionable knowledge gained from the study to 
create a data-driven document that can be executed in the decision making process of treating 
type II diabetes.     This actionable knowledge led to the creation of a new document which 
involves the decision-making process of the healthcare professional.  This document allows the 
rationality of integrating factors that are associated with the standards of care when choosing a 
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medication to treat type II diabetes such as efficacy and safety ~ instead of simply the cost of the 
medication at the pharmacy counter.       
Methodology: 
The impact of type II diabetes on the state of Georgia was determined by using a patient-
centered approach.  Upon gathering data, the process of micro-costing was implemented to 
estimate the cost of treatment(s) and complications related to type II diabetes.  Generic and 
brand name medication pricing were determined by referencing GoodRx.com and Cost Helpers, 
Inc.  An analysis of variance was obtained using inferential and descriptive statistics to compute 
the direct and indirect costs associated with the treatment of type II diabetes.     
Results: 
Upon completion of the comparison of health benefits and cost savings of diabetes medications 
used to treat type II diabetes in the state of Georgia, USA, the results were not statistically 
significant.  However, the literature review revealed a number of studies that not only resulted in 
a statistical significance but a clinical significance as well (Saydah et al, 2004; Carnethon et al, 
2010; Loeppke et al, 2009; Fitch et al., 2017 ).  In fact, this action learning research revealed the 
health benefits of the branded medications outweighed the health benefits of the generic 
medications.  The patient-reported data of less complications and hospitalizations was associated 
with the branded, more expensive products.  This is important because a reduction in diabetes-
related complications results in an overall reduction in the cost to treat type II diabetes in the 
United States (Fitch et al., 2017).      
Conclusions:  
The two theoretical frameworks used for this study included the following:  Choo’s Knowing 
Organization was the foundation used to enhance the knowledge of this writer regarding the 
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prevalence and impact of type II diabetes on the state of Georgia, USA.   The completion of the 
study created actionable knowledge, a depiction of direct and indirect costs associated with type 
II diabetes.  The itemization of these costs indicated that cardiovascular related complications 
were responsible for the majority of the expenses related to type II diabetes.  Simon’s Bounded 
Theory of Rationality was the foundation used to create a modified version of a Pay for 
Performance model.  This model was used to create a document to address the long-term 
complications associated with type II diabetes, namely cardiovascular related complications.  
The implementation of this tool creates a clinically justifiable reason to prescribe a product for 
the type II diabetes.  This rationale is based on efficacy and safety ~ not simply the nominal cost 
of the medication.  The underlying concept of this tool is to strengthen the accountability efforts 
of the pharmaceutical company to produce value-based results for those patients adhering to the 
prescribed regimen.                      
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Operational Definitions 
 
Agent :  A term used synonymously with a pharmaceutical drug - medication    
Antidiabetic Agents:  Medications used to treat type II diabetes. 
Atherosclerotic cardiovascular disease (ASCVD):  A condition caused by plaque 
accumulation on arterial walls; clogged arteries; also known as CHD (Coronary heart disease) 
Bioequivalence:  A term indicating a comparison of two pharmacokinetic preparations deemed 
identical.  
Branded Medication:  Manufactured medication named and developed by a pharmaceutical 
company for the purpose of marketing and advertising.  The term is synonymous with “non-
generic”.   
Cardio-metabolic Risk Factors:  Factors that increase  the chances of one damaging one’s 
blood vessels and or heart.  These risk factors may include obesity, high LDL (bad cholesterol), 
high blood fat (triglycerides), low HDL (good cholesterol), high blood pressure and /or insulin 
resistance. 
Cloud computing:  This term is used when services completed within the integrated technology 
systems, i.e. computer, is stored for future retrieval.   
Cost Savings:  Savings incurred due to decreased healthcare related spending.    
Dialysis (Kidney Dialysis) (Hemodialysis):  A process whereby waste products are eliminated 
from the blood by a hemodialysis machine due to insufficient renal abilities.  The cleansed blood 
is returned to the body upon completion of the filtration process.    
Direct Costs:  Costs incurred to treat the diabetes relating the pharmaceutical treatments, tests, 
procedures, inpatient care, outpatient care and durable medical equipment.   
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Endocrinopathies:  Diseases associated with the endocrine gland such as diabetes, 
hyperthyroidism and hypothyroidism.   
Exocrine Pancreas:  The organ called the pancreas contains exocrine glands the create enzymes 
which are crucial to the breakdown of proteins, carbohydrates and fats. 
Exogenous:  Pertaining to an outside factor - Exogenous insulin administered via an injection as 
opposed to endogenous insulin which is physiologically secreted from the pancreas.   
Generic medication:  A medication that is comparable to a brand named drug.  The product is 
sold at a lower price because it is no longer patent-protected.  The term is synonymously as 
“non-branded”.      
Gold Standard:  The finest and most reliable example of the referenced subject matter  
Health Benefits:  A term indicating a reduction in risk factors and complications associated with 
diabetes secondary to adequate blood glucose control. 
Hemochromatosis:  A genetic disorder characterized by iron salts being present in the tissues of 
the body.  This may lead to hepatic damage, blood sugar abnormalities and skin discolorations (a 
tannish color). 
Hemoglobin A1C (A1C):  A blood test used to identify the average blood glucose level of a 
human for the previous 3 months. 
Hepatic:  Pertaining to the liver    
Hyperglycemia:   Elevated blood glucose level 
Hyperthyroidism:  Over activity of the thyroid gland leading to an increased metabolism as 
well as an elevated heart rate  
Hypoglycemia:  Low blood glucose level 
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Hypothyroidism:   An abnormally low secretion of the thyroid hormone from the thyroid gland 
resulting in stunted growth and delayed development in both children and adults 
Immune – mediated diabetes:  A disorder causing the body to destroy its own cells in the 
pancreas that is responsible for creating the life-saving hormone, insulin  
Incretins:  A group of metabolic hormones in the human body causes a decrease in blood 
glucose levels.       
Indirect Costs:  Non-medical costs associated diabetes such as an absence from work or 
decrease earning abilities due to illness.   
Insulin:  A hormone that regulates the transport of glucose into the body’s cell  
Neoplasia:  Abnormal cellular growth of tissue – occurring anywhere in the body  
Nocturnal Hypoglycemia:  Blood sugar level less than 70mg/dl during the night while sleeping 
Obesity:  A medical condition identified by a BMI of 30kg/m2 
Pancreatitis: An inflammation of the pancreas, which is flat gland located behind the stomach. 
Satiety:  A state of a feeling of fullness upon consumption of a meal 
Tiered Medication Formulary System:  Medications categorized within a formulary system 
clustered into groups designated by cost.  For instance, tier one usually consists of generic 
mediations, tier two usually consists of preferred branded mediations and tier three are non-
preferred (often for specialized conditions) branded medications.  The pricing of these 
medications is based on the assigned tier.  Tier one is usually the least expensive and tier three is 
the most expensive product(s).   
Thematic Research:  A type of research, usually qualitative, that consists of an analysis of 
patterns identified within the data.  Themes in the data are revealed upon completion of  the 
analysis.         
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Type I (one) Diabetes:  A form of diabetes whereas the pancreas secretes very little to no 
insulin - also known as juvenile onset diabetes.  
Type 1.5 Diabetes:  A form of diabetes in the adult population that do not immediately require 
insulin for treatment and are usually not overweight.  These personas have little or no resistance 
to insulin - also known as Latent Autoimmune Diabetes in Adults.   
Type II (two) Diabetes:   A form of diabetes whereas the pancreas either resists the effects of 
insulin or does not secrete enough insulin to maintain a normal blood glucose level 
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CHAPTER 1: INTRODUCTION 
 
 1.1  Introduction 
     This action learning based study is an investigation into the true cost of treating the 
chronic disease, type II diabetes.  It is a comparison study of the health benefits  and 
cost savings of diabetes medications used to treat type II diabetes in the state of 
Georgia, United States of America.  As the healthcare industry evolves, healthcare 
providers find data driven studies, such as this one, beneficial in the decision-making 
process regarding disease management (Lundqvist, Anderson, and Carlson, 2016).  The 
literature confirms that not only is the pharmaceutical industry evolving but so are the 
treatment modalities to treat chronic diseases such as diabetes (American Diabetes 
Association, 2018; Wild, Roglic, Green, Sicree and Kang, 2004).   In fact, one of the 
greatest challenges in healthcare is the cost of medications to treat chronic diseases 
such as type II diabetes (American Diabetes Association, 2018).  Due to the concepts 
surrounding value based medicine and cost profiling, healthcare providers are often 
forced to choose the cheaper / generic medications to treat diabetes.  In the United 
States, the healthcare providers are practicing medicine via a tiered formulary system 
for healthcare choices including prescription medications (Kahn & Anderson, 2009). 
 
1.2 Context of Study 
       For the past nineteen years, I have been a pharmaceutical sales consultant for 
NovoNordisk Pharmaceuticals.  A primary concern for my company includes creating 
a productive sales force because the healthcare industry is changing and the medical 
staff no longer dictates the treatment regimen.  In other words, the managed care system 
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is often the deciding factor in the treatment regimen chosen for the patient.  Therefore, 
the sales team has a tremendous challenge persuading the healthcare provider to order 
a branded medication that is not covered via insurance.  If the medication is too 
expensive and the healthcare provider is penalized for choosing that medication, 
needless to say, the less expensive medication is usually chosen for the patient, albeit 
the more efficacious choice or not. The information gathered and the analysis 
performed in this action learning based study is helpful to the pharmaceutical sales 
consultant to communicate effectively with the business-minded stakeholders within 
the pharmaceutical industry.   
      As a tenured pharmaceutical sales consultant, this is a work place problem that 
continues to intensify not only at an organizational level but at an industry level as 
well (Apovian, 2013; Herman, 2011; Hussey, Sorbero and Mehrotra, 2009 ).  
According to Gavagan et al. (2010), not only are the healthcare providers penalized 
by managed care companies for prescribing the more expensive medication  but they 
are  incentivized for prescribing the  cheaper/generic medications.  To further explain, 
the cheaper / generic medications are generally at a lower tier and cost less than the 
brand name medications.  The generic medications used to treat type II diabetes are 
efficacious to a point; however, their usage may exacerbate some significant health-
related issues such as weight gain and hypoglycemia – which ultimately can affect 
one’s quality of life (DiBonaventure et al., 2011; Cawley et al., 2008).  The newer, 
more expensive brand name medications used to treat type II diabetes are generally 
on a higher tier and cost more but can be more efficacious than generic medications 
(Asnani, Richard, Desouza & Fonseca, 2003; Inzucchi et al.,2012;  American 
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Diabetes Association, 2019).  These medications are often associated with health 
benefits such as weight neutrality or even weight loss (Jacob et al., 2007).  According 
to Caro et al. (2002), when treating type II diabetes, the healthcare provider is 
expected to consider the nominal cost as well as the untoward effects of the 
prescribed treatment regimen.  Researching the true cost of cheap generic medicines 
will demonstrate, in some instances, that a newer more expensive brand name 
medication can be a better healthcare value than lower cost generic medications 
(Conner et al., 2008).  In fact, the concept of value- based healthcare is based on this 
premise (Damberg et al., 2009).  This doctoral thesis will enable healthcare 
professionals to view the treatment of type II diabetes and its complications through a 
broader lens of cost and not just the monetary cost of medications used to treat this 
chronic illness.  The business aspect of this literary document has been revealed as 
the overall value of the medications used to treat type II diabetes in the United States 
is disclosed and demonstrated through theory, decision-making theory (Simon, 1990).        
 
1.3  Problem Statement  
     The pharmaceutical sales industry is a business.  If the sales force is unable to 
generate sales due to managed care constraints, the company is not able to get a return 
on its investment.  For the past three years, NovoNordisk , as many other 
pharmaceutical companies with sales forces in the United States, have experienced 
“lay-offs” resulting in jobs lost due to financial constraints.  The United States of 
America is undergoing some unprecedented changes in healthcare (American 
Diabetes Association, 2016; Hussey, Mulcahy, Schnyeer, & Schneider, 2012).  These 
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changes have been progressing for many years and are affecting the national debt, the 
stakeholders within the healthcare arena (healthcare providers, managed care, 
pharmacists, etc.), the pharmaceutical industry as well as the consumers (King et al., 
1998; American Diabetes Association, 2019).  Type II diabetes is a chronic condition 
that affects both men and women in America.  However, Carnethon et al. (2010) 
reveal that elderly patients, poor socioeconomic portions of the community and 
minorities are impacted far more than other populations.  Diabetes is a major 
contributor to the national debt (American Diabetes Association, 2019; King et al., 
1998; Boyle et al., 2010).   Diabetes and the treatment modalities as well as its 
complications are costly components within this equation (American Diabetes 
Association, 2019; Boyle et al., 2010; King et al., 1998; Caro et al, 2002).   Even 
though this chronic disorder is costly and has reached epidemic proportions,  it is also 
reportedly preventable (Brown et al., 1999).  The surmounting debt surrounding 
diabetes is placing a tremendous burden on not only the national budget but the state 
of Georgia’s budget as well (King et al., 1998; ADA, 2013).  The managed care 
industry restricts certain medications to certain patients in an attempt to “save money” 
(Luce, 2005).  This dissertation shall compare the health benefits and cost-savings of 
diabetes medications used to treat type II diabetes in the state of Georgia, United 
States of America in an effort to provide a solution to the problem in generating 
prescriptions in a compromised managed market.  This comparison study is a type of 
health impact assessment designed to identify value association with treatment 
regimen(s) used to treat the chronic disease, type II diabetes (Harris-Roxas, Villani, 
Bond, Cave, Divall, Furu, et al., 2012).  From an organizational management 
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perspective, the actionable knowledge generated from a health impact assessment, 
such as this study, is transferrable (Das, Everett, Birtcher et al., 2018; Friedhoff, 
2009). Transferrable, in an effort to address complex issues albeit within an 
organization or an industry.  This complex issue of cost surrounding chronic illnesses 
is an organizational issue within our pharmaceutical company as well as within the 
industry (Dietz, Belay, Bradley et al., 2017).  Providing a viable solution to 
addressing the true cost associated with chronic diseases, such as type II diabetes  
affects the triple bottom line of the (pharmaceutical) company and ultimately the 
overall well-being of the (pharmaceutical) industry (Pava, 2007).     
 
1.4  Aim / Objectives 
      Cost is a leading factor in the decision-making process of prescribing medications 
used to treat chronic illnesses in the United States of America, such as type II diabetes 
(Narayan et al., 2006).  The aim for this study was to conduct a comparison study 
using a demographical and geographical diverse population within the state of 
Georgia to make inferences about the health benefits and cost-savings of diabetes 
medications used to treat type II diabetes.   
 
The objectives of the study were as follows:  
• identify the health benefits and cost savings of diabetes medications used to 
treat type II diabetes in the state of Georgia through evidence - based data 
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•  transition this evidence – based data into actionable knowledge by creating an 
algorithm to address the work - place problem concerning sales lost due to 
managed care restriction at the healthcare provider level of treatment.    
 
     According to the Annual Report of America’s Health Rankings (2017) Georgia, 
the geographical workplace of the investigator ranks amongst the highest in 
individuals diagnosed with diabetes at 12.1% (America’s Health Rankings, 2017).  
The description of the correlation of direct/indirect expenditures, individual 
demographic traits, pharmacological agent(s), diabetes related complications and 
comorbidities associated with individuals diagnosed with type II diabetes has been 
revealed.  These variables are being considered to determine the overall value of the 
medications used to treat type II diabetes in the state of Georgia, United States of 
America as well as the overall complications associated with this chronic disease.  
 
1.5 Significance of the Study 
     The significance of creating this knowledge is to serve as a component to develop 
a model, that when implemented, will make a difference within my place of 
employment, a pharmaceutical organization, as well as the pharmaceutical industry.  
As an investigator, I am able to discuss the comparison of the health benefits and cost 
savings of diabetes medications used to treat type II diabetes in the state of Georgia.  
As this data was obtained, a monetary value was associated with not only the disorder 
but the complications associated with diabetes as well.  Reviewing the raw data 
coupled with an extensive literature review and the opportunity to create a viable 
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option for my sales force in an effort to “prevent another company layoff” truly 
signifies a trait of a leader. As a leader in the industry of pharmaceutical sales, I 
recognize that this dilemma of cost associated with diabetes has caused a rippling 
effect within the healthcare industry.  The pharmaceutical industry is often labeled a 
part of the problem (Friedhoff, 2009).  However, as an investigator, this study will 
allow us to be a part of the solution as the “value” component of the equation, as it 
relates to treatment, will be assessed.   
     Performing this health impact assessment allowed this writer to examine the 
changes incorporated into healthcare reform and its relationship to the escalating cost 
of healthcare in America.  Creating viable options to deal effectively with managed 
care is truly the key to addressing this action learning based problem.  To further 
elaborate, healthcare reform affects how the providers choose treatment modalities 
for the patients (Kahn & Anderson, 2009).  As discussed earlier, in the United States, 
a tiered copay system is used to decide on the purchasing price of medications 
(Austvoll – Dahlgren et al., 2008).  In Georgia, the older medications used to treat 
diabetes are often generic and are tiered at lower co-pays than the newer branded 
agents. Each of the aforementioned stakeholders within the pharmaceutical industry, 
have interests that are indeed vested in the medications chosen for treatment (Curtin 
et al., 2006).  Implementing a study designed to examine the benefits versus cost 
savings of the diabetes medications used in Georgia is a clinically relevant approach 
that can be used to significantly impact the decision-making process of those utilizing 
the algorithm for diabetes management (Aron et al. 2008; Austvoll – Dahlgren et al., 
2008).  Those decision-makers utilizing the algorithm for diabetes management in the 
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United States will be able to use the quantifiable evidence from this study to identify 
the true cost (indirect and direct) of diabetes medications used to treat type II diabetes 
in the state of Georgia (Boyle et al., 2010; American Diabetes Association, 2013).  
The theoretical concepts of Herbert Simon, bounded rationality – which will be fully 
explained in Chapter 2 - supports the algorithmic procedures to strategize in an effort 
to solve problems within an organization (Barros, 2010; Simon, 1990).  Furthermore, 
Choo (2002) reveals a framework ideal for use in organizations aiming to expand 
upon knowledge in order to create advancements within the industry.  Establishing a 
‘knowing organization’, which will also be fully explained in Chapter 2, can be 
created effortlessly with stakeholder preparation and participation (Choo & Johnson, 
2003).  Implementing the concepts within the knowing organization will be beneficial 
as the decision-makers create a viable solution to address managed care constraints 
associated with the generation of a prescription for branded products used to treat 
type II diabetes. 
 
1.6  Summary 
 
     The prevalence of type II diabetes continues to rise, regardless of the number of 
new treatment modalities manufactured for the market (American Diabetes 
Association, 2013; Dybicz et al. 2011; King et al., 1998).  As the national debt rises 
in the United States of America, the healthcare community recognizes the effects on 
the various entities involved such as the healthcare providers, managed care 
providers, pharmaceutical industry and most importantly, the consumers.  Chronic 
disorders, such as type II diabetes, have created an economic burden on the national 
economy of the United States (Cheng et al., 2013; Boyle et al., 2010; Poisal et al., 
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2007).  This economic burden has forced the administration of the United States 
government to review these expensive health-related issues and create a plan of 
action.  This plan of action has been identified as the new ‘healthcare reform’ (Wild 
et al., 2004; Kahn & Anderson, 2009).  This plan of action addresses many issues; 
however, the involvement of the American people allows one to view it from a public 
health perspective.  According to Eggleston et al., (2009), this will often require 
support from the state, federal or international level.  Implementing this study at the 
state level will allow the policy-makers to heighten recognition for the need to view 
the indirect and well as direct cost for the treatments used for type II diabetes.       
     Educating the stakeholders about the correlation of health benefits and medication 
costs have become increasingly important in addressing the escalating rate of 
healthcare expenditure in the United States (Kantarjian et al., 2013).   The survey 
conducted in this study has been designed to identify the comparison of the health 
benefits and cost-savings of diabetes medications used to treat type II diabetes in the 
state of Georgia, United States of America.  It was conducted solely for the purpose 
of characterizing the type II diabetic population in Georgia.  The population targeted 
for this study was type II diabetic patients who are actively involved in diabetes 
education classes via diabetes support group meetings throughout the state.  The 
significance of this work place problem is that failure to address the interrelated 
issues of cost-savings and health benefits of pharmaceutical agents used to treat 
diabetes could be detrimental not only for the economy but for the person diagnosed 
with type II diabetes as well (Caro et al., 2002; Ogden et al., 2012; Boyle et al., 
2010).    
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     The questionnaire distributed to the subjects was designed to identify subject 
characteristics (i.e., age, sex and race), duration of illness, pharmacological agents 
used to treat diabetes, diabetic complications and comorbidities – including weight 
gain, stroke, heart attack, blindness, dialysis and amputation.  An assessment was 
conducted to determine time loss from work as well as medication / treatment 
regimen satisfaction. The study results were statistically calculated based on the 
findings and the limitations of the study. 
     The theoretical framework of creating a “knowing organization” was implemented 
to address this workplace problem of knowing the specifics relating to the local 
population plagued with this chronic disease.  These concepts of goal-setting through 
cycles of sense making, knowledge creation and decision making, allow the 
stakeholders to view a return on investment with a consumer-centered approach 
(Choo, 1998).  As the actionable knowledge is revealed, the theoretical framework of 
bounded rationality was implemented to support the decision- making process  to 
create a model to implement as a solution to the workplace problem  (Velupilai, 
2010; Barros, 2010).  
     This doctoral dissertation consists of seven chapters.  Chapter 1 has been 
explained in its entirety in the aforementioned paragraphs.  Chapter 2 is a 
comprehensive literature review for this study.  In this section, the following areas of 
study were reviewed:  the management related perspectives of the study, the actual 
business problem, two theoretical frameworks, diabetes management and its 
relationship to goal development.  Hypotheses are identified in the latter portion of 
this section.  Chapter 3 depicts the research methodology for this study.  The general 
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approach implemented to carry out this study has been reviewed in the research 
setting, population sampling, ethical considerations, research design, research 
instrument, data collection and recording as well as the analysis of the data.  Chapter 
4 identified the story of cycles of action within the study, a vivid reflection of the 
demographics of the sample population and the sense-making of the results 
discovered within the group.  Chapter 5 discloses an extensive evaluation of the 
outcomes of the study.  The research outcomes have been reviewed in its entirety.  A 
full discussion of the cost savings and health benefits of these findings are revealed as 
well.  The FDA approved pharmacological treatments used to treat type II diabetes in 
the United States of America, monotherapy as well as combination therapy, has been 
reviewed.  A summation of the direct and indirect cost of the treatment regimen(s) 
has been statistically analyzed and the hypotheses tested accordingly.  Chapter 6 
depicts a conclusion and an overall summation of this study.  The final chapter, 
chapter 7, related the findings to the actionable knowledge and practice of the 
research.  The limitations, recommendations for further research as well as my 
reflections on lessons learned throughout this academic process has been revealed in 
the latter section of chapter 7.                           
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CHAPTER 2:  LITERATURE REVIEW 
 
2.1   Introduction      
Chapter 2 represents an extensive literature review into the topic of evaluating the 
health benefits and cost savings of medications used to treat type II diabetes in the 
state of Georgia, United States.  In this data driven study, areas of interest include the 
management related perspective of the study, pathophysiology associated with the 
disease process, epidemiological cost factors, pharmacological agents used to treat 
type II diabetes, diabetes management development as well as diabetes management 
and cost effectiveness.  In this action learning based research, work place relativity is 
of utmost importance as well; therefore, various aspects of these components are 
reviewed.  These areas of interest include an extensive review of workplace relativity, 
the action learner relevance and profile, evaluating this process via scientific thinking 
for both the investigator and the stakeholder within the pharmaceutical industry.  
Lastly, this study is a form of assessment – a health impact assessment.  The 
significance of health impact assessments shall be reviewed in its entirety.   
 
2.2  Management related perspective of the study:  
The management perspective of this study stems from the high cost of prescription 
medications to the stakeholders within the industry (American public, government, 
employers, health insurance companies, managed care organizations, etc.) and the 
consequences associated with such pricing.  The literature review in section 2.2.1 
reveals the models created for value based healthcare which were developed by the 
U.S. Department of Health and Human Services (HHS),    These models were created 
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in an effort to correlate a strategy whereas the healthcare provider would treat the 
consumer as per established medical guidelines while being mindful of the cost.  
Treating the consumer with quality care while being as frugal as possible seems to be 
the goal for each of the value based healthcare models.  Goal achievement is 
identified via actual cost savings (Chung, Palaniappan, Wong, Rubin, and Luft 
(2010); Damberg, Shortell, Raube, Gillies,  Rittenhouse, McCurdy, Casalino and 
Adams (2010)).    These value based healthcare programs were created to establish 
accountability amongst the healthcare industry.  There are three major value based 
healthcare models implemented throughout the managed care  market in the United 
States of America ~ Pay for Performance, Accountable Care Organizations and 
Bundled Payments.   
 
2.2.1  Value Based Healthcare Models 
• Pay for performance (P4P):  In this particular model, the healthcare 
provider is either incentivized with bonuses or penalized via reduced 
payments,  depending on patient outcomes.  These patient outcomes are 
evaluated using preset quality measures.  These preset quality measures are 
established by the payer i.e., managed care organization(s).  
• Accountability care organization (ACO):  An ACO is more of a voluntary 
team effort.  In this type of model, every healthcare provider within the 
system agrees to be held accountable for not only the quality of care but the 
total “bottom line” cost of treating the consumer.  In an ACO, performance 
regarding quality care and (the consumer) meeting clinical metrics with 
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prescribed treatment regimen(s) are linked to optimal reimbursement rates.  
With this agreement, the providers are aware of the risks.  If an audit is 
completed and the group does well i.e. the consumers have blood pressures, 
blood sugars, BMI’s and cholesterol levels in range and the goal has been 
accomplished within “budget” then the group is incentivized with a bonus.  
This tactic is identified as improved care delivery.  The managed care 
organization shares the savings with the ACO. On the other hand, if the 
metrics are not met, albeit through the physical assessments or the budget, 
then the ACO is penalized via less reimbursement for the care rendered.   
• Bundled payments:  This form of value-based healthcare is usually 
associated with physicians and facilities associated with home health care, 
outpatient surgical centers, mental health facilities, long term skill care, 
nursing homes, oncology / hospice, or ambulatory care centers.  The 
healthcare facility/ provider is compensated a set nominal amount for each 
episode of an illness ~ time is a factor.  The following scenarios will further 
explain:   if a contract has been created for Mr. John Doe and a nominal fee of  
four thousand dollars has been provided to XYZ mental health facility for an 
admission of a chronic disorder such as schizophrenia then the facility is 
compensated that amount.  However, if Mr. John Doe should have an 
exacerbation of his illness and require readmission within thirty days of 
discharge from the facility then the facility will not receive compensation for 
the care rendered upon this readmission.   Scenario # 2: If a contract has been 
implemented for a broken limb for an outpatient surgical center and a nominal 
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fee of ten thousand dollars has been provided to XYZ ambulatory surgical 
center for a broken femur for Mrs. Jane Doe then it is granted.  However, if 
the consumer reinjures that affected area within thirty days and requires 
readmission, the facility will not receive compensation for treating the new 
episode.                         
 
2.2.2  Incentives 
     The literature review reveals that the value based healthcare programs incentivize 
the healthcare providers and facilities in a number of ways.  Shen (2003) contends 
that the incentives may include not only bonuses to the medical staff but higher 
reimbursement rates within the fee schedule, preferred status on the insurance plan 
(meaning less copay for the consumer) even on-line sign up with the managed care 
provider.  It is customary to implement one or more of these incentives 
simultaneously (Chien, Eastrman and Rosenthal, 2012).  Chronic diseases place such 
a heavy burden on the healthcare system and managed care has established a plan of 
using quality measures and incentives to address the issue(s).  The literature reveals 
an abundance of feedback regarding performance of quality measures as it relates to 
value based healthcare programs; however, studies regarding the return on 
investment from a clinical standpoint of such programs are limited ~ especially with 
chronic disorders such as diabetes.   Chen et al. (2010) conducted a longitudinal study 
assessing the return on investment for a pay-for-performance program designed to 
increase quality care and decrease hospitalization rates among patients with diabetes. 
The findings concluded that the consumer who was assigned to the pay-for-
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performance healthcare provider was more likely to receive quality care and less 
likely to be hospitalized.  However, the study revealed that there was no significant 
difference in the quality of care received from the “newly appointed” pay-for-
performance provider and the non-participating pay-for-performance provider.  
Selection bias was identified as a potential flaw in this study.  Curtin, Beckman, 
Pankow ,Milillo and Green (2006) conducted a study on a program with a five year 
partnership between a health plan and an independent practice association.  The 
performance was based on quality, consumer satisfaction and efficacy of the 
healthcare provider.  The program reported a positive return on investment 1.6:1 
within three (3) years of the study and 2:5.1 within (4) years of the study.          
 
2.2.3  Implications of value based healthcare    
     Fendrick and Chernew (2006) contend that the value based healthcare programs 
were designed to specifically address quality of care and cost containment.  In fact, 
these programs focus on initiatives surrounding disease management and quality of 
care.  These programs make certain that quality measures are identified in the goal 
setting process and proper tracking is crucial.   Even though proper tools are 
identified for assessment and medications are provided, the higher priced medications 
with the safer side effect profile are often not chosen.  According to Fendrick and 
Chernew (2006), when a consumer is required to pay more for their care, they have a 
tendency to buy less, even for management of a chronic disease.   
     If a provider has been penalized for prescribing an expensive medication to treat a 
chronic disease, such as diabetes, he/she may not be on the preferred list of healthcare 
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providers.  When the consumer does visit this (out of network) provider, the copay is 
more expensive and often times they are less likely to purchase an expensive 
medication.  When the healthcare provider is not on the preferred list, many opt to 
simply choose another healthcare provider.  These are consequences associated with 
value-based healthcare.                  
When viewed in isolation, the direct cost of branded prescription medications can 
seem quite expensive.  However, according to Herman (2011), a broader view of the 
cost of medications is needed in order to treat the consumer.   According to Zhuo, 
Zhang and Hoerger (2013) and Herman (2011), the following must be considered 
when choosing medications for treating various conditions:  drug related 
complications, avoided inpatient hospitalizations including emergency department 
visits and overall efficacy and safety of the medication chosen.  These viewpoints can 
provide greater clarity as it relates to data based evidence in the assessment of the 
true cost of medication therapy. 
 
2.2.4  Direct and indirect cost associated with type II diabetes     
This study examined the direct and indirect cost of medications used to treat type II 
diabetes using a broader view of the actual cost of these medications.   A process 
known as Budget Impact Analysis (BIA) along with Cost-Effective Analysis (CEA) 
are used to determine the true cost of medications used to treat type II diabetes in 
specific clinical situations.  The literature reveals that every twenty-one seconds a 
person is diagnosed with diabetes in the United States (American Diabetes 
Association, 2017).    According to the American Diabetes Association (2013), the 
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direct medical cost to the U.S. economy related to diabetes in 2012 was estimated to 
be 176 billion dollars.    
The categorization of the cost used to treat diabetes in 2012 (American Diabetes 
Association, 2013) is listed in Chart A below: 
Cost Direct 
medical  
Meds to 
treat 
diabetes 
Inpatient 
hospital  
Meds to treat 
diabetes 
complications 
2012 $176 billion $21.1 
billion 
$75.7 
billion 
$31.7 billion 
 
CHART A: Categorization of costs to treat diabetes in 2012  
 
In the United States, the majority of the cost (107.4 billion dollars) associated with 
the treatment of this chronic disorder, diabetes, is associated with inpatient 
hospitalizations and the medications used to treat diabetes-related conditions 
(American Diabetes Association, 2013).  Lundqvist et. al.  (2016 p.29) contends that  
any medication or intervention implemented to decrease the risk of an inpatient 
hospitalization related to diabetes, or at least decrease the need for medications used 
to treat complications associated with diabetes, will likely be beneficial from a cost 
and health standpoint.   As a pharmaceutical sales consultant, I presently market a  
medication classified as a GLP1 which has been proven to reduce the risk of several  
conditions that require hospitalizations (Hodgson and Kizior, 2014).      
As the chart in Chart A indicates, the annual cost of medications used to treat 
diabetes in 2012 was 21.1 billion dollars (American Diabetes Association, 2013).  A 
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more useful way to examine the cost of medications used to treat diabetes for this 
doctoral thesis is to review the monthly, annual, direct and indirect costs of these 
medications.  This doctoral thesis will only examine the cost of FDA approved 
medications used to treat type II diabetes in the United States.   The direct cost of 
diabetes medications is defined as the amount paid for a monthly or annual supply   
of medications used to treat type II diabetes in the United States (Lee et al., 2008).  
The average price of these diabetic medications in Georgia is based on price data 
from GoodRx.com.   Most often, when the cost of medication is considered, there is 
an over emphasis on the direct monthly or annual cost of a medication rather than the 
evaluation of the cost of a medication in the context of the total cost to treat a patient 
with type II diabetes (Lee et al., 2008).   Indirect cost associated with specific 
diabetic medications is defined as the cost to treat complications from specific 
diabetic medications such as hypoglycemia (low blood sugar), weight gain, fungal 
infections, increased risk of amputation or fractures (American Diabetes Association, 
2017; Herman, 2011).  In addition, hospitalization costs associated with 
complications related to type II diabetes contribute significantly to the indirect cost 
and hence total cost of type II diabetes treatment (Lundqvist et al., 2016).   As 
previously noted, 107.4 billion dollars were spent in 2012 on medications used to 
treat diabetes-related complications as well as hospitalizations related to the disorder 
(American Diabetes Association, 2013).  Needless to say,  the non-medication related 
cost to treat diabetes is quite significant (American Diabetes Association, 2013; 
Lundqvist et al, 2016).   
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As a pharmaceutical sales consultant with NovoNordisk Inc., my primary goal is to 
effectively market my assigned product, Liraglutide, a medication categorized as a 
GLP1 used to treat type II diabetes.  This medication has a high direct monthly cost 
to the diabetic consumer (Skidmore-Roth, 2015).  However, the indirect cost of the 
medication in my portfolio is quite small to nonexistent when compared to the costs 
associated with the adverse events  linked to other classes of medications approved to 
treat type II diabetes such as weight gain, cardiovascular risks and hypoglycemic 
episodes (American Diabetes Association, 2013).  These adverse events are not 
routinely associated with Liraglutide, the medication in which I market for 
NovoNordisk, Inc. ( Zhuo, Zhang and Hoerger, 2013).  Needless to say, emergency 
department visits or hospitalizations related to GLP1 pharmacotherapy are indeed 
rare (Lundqvist et al., 2016; Robinson et al., 2013).   In fact, Liraglutide, a glucagon-
like peptide (GLP1), has been proven to decrease the risk of two expensive 
complications directly related to type II diabetes i.e. nonfatal myocardial infarction 
(heart attack) and stroke (Lundqvist, 2016; Marso et. al., 2016).  Even though studies 
regarding GLP1 medications have proven to reduce the risk of complications and 
hospitalizations associated with diabetes, marketing medications with a high monthly 
direct cost is an added sales challenge (Marso et al., 2016; Du et al., 2014; Carnethon 
et al., 2010).  Therefore, it is of utmost importance that indirect medication costs are 
considered when prescribing medications to treat chronic illnesses such as type II 
diabetes.  This is important because my customers i.e. physicians, nurse practitioners, 
and physician assistants, are often forced to select medications from a drug formulary 
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with a low direct cost, meaning inexpensive or cheap medications due to managed 
care constraints (Nathan et al., 2006; Lundqvist et al., 2016).  
 
2.2.5  Drug formulary and classes of medications used to treat type II diabetes 
A medication formulary or drug formulary is a list of medications that are used to 
treat specific diseases and are the preferred treatment medications for a disease by 
health plans in the United States (Bradbury-Huang, 2010).   In the United States, 
medications on a health plan’s drug formulary are most often less costly to patients 
than medications that are not on the formulary (Friedhoff, 2009).   According to 
Friedhoff (2009), health plans select medications to add to their medication formulary 
mainly based upon the actual pecuniary cost of the drug.  Therefore, not all 
medications available to treat a specific disease are included in a health plan’s 
medication formulary.   For example, although there are three medications from the 
glucagon-like peptide (GLP1) agonist class used to treat type II diabetes on a daily 
basis, most health plans select only one GLP1 agonist to add to their medication 
formulary.    
     According to Hodgson and Kizior (2014), medications on a drug formulary are 
assigned to various categories known as tiers and these tiers range from tier 1 – tier 5 
or tier 6. The tier level placement of a medication on a drug formulary in the United 
States is influenced by the actual monetary cost of a medication to the health plan 
(Menzin et al., 2001).  Medications on tier 1 level are much less expensive than 
medications in the upper tier levels. Below is an example of the tiered system for a 
22 
 
drug formulary (https://www.planprescriber.com/medicare-part-d/drug-formulary/): 
Accessed: November 15, 2016 
  
Tier 1 — Preferred generic drugs, lowest cost-sharing 
Tier 2 — Non-preferred generic drugs 
Tier 3 — Preferred brand-name drugs 
Tier 4 — Non-preferred brand-name drugs 
Tier 5 — Specialty drugs, highest cost-sharing 
 
The tier level placement of a medication on a formulary determines the amount of out 
of pocket expense known as cost sharing.  A patient has to purchase medication each 
month in order to continue pharmacological treatment.  Balkrishnan et al., (2003) 
contend tier level placement of a medication significantly influence whether or not a 
patient will adhere to the prescribed medication regimen. This is primarily due to the 
out of pocket cost of the medication.  Needless to say, when a medication has a high 
out of pocket cost, patients are much less likely to fill prescriptions and adhere to the 
medication regimen as prescribed (Fendrick and Chernew, 2006).   When a patient 
purchases a medication and administers the medication as prescribed, this is known 
as adherence to medication therapy (Balkrishnan et al., 2003).   According to 
Balkrishnan et al. (2003) and Lundqvist et. al, (2016)  adherence to medication 
therapy has a significant impact on the total cost of care for a health plan.  The 
implication concerning  the total cost of care is one of several reasons health plans 
should emphasize additional criteria beyond direct medication cost when engaging in 
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the decision-making process of creating the medication formulary ~ including the 
categorization process of the medication tier levels.       
In the United States, it is customary on the drug formulary Tier System for the brand 
named medications to be tiered at tier 3 or tier 4.  As a result of this tiered 
categorization, brand name medications will generally have a higher out of pocket 
cost to patients than preferred generic drugs or non-preferred generic drugs 
(Balkrishnan et al., 2003).  
Below is a modified table example of how the Tier System determines the patients’ 
out of pocket cost for medications from a health plan in the United States, Blue Cross 
Blue Shield Medicare (http://www.bcbsm.com/medicare/help/understanding-
plans/pharmacy-prescription-drugs/tiers.html) : Accessed November 14, 2016 
 
Drug 
Tier 
Drug tier meaning  Out of pocket patient 
cost 
Tier 1 Preferred generic drugs  $1 to $3 for drugs in this 
tier 
Tier 2 Non-preferred generic drugs   $7 to $11 for drugs in this 
tier 
Tier 3 Preferred brand name drugs  $38 to $42 for drugs in 
this tier 
Tier 4 Non-preferred brand name drugs 45% to 50% of the drug 
cost in this tier 
Tier 5 Specialty drugs  25% to 33% of the retail 
cost for drugs in this tier 
Chart B- Drug Formulary Tier System 
http://www.bcbsm.com/medicare/help/understanding-plans/pharmacy-prescription-
drugs/tiers.html. Accessed November 14, 2016 
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As mentioned earlier, based upon the drug formulary Tier System, the out of pocket 
cost to patients for preferred brand named drugs may cost as much as 3 to 5 times 
more than non-preferred generic drugs and considerably more than preferred generic 
drugs (Balkrishnan et al., 2003).  
 
      As Chart B indicates, non-preferred brand named drugs and specialty drugs which 
have the highest out of pocket cost to patients. Medications categorized as a GLP1, 
which I market, are likely to be assigned to either tier level 3 or 4.  They are usually 
assigned to tier level 3 or 4 because these products are considered brand named 
products as discussed below.  
 
2.2.6 Class of medications used to treat type II diabetes 
According to the American Diabetes Association (2017, p.S66), there are 7 classes of 
medications most commonly used to treat type II diabetes in the United States and 
they are as follows:  
Metformin 
Sulfonylurea  
Thiazolidinedione (TZD)  
DPP – 4 Inhibitors 
SGLT2 Inhibitors  
GLP1 Agonist 
Basal Insulin.  
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 Chart C identifies these pharmaceutical agents along with important characteristics 
of each agent within the classes.   
 
Chart C: American Diabetes Association (2017, S66 ) ~Pharmacologic Approaches 
to Diabetes Treatment  
 
The above algorithm indicates that Metformin is the initial medication used to treat 
patients diagnosed with type II diabetes. When a patient is treated with Metformin 
and their type II diabetes remains poorly controlled, one or two medications from the 
remaining six (6) classes of medications are added to Metformin based upon 
treatment guidelines from the national organization, the American Diabetes 
Association (American Diabetes Association, 2017). 
Later in this Chapter 2, the treatment recommendation for type II diabetes is  
discussed.  In the meantime, I shall examine the characteristics of drug classes that 
are used to treat type II diabetes.  These products affect the drug placement into a 
specific tier level within the drug formulary tier system.  
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Below, Chart D (a modified version of Chart C) is used to highlight some important 
differences among the various classes of drugs used to treat type II diabetes. The 
differences among the medications within and among the classes of medications used 
to treat type II diabetes will have an important impact on the direct and indirect cost 
of care.  As a result, this will significantly influence the total cost of care delivered to 
the person diagnosed with type II diabetes.  The identification of these differences 
plays an intricate role in the creation of this data-driven study.   This data will aid in 
the creation of the discovery of the true comparison of health benefits and cost 
savings of diabetes medications used to treat type II diabetes in the state of Georgia, 
United States of America.  This discovery will, in turn, allow this writer to create an 
action learning plan designed to reveal a value-based rationale as to why the 
medications in which I market for NovoNordisk Inc. should be included on drug 
formularies and patients should have a low out of pocket cost for the medication as 
well.  Recognizing the importance of cost, many healthcare providers as well as 
consumers are accessing the internet to compare prices.  Thomas (2016) identifies 
GoodRx.Inc as one of the most popular internet – based  research methods to 
compare the cost of medications.  GoodRx, Inc. is a private company and is not 
affiliated with any company and the pricing is considered fair an unbiased (Thomas, 
2016).         
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 MetforminA – Recommended initial medication 
 
 
 Sulfonylurea TZD1 DPP2- 4 
Inhibitor 
SGLT23 
Inhibitor 
GLP14 
Agonist 
Basal 
Insulin 
Efficacy High high intermediate intermediate high High 
Med Cost Low low High High high High 
       
Hypoglycemia 
risk 
moderate 
risk 
low risk low risk low risk low risk high risk 
Weight Gain gain Neutral Loss loss Gain 
Side 
effects 
hypoglycemia edema, 
HF, 
fractures 
possible 
heart failure 
dehydration, 
GU, 
fractures 
nausea hypoglycemia 
Chart D: Characteristics of Medications used to treat Type II Diabetes  
(Modified version of Chart C) 
 
 
As mentioned earlier, the cost of medication is a very important factor when health 
plans determine which tier level to assign medications on within a drug formulary. 
Review of Chart D reveals four (4) classes of medications used to treat type II 
diabetes that are considered expensive or “high” in cost: 
 
DPP – 4 Medication Class 
SGLT2 Medication Class 
GLP1 Agonist Medication Class 
Basal Insulin Medication Class  
 
In addition to being “high” in cost, the medications in these four classes are 
considered brand-named medications. So, based upon the Drug Formulary Tier  
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System, the medications in these four classes will be assigned to either the tier level 3 
or tier level 4 on a medication formulary.  Villagra and Ahmed (2004) reveal that 
there are consequences when a medication is categorized at a tier level 3 or tier level 
4.  These consequences are related to cost.  These cost related consequences are as 
follow:  
a. Patients will have a high out of pocket cost for the medication 
b. Due to the high out of pocket medication cost, patients may not purchase the 
medication  
c. When patients do not purchase the medication, their risk for complications 
related to diabetes increase as well as their risk of being hospitalized 
d. When patients do not purchase the medication due to the high out of pocket 
cost, the cost to a health plan is likely to increase due to the increased risk of 
hospitalizations and disease-related complications    
It is important to note that in Chart D some classes of medication used to treat type II 
diabetes are associated with weight gain, hypoglycemia (low blood sugar), fractures, 
and heart failure. These are identified as indirect costs associated with medication.  
When these medications are prescribed, the potential adverse events should be 
considered.  They should certainly be considered when attempting to make a 
determination of the true financial and overall cost of a medication ~ especially as it 
pertains to the patient’s overall health (American Diabetes Association, 2017; Boyle 
et al.,2010).   An extensive discussion of the medications used to treat diabetes is 
presented within the heading of Overview of medications used to treat type II 
diabetes later within this Literature Review.  
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     Throughout the nineteen (19) years that I have been employed with NovoNordisk,  
I have marketed not only the medication categorized as a glucagon-like peptide but I 
have also marketed basal insulin as well.  Respectively, these pharmaceutical agents 
are identified in the GLP1 agonist class and the basal analog insulin class.  Both of 
these medications have been approved to treat type II diabetes (Inzucchi et al.,2012; 
Friedhoff, 2009) .  As a pharmaceutical sales consultant, I have marketed these 
medications to healthcare professionals such as physicians, nurse practitioners and 
physician assistants throughout the state of Georgia.   
Both of these medications are considered branded products, not generics. Based upon 
the Drug Formulary Tier System, these medications will generally be placed on the 
Tier 3 or Tier 4 level because they are categorized as branded products.  As explained 
earlier, since these medications are on a higher tier level, the direct monthly 
medication cost to patients and health plans will be more expensive than medications 
on the lower tiered levels.  
A cost comparison of different classes of medications used to treat type II diabetes in 
the United States is depicted in Chart E.  
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Chart E - Monthly Cost Type II Diabetes Meds by Class, GoodRx.com, 10/2017 
 
The direct monthly cost of the GLP1 agonist medication, Liraglutide, is more 
expensive than the medications from the other classes used to treat type II diabetes. 
There are three classes of medications used to treat  type II diabetes in the United 
States that have a safer side effect profile than the older generation of products used 
to treat diabetes (Nauck, 2016; McGuire et al., 2016) . These classes of medication 
are listed as follows: DPP4 (dipeptidyl peptidase 4) inhibitor, SGLT2 
(sodium/glucose co- transport 2 inhibitor) and GLP1 (glucagon-like peptide) agonist.   
As identified in Chart E, among the three categories of medications used to treat type 
II diabetes in the United States, the GLP1 agonist, which I market (Liraglutide), is the 
most expensive medication within these three categories, depicted in Chart E .  
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Chart F - Monthly cost GLP1 Agonist, GoodRx.com, 10/2017 
 
A treatment regimen, which I have marketed in the past for NovoNordisk, Inc. known 
as basal analog insulin, is indicated to treat type II diabetes as well (American 
Diabetes Association, 2017).  Basal analog insulin, sold by the vial and not by 
individual units,  can be prescribed as a solo regimen or part of a combination 
treatment regimen (Rosenblum and Kane, 2003).  According to the Standards of Care 
identified by the American Diabetes Association (American Diabetes Association, 
2017; American Diabetes, 2019), the use of basal analog insulin has a safer side 
effect profile than NPH (Neutral Protamine Hagedorn) insulin.  NPH insulin is a 
considered a generic product and is less expensive than the basal analog insulin.   
Basal analog insulin is considered peakless and is identified as a safer product 
because of the decreased risk of adverse events such as weight gain and 
hypoglycemia, especially nocturnal hypoglycemia (American Diabetes Association, 
2017).                       
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     Upon review of the basal analog insulins, the basal insulin product manufactured 
by my workplace, Levemir, is not the most expensive; however, it is also not the least 
expensive either. Chart G represents the monthly cost of three basal insulin products 
in the United States of America.  
 
 
Chart G - Monthly Basal Insulin Cost, GoodRx.com, 10/2017 
 
As represented in Charts E, F and G the monthly monetary cost of diabetes medicines 
in the United States may vary significantly.  The two products in which I have 
marketed to treat type II diabetes are among the most expensive, in terms of  the 
monthly monetary cost.  As previously mentioned, the monetary cost of a medication 
is an important factor when determining if a medication will be placed on a drug 
formulary as well as which tier level a medication will be assigned (Balkrishnan et 
al., 2003).  
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2.3  My Business Problem 
 
The business problem I have as a pharmaceutical sales consultant is that the GLP1 
agonist, which I presently market and the basal insulin, which I have marketed in the 
past, to treat type II diabetes are branded medications.  The direct monthly monetary 
cost of these medications is traditionally more expensive than other medications used 
to treat type II diabetes (Skidmore – Roth, 2015).  According to Hodgson and Kizior 
(2014), due to the higher direct cost of these medications, they are likely to be 
omitted from the drug formularies by health plans.  Subsequently, when the 
medication(s) , which I market, are placed on drug formularies, patients will have a 
higher out of pocket cost.  This higher out of pocket cost is due to the fact they are 
usually placed on tier level 3 or tier level 4 on the drug formulary plans. My business 
problem is even more challenging because physicians, nurse practitioners, and 
physician assistants are under pressure to keep cost down.  As a result, these 
healthcare providers often avoid prescribing medications that are considered high 
“out of pocket” cost medications.  It has been my professional experience that this 
remains true even when there is considerable clinical benefit to patients when higher 
cost medications are prescribed.   Accessing evidenced based data to support this 
statement is challenging and one of the primary reasons for the development of this 
doctoral dissertation.   
     The breadth and depth of a sufficient literature review is interrelated.  According 
to Altman and Anderson (2009), when attempting to embark upon relatively new 
territory within research the literature is often limited.  In these cases, the viewpoints 
of the participants are often limited as well and the responses do not always reflect 
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the general population (Leedy and Ormrod, 2005).  An insufficient sample size can 
potentially skew the results questioning the validity of the results (Easterby – Smith 
et al., 2008; Leedy and Ormrod, 2005).      
        
2.3.1  My Action Learning Plan  
 
It is not uncommon for patients or customers to purchase a more costly product when 
a less expensive product is available if the more expensive product can demonstrate a 
better value (Cheng et al., 2013).  My Action Learning Plan demonstrates how 
products such as a GLP1 agonist and basal analog insulin are better value 
medications despite their higher monthly out of pocket cost.  This is determined by 
properly analyzing the data.  In order to properly analyze this clinical data, a Budget 
Impact Analysis and a Cost Effective Analysis seem most appropriate.  According to 
Yagudina et al. (2017), the concept of combining a Budget Impact Analysis (BIA) 
and a Cost Effective Analysis (CEA) is common because it is evidence-based data 
that properly assesses the pharmaco-economic state of a chronic disease.  Yagudina 
et al. (2017) explains that BIA is a structured examination of the financial impact of a 
new intervention, in my case, prescription medicines, on a system or a population. A 
BIA is usually performed from the perspective of a Payer or health insurance 
company. Applying an analytical tool, such as this, uses cost as well as the 
perspective of a Payer.  This is beneficial to my business problem because the Payers 
are the entity that will ultimately determine which medications will be added to the 
drug formulary.  It is important to note that the Payer or the health insurance 
company also determines the tier level on which the medication should be 
categorized.  The BIA will be performed based upon criteria established by the 
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International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
(Yagudina et al., 2017).  A BIA is performed over a specific period, usually 1 – 5 
years and involves specific scenarios.  This type of analytical framework is helpful 
because the different scenarios I will examine are likely treatment regimens for type 
II diabetes in the United States versus revised treatment regimens for  type II diabetes 
after a BIA and CEA.  Importantly, I will examine out of pocket expense scenarios of 
patients and these scenarios will be heavily influenced by the cost of the medications.  
   Medication cost is one of the primary concerns within this concept.  Edejer et al. 
(2003) defines a Cost Effective Analysis (CEA) as an analytical method to review the 
cost and health benefits of certain approaches to the treatment of a disease state.  
Usually, the overall disease state, present and previous treatment regimens are 
thoroughly evaluated.   
Key parts of a BIA for my business problem are identified as follows: 
1. Size of population eligible for treatment of type II diabetes 
2. Likely treatment regimens based upon current drug formulary and Tier 
System 
3. Cost of current treatment regimens and out of pocket patient expense 
4. Revised treatment regimens after a BIA and CEA with revised drug formulary 
and Tier System 
5. Cost of revised treatment regimens and out of pocket patient expense 
6. Changes in  type II diabetes related cost including complication development, 
cost or hospitalization or cost related to a revised treatment regimen     
 
2012 Direct Diabetes Medical Expenditures, United 
States of America 
 
Diabetes Medications and Supplies $21.1 Billion 
Diabetes Hospitalization Cost $75.7 Billion   
Prescription Meds to Treat Diabetes Complications $31.7 Billion 
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Skilled Nursing Facility $14.1 Billion 
Diabetes Physician Office Visits $15.8 Billion 
Other Diabetes Expenses $17.6 Billion 
2012 Total Direct Diabetes Medical Cost $176 Billion  
Chart H – American Diabetes Association, 2012:  USA Direct Diabetes Medical 
Expenditures 
 
 
Upon further review of this hypotheses emergence, it is crucial to reiterate the point 
that the lack of adherence to medication therapy will lead to an increase in the total 
cost to a health plan to treat a chronic disease, such as diabetes (Balkrishnan et al., 
2003; Edejer et al., 2003).  As you will learn as you read through this doctoral thesis  
lack of adherence to medication therapy for  type II diabetes increases the risk of not 
only complications related to type II diabetes but hospitalizations as well (Bradbury-
Huang,2010; Lundqvist et al., 2016).  Needless to say, these are two reasons why 
health plans should have more expansive criteria beyond medication cost when 
determining the tier level placement of a medication on the drug formulary.   
 
 
 
2.3.2  Direct Cost: Medications used to treat type II diabetes 
In most cases, the predominant factor for determining the selection and categorization 
of a particular medication to a managed care formulary is a direct cost to the health 
care plan (Balkrishnan et al., 2003; Lundqvist et al., 2016).  The decision-makers 
within the company simply want to know “how much will this medication cost the 
company”.  Direct cost is also a primary concern of the consumer.  According to 
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Lundqvist et al., (2016), the tier in which the medication is placed significantly 
impacts the patient’s out of pocket expense for medications.  Pricing / cost identified 
in the following direct cost charts aa through ee is indicated in US dollars (USD).     
 
(Direct Cost Chart aa) Good Rx Fair Price cost difference for GLP 1Agonists: 
 https://www.goodrx.com/glp-1-agonists  (Accessed March 01, 2015) 
GLP1 agonist 
Liraglutide 
Competitor  
GLP1 agonist 
Monthly cost 
difference 
Yearly cost 
difference 
761 per month 
cost 
690 (Byetta) 71 852 
761 per month 
cost 
577 (Adlyxin) 184 2392 
761 per month 
cost 
730 (Trulicity) (-)31 (-)372 
 
 (Direct Cost Chart bb)  Good Rx Fair Price for GLP1 Agonist (Liraglutide) versus 
SGLT2 Inhibitors: https://www.goodrx.com/glp-1-agonists  versus 
https://www.goodrx.com/sglt2-inhibitors (Accessed March 01, 2015) 
 
GLP1 agonist 
Liraglutide 
SGLT2 Inhibitor 
Cost 
Monthly cost 
difference 
Yearly cost 
difference 
761 per month 
cost 
453 Farxiga 308 3696 
761 per month 
cost 
450 Invokana 311 3732 
761 per month 
cost 
415 Jardiance 346 4152 
 
 
(Direct Cost Chart cc)  Good Rx Fair Price for GLP1 Agonist (Liraglutide) versus 
DPP4 Inhibitors: https://www.goodrx.com/glp-1-agonists  versus     
https://www.goodrx.com/dpp4-inhibitors  (Accessed March 01, 2015) 
 
GLP1 agonist 
 Liraglutide 
DPP4 Inhibitor 
Cost 
Monthly cost 
difference 
Yearly cost 
difference 
761 per month 
cost 
420 Januvia 341 4092 
761 per month 
cost 
370 Onglyza 391 4692 
761 per month 
cost 
330 Tradjenta 431 5172 
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(Direct Cost Chart dd)  Good Rx Fair Price for GLP1 Agonist (Liraglutide) versus 
Thiazolidinediones: https://www.goodrx.com/glp-1-agonists  versus     
https://www.goodrx.com/thiazolidinediones (Accessed March 01, 2015) 
 
 
GLP1 agonist 
 Liraglutide 
Thiazolidinediones Monthly cost 
difference 
Yearly cost 
difference 
761 per month 
cost 
12   Actos 749 8988 
761 per month 
cost 
174 Avandia 587 7044 
 
 
 
 
(Direct Cost Chart ee)  Good Rx Fair Price for GLP1 Agonist (Liraglutide) versus 
Sulfonylureas: https://www.goodrx.com/glp-1-agonists  versus     
https://www.goodrx.com/sulfonylureas (Accessed March 02, 2015) 
 
 
GLP1 agonist 
 Liraglutide 
Sulfonylureas Monthly cost 
difference 
Yearly cost 
difference 
761 per month 
cost 
7    Glucotrol 754 9048 
761 per month 
cost 
10  Amaryl 751 9012 
761 per month 
cost 
10  Glyburide 751 9012 
 
 
 
An extensive discussion of the medications used to treat diabetes is presented within 
the heading of Overview of medications used to treat type II diabetes later within this 
Literature Review. The clinical components i.e, indications, benefits, adverse events 
and limitations of these categories of medications have been identified in its entirety. 
 
     When comparing the health benefits and cost savings of diabetes medications used 
to treat type II diabetes in Georgia, it is crucial to review the complications associated 
with diabetes.  Addressing this workplace problem allows this writer to inform 
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healthcare providers and managed care administrators of the long term complications 
as well as difficulties encountered in managing the disease process of the type II 
diabetic patient.  To clarify, according to the American Diabetes Association 
(American Diabetes Association, 2017), diabetes related complications can be 
identified as health conditions that affect those persons diagnosed with diabetes more 
often than the general population of non-diabetic persons.     
     The annual costs, in Georgia, associated to diabetes by managed care payer 
sources are dutifully noted in Chart I (American Diabetes Association, 2013).  The 
managed care industry recognizes that the cost of treating the diabetic patient is a 
large contribution to the nation’s debt (Lundqvist et al.,2016).  These payer sources 
included Georgia Medicaid, private insurance and employer based insurance plans. 
Cost identified in the following charts is indicated in US dollars (USD).     
                 
 
 
 
 
GEORGIA 
2013 Annual Costs Associated to Diabetes by Managed Care Payer Source 
 
Payer source Age Group Millions 
(USD) 
Cost per person 
(USD) 
GA Medicaid 18-64 $268 $3439.10 
 >65 $160 $2674.68 
Private 
Insurance 
18-64 $142.6 $5473.06 
 >65 $249 $2183.02 
Employer 18-64 $300.8 $9921.67 
 >65 $210 $5781.07 
    
CHART I 
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Treating a chronic disorder like type II diabetes can be troublesome for the aging 
population.  The aging populations, those persons at the age of 65 and older, have 
diabetes and diabetes-related complications more often than the younger population 
of people in the United States of America (American Diabetes Association, 2017).  It 
can be troublesome because it affects their ability to ‘self-manage’ their disease, 
especially if the cost of therapy is an issue (Edejer et al., 2003).  Chart J  is a chart 
that illustrates the Medicare data identifying diabetes-related diseases in Georgia in 
2013. This is considered important because due to technology and advancements in 
medicine, people ages 65 and older are living longer and healthier lives (Center of 
Disease Control and Prevention, 2017).   
 
   
           
 
GEORGIA 
2013 Diabetes Related Diseases from 
Medicare Data  
 
Diabetes Related  Diseases Total 
Number 
Coronary Artery Disease 67,525.34 
  
Chronic Kidney Disease 57,885.02 
  
Peripheral Vascular Disease 31,987.59 
 
CHART J 
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Chart K shows the hospitalizations in Georgia for the diabetes - associated conditions 
in 2014.    
2014    Georgia Hospitalizations with Diabetes Associated Conditions  
 
Medical Condition Total Hospitalizations Diabetes-Related  
Heart Failure 13507 5760 
Stroke 8230  
Myocardial Infarction 6333 1360 
Lower Extremity 
Amputations (LEA) 
3582 2900 
*Hypoglycemia  1882 1822 
*Hyperglycemic 
hyperosmolar  
non-ketonic syndrome 
(HHNS) 
1113 1113 
*Diabetic Ketoacidosis 6937 6937 
*Condition uniquely associated with blood sugar abnormalities 
CHART K 
 
 
Diabetes management in the United States is an expensive task shared by many such 
as the healthcare provider, managed care administrator as well as the consumer.  
According the American Diabetes Association (American Diabetes Association, 
2017).  On average the cost to treat an American diabetic person can cost up to ten 
thousand dollars more annually than to treat a person without this chronic disorder. 
The aforementioned data in Chart K illustrates the various costs associated with 
diabetes.  Creating a plan of action to decrease the diabetes related complications 
would ultimately reduce the overall cost to treat the disease (Edejer et al., 2003).  
This plan of action includes a foundation of a cost effectiveness value-based model 
for formulary usage.  The algorithm and value-based contract developed template is 
disease and value based.  The theoretical framework of Herbert Simon, Bounded 
Rationality, supports the concept surrounding creating algorithms in order to support 
uniformity.   According to Simon, it is through heuristic exploration that we uncover 
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new dimensions (Kalantari, 2010).   As managers within the organization 
implementing a plan of action with the information that is readily available can be 
rewarding (Simon, 1990).  The creation of algorithms can be quite beneficial as they 
create a “step by step” process to an identified problem, it is noted by management as 
a viable solution with quantifiable interventions and it is easily comprehended 
(Kalantari, 2010) .  Upon review of the data, the following is noted to be depicted 
within the template:   
a)  Disease or condition, patient population, natural history, clinical course and 
outcomes. 
b) Primary treatment options and the treatment process for each option – preferably 
based on treatment guidelines or actual practice 
c) Costs of product and other medical resources consumed within each clinical 
pathway. 
d) Outcomes of therapy for each clinical pathway 
e) Incremental cost and outcomes analysis presented in cost/consequences tables and 
as cost-effectiveness ratios. 
 
     According to the Standards of Care created by the American Diabetes Association 
(2017), there is an algorithm for treatment for the person who has been diagnosed 
with diabetes.  Clinicians in the United States routinely refer to these Standards of 
Care created by the national organization, American Diabetes Association when 
creating a plan of care for the person with type II diabetes (American Diabetes 
Association, 2017).  The algorithm, as noted in Chart C, has been identified by the 
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American Diabetes Association for treating the person diagnosed with type II 
diabetes is as follows (American Diabetes Association, 2017):    
In clinical pathway A, when the clinician diagnoses the person with type II diabetes, 
counseling is implemented to incorporate lifestyle changes including diet and 
physical activity.  The standard of care guidelines recommended this counseling to be 
conducted via diabetes self-management training.  In clinical pathway B, if the 
hemoglobin A1C is 9-10%,  Metformin is recommended in combination with a 
sulfonylurea or GLP1 agonist.   In clinical pathway C, if the hemoglobin A1C is 
greater than 10% then basal analog insulin therapy is recommended.  The insulin is 
titrated until an acceptable range of an A1C of  less than seven (7) is obtained.  The 
hemoglobin A1C is reassessed after three (3) months of therapy.  In clinical pathway 
D, if the hemoglobin A1C is seven percent (7) but less than eight (8) percent, a 
sulfonylurea, GLP1 agonist, Pioglitazone or a DPP4 inhibitor is incorporated into the 
regimen.  In clinical pathway E, if the hemoglobin A1C is eight (8) percent but less 
than 8.5%, then a sulfonylurea, Pioglitazone or a GLP1 agonist is the therapy of 
choice.  In clinical pathway F, if the hemoglobin A1C is greater than 8.5% but less 
than nine percent (9), a sulfonylurea or a GLP1 agonist is the therapy of choice.  In 
clinical pathway G, if the hemoglobin A1C is greater than nine (9), basal analog 
insulin is the medication of choice.  If the hemoglobin A1C is not less than seven (7) 
percent after three months, then the clinician shall continue with the aforementioned 
algorithm.    
       The aforementioned overview of the pharmacological agents used to treat 
diabetes, complications associated with diabetes, usage of budget impact and cost 
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analysis, as well as the algorithm associated with the treatment of type II diabetes 
creates tremendous insight into the emergence of the hypotheses for this doctoral 
thesis.  As indicated in the overview, creating a budget impact analysis and a cost 
effectiveness analysis on the pharmacological agents used to treat  type II diabetes 
provides true insight of the potential cost implications of these medications used to 
treat an entire cohort of Georgians who have been diagnosed with type II diabetes.  In 
fact, the significance of a budget impact analysis and a cost effective analysis will be 
especially impactful when examining the comparison of health benefits and cost 
savings of diabetes medications used to treat type II diabetes in the state of Georgia.    
     These study results will be even more impactful on my role as a pharmaceutical 
sales consultant who markets medication used to treat type II diabetes.   The 
medication in my portfolio used to treat type II diabetes is associated with weight loss 
or at least, no weight gain.  The budget impact analysis of the medication in which I 
market seems quite favorable when cost is viewed through a broader lens.    A 
completed budget impact analysis and a cost effective analysis will be able to 
demonstrate to health plan decision makers the economic value of the medication in 
which I market.  Demonstrating the economic and clinical value of a medication to 
health plan decision- makers is important because these decision makers determine 
which tier a medication is placed within in the medication formulary system. When 
marketing a medication with high “out of pocket” cost, this literary document will 
reveal that it is important to review the true cost of that pharmaceutical agent.   This 
action-learning plan has been created to identify a framework that examines the true 
cost of medications used to treat type II diabetes.  The true cost of a pharmaceutical 
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agent is viewed by assessing the overall value of the agent.  This includes not only 
the  direct but indirect cost of the agent as well.  
 
2.3.3  Pathophysiology embedded within the conceptual framework 
     According to Powers (2005), diabetes mellitus (DM) is not considered a single 
disease; in fact, it is classified as a group of chronic diseases.  Diabetes mellitus is 
often responsible for abnormalities in high blood sugars (hyperglycemia) and other 
metabolic complications due to a decline in the effectiveness of incretin hormones, an 
insufficient response to insulin and an excess of its opposing hormone, glucagon.  
The causative factor of hyperglycemia varies with the specific type of diabetes.  All 
forms of diabetes create progressive metabolic changes that are damaging to the  
internal organs of the human body.  Diabetes is actually classified as type I or type II.  
The classification is based on the etiology of the underlying development of the 
disease (ADA, 2013).  According to Powers (2005), type I diabetes can be defined as 
an autoimmune disorder that leads to beta-cell destruction.  This type of diabetes 
usually leads to absolute insulin deficiency and is responsible for about 5-10% of all 
diabetic cases (ADA, 2013).  Type II diabetes is considered a progressive disorder 
caused by insulin deficiency and or insulin resistance.  This form of diabetes accounts 
for over 90% of the cases of diabetes in America (ADA, 2013).  Gestational diabetes 
mellitus is diagnosed during pregnancy (Powers, 2005).  It is important to note that 
not all patients with diabetes can be identified within one category (ADA, 2013) 
(Harris, 2004).  According to Harris (2004), an individual may appear to exhibit 
symptoms of type II diabetes but actually have a modified form of type I diabetes – in 
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this case the individual has what is known as type 1.5 diabetes.  This disorder can 
also be identified as latent autoimmune diabetes in adults (LADA).  There are often 
other, more rare, identified types of diabetes as well such as genetic defects of the 
beta cell functioning; genetic defects in insulin action; diseases of the exocrine 
pancreas,  endocrinopathies, drug or chemical induced; or immune-mediated diabetes 
(Harris, 2004).    
     As mentioned earlier, type II diabetes is the most prevalent form of diabetes in the 
United States.  An individual is diagnosed when he/she has low incretin levels, 
diminished pancreatic beta cell functioning (insulin deficiency), and/or an inadequate 
tissue response to insulin (insulin resistance) (Harris, 2004).  The hepatic system 
usually produces an excess amount of glucose and the cells within the muscles do not 
absorb an ample amount of glucose (Harris, 2004).  Even though genetics may play a 
role in the progression of this disease, obesity is the leading factor in type II diabetes 
(ADA, 2013; King et al., 1998; Harris, 2004).  
     Farooqi (2011) defines obesity as a disease encompassing a number of influential 
factors.  These factors associated with obesity may include one’s standard of living, 
socio-economic status, familial history, psychological and or physiological 
components.  According to Mokdad et al (2001) and the Center of Disease Control 
(2014), there is a gender difference in the prevalence of obesity.  Amongst men the 
prevalence of obesity is generally similar at all income levels as well as education.  In 
women, however, the prevalence of obesity increases with the female who is less 
educated with lower income levels. In the United States, obesity seems to affect 
certain cultures more so than others (Center of Disease Control, 2014).  According to 
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the Center of Disease Control (2014), the rates of obesity are as follow: 47.8% in 
non-Hispanic blacks, 42.5% in Hispanics, 32.6% in non-Hispanic whites and 10.8% 
in non-Hispanic Asians.  Ogden et al. (2012) reveals that obesity is not always related 
to genetics and is often affected by environmental factors within a culture because of 
the impact it has on the eating habits of an individual.  Families have a tendency to 
share the lifestyle habits of their family and friends (Center of Disease Control, 
2014).  Individuals are more likely to be obese if they have family and friends who 
are obese.  Ogden et al. (2012) contends that obesity is often a disease that is 
stigmatized by society.  It is important to recognize that the attitudes of personnel, 
researchers and even other study participants must be considered during the interview 
process regardless of the study topic (Keegan, 2009; Leedy and Ormrod, 2005).  
Berthoud (2012) contends that in the past fifty years the lifestyle changes within the 
United States have contributed to the increase incidences of obesity.  The changes 
include the increase foods with higher fat content, busy lifestyles with less rest and a 
lack of energy expenditure.  According to Davis (2013), there is a biological 
predisposition to consume more calories when high calorie foods are readily 
available.  This has been referred to as being in an obesogenic society – one that 
promotes the acquisition of obesity.  Throughout the world our professions have 
changed and the physical activity has been altered in the work environment as a result 
(Davis, 2013).  In fact, there are very few jobs in the United States that are associated 
with strenuous physical movement and Americans are not usually compensated by 
voluntarily increasing their physical activity (Herring et al., 2014).  As a society, 
Americans are not known for great physical activity.  In fact, according to Davis 
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(2013), many Americans spend quite a bit of time watching television or in front of 
the computer.  In addition, Americans primarily rely on their cars for transportation.  
Schmidt et. al, (2014) report the contributions of the metabolic burden of sleep loss as 
it relates to the increased body weight and obesity.  The study reveals that the number 
of hours of sleep correlated negatively with the body mass index (BMI); the less 
sleep individuals had, the higher the BMI.  Furthermore, those persons who sleep less 
than five hours per night had an increased risk of obesity.  Lack of sleep can result in 
hormonal changes within the body resulting in an increase in appetite – particularly 
for foods that are high in calories (Schmidt et al., 2014).       
     According to Ul-Haq et. al (2013), obesity is identified via classifications.  An 
individual with a BMI (Body Mass Index) of 25.0 - 29.9  is considered overweight.  
The classifications of obesity are as follow:  Class I is considered a BMI of 30 – 34.9; 
Class II is considered a BMI of 35 – 39.9; Class III is considered a BMI of greater 
than 40.  According to Caro et al. (2002), type II diabetes, is a weight related 
comorbidity associated with diabetes and satiety is a major factor when considering 
treatment.           
      The pathophysiology of satiety is an important aspect of obesity and is linked to 
GLP-1.  As mentioned earlier, the medication in which I market is classified as a 
GLP-1 receptor agonist.  Satiety can be explained via a further understanding of 
molecular mechanisms.   Simpson et al. (2008) reports that ghrelin activates the 
signal of ‘hunger’.  A person with normal body functions has levels of ghrelin that 
increase during fasting periods and decrease in response to an intake of glucose. The 
pathophysiology of satiety can be further explained by providing a more 
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comprehensive review of satiety signals.  Suzuki et al (2012) reveal that satiety 
signals can be separated into a couple of categories.  The first category can be 
identified as short-term signals.  Short-term signals are noted in the immediate 
responses to an intake of food and include a number of signaling molecules 
originating in the intestinal tract.  One of these key signals is glucagon-like peptide 
(GLP-1).   The long-term signals, on the other hand, include insulin and leptin.  
These are different and are known as adiposity signals because their production is 
linked to the amount of adipose tissue, also known as fatty tissue, in the human body.  
Natural GLP-1 is secreted from L-cells of the intestine following ingestion of food in 
proportion to the amount of calories ingested and its levels decrease during fasting 
states.  GLP-1 has a number of physiological functions as well (Vrang et al., 2010).  
For instance, GLP-1 regulates glycemic control by both stimulating insulin secretion 
and decreasing glucagon secretion in a glucose-dependent manner.  Additionally, 
GLP-1 contributes to energy homeostasis by reducing appetite and energy intake.  
Furthermore, it also decreases gastric acid and gastric emptying.   
     The long-term signals of satiety include hormones known as leptin and insulin.  
Leptin is involved in the long-term regulation of energy balance and appetite.  
Schwartz et al.,(2000) reveals that it is actually a satiety signal that is synthesized and 
secreted directly by fat cells at levels of proportional to adipose tissue mass in the 
body.  Leptin plays a role in immune functions, hematopoiesis, angiogenesis and 
bone development.  Leptin is also responsible for regulating glucose metabolism 
independently of energy balance (Kershaw et al., 2004).  This decreases ones appetite 
and body weight and increases energy expenditure.  Kershaw and Flier (2004) 
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contend that in animal models, leptin actually stimulates gluconeogenesis and inhibits 
glycogenolysis while improving insulin resistance.  Leptin also induces 
thermogenesis through the sympathetic nervous system by increasing spontaneous 
physical activity and reducing metabolic efficiency.  A decrease in leptin levels, as a 
result of reduced food intake and weight loss, causes an adaptive physiological 
response, characterized by increased appetite and decreased energy expenditure 
(Kershaw & Flier, 2004).  According to Kershaw and Flier (2004), obesity is a 
chronic disease.  Persons who have been diagnosed with obesity usually have 
elevated levels of leptin in their bloodstream.  However, these studies indicate that 
these individuals do not experience a decreased appetite and increased energy 
expenditure. This disorder is known as leptin resistance (Kershaw & Flier, 2004).          
The second long term signal associated with satiety is the hormone, insulin (Schwartz 
et al.,2000).   As a pharmaceutical sales consultant for NovoNordisk, I market a long-
acting insulin product called Levemir.  Insulin is actually a life-saving hormone 
produced by the beta cells within the pancreas.  As a human ingests food, insulin is  
synthesized and secreted in the body.  An individual’s insulin levels circulate in 
proportion to adipose tissue mass (Suzuki et al., 2012).  Insulin is an important 
hormone that is responsible for decreasing blood glucose levels.  In a healthy person, 
this normal body function happens as a homeostatic response to elevated blood 
sugars (Gerich, 1993).  This communication of body signals promote the sensation of 
satiety and ultimately causes weight loss in the individual (Morton et al., 2011; 
Menzies et al.,2012).  It is important to recognize that long-term release of insulin 
occurs if blood sugar levels remain elevated in the human body.  These two chronic 
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disorders, obesity and type II diabetes, are both characterized by insulin resistance.  
According to Morton and Schwartz (2011), insulin resistance is a condition signified 
by elevated circulating insulin levels in the body.                                   
  
2.3.4  Epidemiological cost factors 
     In this action learning based research, it is important to recognize the etiology and 
the disease course as well as the epidemiology of diabetes in order to understand the 
level of intensity created by this epidemic on the healthcare system in the United 
States.  Powers (2005) contends that obesity is the culprit in the midst of this 
epidemic.  In fact, it is the centrally obese individual that has issues with the fat 
accumulating around the intra-abdominal organs which often causes long- term 
complications associated with diabetes  (Harris, 2004).   As our culture evolves with 
age, the complications associated with chronic disorders such as diabetes have been 
responsible for creating a greater healthcare awareness within the nation (Dybicz et 
al. 2011).  As a result of this heightened level of awareness, healthcare in the United 
States is undergoing significant reform and decreasing the rising cost of healthcare is 
a big part of this reform (Doherty, 2013). An important contributor to the rising 
healthcare cost seems to be the increased incidence of type II diabetes among obese 
patients and elderly patients. In fact, the ADA (2013) reports that the total cost of 
diabetes related care increased from 170 billion dollars per year in 2007 to 245 billion 
dollars per year in 2012, a staggering 41% increase in cost . Interestingly, 43% or 69 
billion dollars per year is the amount spent on the care of diabetic patients in inpatient 
facilities such as hospitals, nursing homes or hospice care to treat chronic 
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complications of diabetes (ADA, 2013).  Therefore, any intervention that minimizes 
chronic complications can lead to a substantial cost savings (ADA, 2013).  
According to the American Diabetes Association, 12% or 21.12 billion dollars is the 
amount spent on medications used to treat diabetes and diabetes supplies (ADA, 
2013). What may surprise many is that 31.68 billion dollars per year is the amount 
spent on medications used to treat the complications associated with diabetes. 
Therefore, about 10 billion dollars more per year is the amount spent on medications 
used to treat the complications of diabetes alone than on medications used to treat the 
actual disease of diabetes itself.  
     Choo (2006) contends creating a knowing organization, which is fully explained 
in section 2.4 through 2.4.4, can be accomplished through extensive research of the 
literature.  The literature reveals a number of studies addressing the correlation of  
knowledge level and cost/benefit analysis of those individuals suffering from chronic 
illnesses such as diabetes.      
     To begin with, the literature reveals that early intensive outpatient pharmacologic 
therapy or intensive lifestyle modifications are cost effective long term therapies in 
the treatment of diabetes because these approaches decrease the chronic 
complications associated with poorly controlled diabetes, especially cardiovascular 
and renal complications in the elderly (Saydah et al., 2004; Carmethon et al., 2010). 
A strategy of reducing these complications will have a significant impact on not only 
the cost of in-patient care but also on the cost of medications used to treat the 
complications of diabetes (Loeppke et al., 2009 ; Brown et al., 1999; Boyle et al., 
2010).  Although all aspects of healthcare are being reformed limiting the cost of 
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prescription medications is a major part of lowering the cost of healthcare (Kahn and 
Anderson, 2009).   In the industry of pharmaceutical sales , when a prescriber 
restricts a patient’s access to brand name medications through the use of medication 
formularies and tiered co-pay pricing for prescription medications also (theoretically) 
decreases the cost of healthcare. In the United States, a tiered co-pay pricing system 
provides generic medications at a discounted price.  It is considered a “cheaper price” 
as compared to brand name medications.  For instance, the “out of pocket cost for the 
patient” of a generic medication has a discounted price of 4 US dollars for a 30-day 
supply of medication versus 35US dollars or 75US dollars for a 30-day supply of a 
brand name medication in the same class. It is important to emphasize that the 
discounted priced generic medication is usually within the same medication class; 
however, the medications are not the bio-equivalent. For example, Skidmore-Roth 
(2015) reveals that insulin is considered a class of medication and within the class of 
medications that are categorized as insulin, there are several brand name insulin 
products identified in the categories as human insulin and analogue insulin. The 
tiered copay pricing system for medications and the medication formulary system 
consider all medications within the class of insulin products to be bio-equivalent. 
Insulin selection within the tiered copay system / medication formulary system is 
heavily influenced by the cost of insulin.  The older (human insulin) brands are 
usually chosen as a treatment option by the healthcare provider because they are 
cheaper; however, they are less sophisticated and are associated with more adverse 
events than the newer (analogue) insulins (Skidmore-Roth, 2015). As a stakeholder 
within the pharmaceutical industry in favor of brand named medications used to treat 
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type II diabetes, this cost difference between generic medications and brand name 
medications is a primary concern.  Our company hires a sales force to market the 
insulin analogue products.  Restricting the access to brand name medications, due to 
medication formularies, imposes a tremendous strain on the sales volume of brand 
name medications.  The idea of all medications within a specific class being labelled 
as bio-equivalent is simply incorrect.  For example, under the bio-equivalency idea, 
genetically engineered insulin products are considered to be bioequivalent to regular 
insulin and this is simply not true (Jameson, 2006 p. 319). This bio-equivalence 
explanation is advanced simply so medication selections for the tiered system and 
medication formulary system can be heavily influenced by the cost of medications. 
Although most generic medications and older brand name insulin products, especially 
a class of medications known as sulfonylureas, insulins, are effective in controlling 
diabetes, the adverse effects are significant in terms of treatment (Jameson, 2006 p. 
321). These adverse effects include weight gain and hypoglycemia. The weight gain 
component is inter- linked to cardiovascular disease, obesity, kidney disease, and 
various other risk factors (Mokdad et al., 2001). When the healthcare and human cost 
associated with the adverse effects of these generic medicines or older brand name 
insulin products are calculated, then these medications are not as cheap as they may 
seem (Kim, 2007; Loeppke et al., 2009).   
     Secondly, the UKPDS (1998) study is considered the gold standard as it relates to 
treating diabetes.  One of the reasons for being considered a “gold standard” study is 
associated with the fact that the study is considered reliable and valid.  Establishing 
reliability and validity are pertinent factors because it allows the researcher to gain 
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well-founded and correct outcomes.  It is also instrumental in generalizing the 
findings to an expanded population of people.  According to Coghlan and Brannick 
(2010), being able to relate to a wider population enhances the ability to apply the 
research results to a wider range of people in an effort to improve the lives of others 
who are affected by the research topic(s) (Coghlan and Brannick, 2010;  Leedy and 
Ormrod, 2005).  The UKPDS (1998) study reveals the weight gain component of 
pharmacological therapy has been the center focus of the treating the chronic disease, 
diabetes, for quite some time.  The literature reveals that the rate of the category of 
‘severely obese’ in the United States is rising more rapidly than the population who 
has been defined as ‘moderately obese’ (Unick et al., 2011; Ogden et al.,2014).  To 
further explain, the term ‘severely obese’ refers to the person who is 100 pounds or 
more above their ideal body weight or has a BMI greater than 40.  Regardless of the 
teachings concerning healthy eating habits, exercise and the consequences associated 
with weight gain, the population of people at the ‘moderately and severely obese’ rate 
continues to rise at a steadier rate than any other category of obese people (Unick et 
al., 2011; Ogden et al., 2014).  In fact, the 6.6% of the American population is 
considered severely obese.  A decade ago, the rate was at 3.9%. If Americans should 
continue this pattern, statistics show that by the year of 2030, this percentage should 
be at a rate of 11% (Flagal et al., 2012).  The rate of moderate obesity is increasing in 
America as well.  In fact, in the year 2000, 31% of Americans were considered obese.  
By the year 2010, the rate had increased to 36% of the American (adult) population 
(Flagal et al., 2012)   Statistics show that expected percentage is to be 42% by 2030 
(Ogden et al., 2012).  If this is accurate, the number of obese people in the United 
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States is growing at an accelerated rate – surpassing the actual growth of the 
population of the American people.     
 
2.3.5  Overview of medications used to treat type II diabetes  
     The FDA approval process is often a rigorous one in the United States (Friedhoff, 
2009).  At the time of this investigative study, there were six classes of medications 
approved to treat type II diabetes.  These six classes of antidiabetic agents are 
categorized into four areas based upon their mechanisms of action (MOA).  These 
pharmaceutical agents target the various steps involved in blood glucose regulation 
including intestinal absorption of glucose, pancreatic insulin secretion, hepatic 
glucose production, glucose uptake by muscle and fat cells and glucagon-like peptide 
1 (GLP-1) regulation.   
     Secretagogues are oral antidiabetic agents that function by stimulating the beta 
cells in the pancreas to secrete more insulin.  They are only effective with the 
individual who has a pancreas with functioning beta cells.  Since type I diabetic 
individuals do not have functioning beta cells, the secretagogue is ineffective for the 
type I diabetic.   They are ineffective primarily because these individuals require 
exogenous insulin because their pancreas is no longer able to secrete insulin from the 
beta cells (Dybicz et al.,2011).  Sulfonylureas (SUs) have been available for over 
fifty years and are classified as either first-generation, second generation or third 
generation agents.  According to McCann (2007), these second-generation SUs were 
approved by the FDA over thirty years ago.  These secretagogues are available as 
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generic prescription drugs and are often the “treatment of choice” for type II diabetics 
in America due to cost.   
     Secretagogues are indicated as an adjunct to diet and exercise to decrease the 
blood glucose levels in patients with type II diabetes whose elevated blood glucose 
level is uncontrolled.  SUs are also indicated for combination therapy along with the 
biguanide, Metformin.  There is one SU, Amaryl (glimepiride) that is indicated for 
combination therapy with insulin.  The ADA and AACE standards recommend SUs 
(along with other pharmaceutical options) as second line treatment for individuals 
with type II diabetes.  Metformin is considered the ‘gold standard’ and is preferred as 
the first-line oral agent because of the low risk of adverse events when compared to 
the category of SUs (AACE, 2007) (Kooy et al., 2009).  Individuals diagnosed with 
type II diabetes who are not overweight or obese may be appropriate candidates for 
SU therapy.  The mechanism of action for the sulfonylurea is dependent upon the 
pancreatic beta cell function.  According to McCann (2007), sulfonylureas operate by 
imitating the effects of circulating blood glucose on stimulating insulin secretion 
from pancreatic beta cells.  The increased insulin concentration decreases blood 
glucose levels; however, it can also increase the chances of experiencing a decrease 
in the body’s blood sugar.  This triggers a condition known as   hypoglycemia.  This 
is considered an adverse event because the SU-stimulated insulin secretion is 
implemented whether the individual has an elevated blood glucose level or not.  In 
other words,  the mechanism of action of the sulfonylurea is not glucose dependent 
and could result in a hypoglycemic episode (Krentz and Bailey, 2005). 
58 
 
     The first, second and third – generation SUs vary as it relates to potency, safety, 
dosing and pharmacokinetics.  The first-generation SUs include agents such as 
acetohexamide (Dymelor and generics), chlorpropamide (Diabinese and generics). 
Tolazamide (Tolinase and generics) and tolbutamide (Orinase and generics).  
According to Krentz and Bailey (2005), this class of medication is not considered as 
effective as the second-generation SUs.  They are also not recommended as first line  
treatment for type II diabetes.  Due to the lack of efficacy in these first generation 
SUs, higher doses are often required.  With the higher doses, there are greater 
chances of experiencing adverse events such as hypoglycemia (McCann, 2007).  
Because the first generation SUs have a lower binding affinity to SURs in the 
pancreas and must be given in higher doses than second-generation agent they tend to 
bind securely to plasma proteins.  This action may cause an interaction with other 
pharmaceutical agents that bind to plasma proteins.  This can be dangerous because it 
intensifies the actions of the SUs or other medications being processed in the body 
(McCann, 2007).  The medication Chlorpropamide, in fact, is the only first 
generation SU still in use today in the United States.  The duration of action of sixty 
hours creates a concern for many healthcare practitioners because of the likelihood of 
hypoglycemia as compared the second-generation SUs (DeFronzo and Nauck, 1999).  
The second-generation SUs are fifty to two hundred times more potent than the first-
generation agents.  Consequently, the treatment regimen requires smaller doses.  
Most second-generation SUs have a decreased risk of hypoglycemia compared to the 
first-generation agents.  Providers are more likely to prescribe second-generation 
agents because the potential to interact with other agents is greatly diminished 
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(DeFronzo, 1999; McCann, 2007).  Glimepiride (Amaryl) is widely used in the 
United States and is a third-generation SU.  Glimepiride has the lowest potential for 
hypoglycemia than any of the other SUs, has more modulated insulin release and the 
treatment regimen is once a day.  All SUs are well absorbed and metabolized via the 
hepatic system.  However, the elimination process of the medication varies among 
the unique compounds (Davis, 2004).  The primary advantages with the SU category 
include efficacy and cost.  Due to the fact that all SUs are generic, they are 
inexpensive compared to other antidiabetic agents on the market (Nathan et al., 
2006).   There are some limitations to the SU category.  As mentioned earlier, 
hypoglycemia is a common adverse event and it occurs most often in the longer 
acting agents and the first-generation agents.  These medications are eliminated 
through the kidneys, individuals must be cautioned that hypoglycemia becomes a 
greater potential for the person with a compromised renal system.  Dosages need to 
be altered in this particular population of patient (DeFronzo and Nauck, 1999).  
Weight gain is another adverse event worthy of notation.  According to Nathan et al., 
(2006) , individuals prescribed SUs gain an average of 4.4 pounds per year.  Donath 
et al.(2005) reports that SUs may also result in pancreatic cell burnout.  When an 
individual experiences pancreatic cell burnout, exogenous insulin is prescribed as 
treatment.  The healthcare provider and other stakeholders within the industry must 
recognize that this may result in a limitation with regard to long-term durability in 
maintaining glucose control.  SUs duration of action lasts up to 12-24 hours.  Many 
of the first-generation sulfonylureas require two or three doses per day.  Individuals 
who are required to take medications more than once a day often fail to comply 
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(DeFronzo, 1999).  The second-generation agents are prescribed once or twice daily 
(Davis, 2004).  They also carry an increased risk of cardiovascular mortality 
(Davis,2004). In the United States, cardiovascular studies are of utmost importance 
when approving medications used to treat diabetes.  In fact, this original warning was 
due to the results of the University Group Diabetes Program (UGDP) in the 1970’s 
(Knatterud, 2005).  However, the findings of the United Kingdom Prospective 
Diabetes Study (UKPDS, 1998) contradicted these findings and did not agree with 
the results of this University Group Diabetes Program (UGDP).   
     The meglitinide class consists of two agents: repaglinide (Prandin) and nateglinide 
(Starlix).  These agents were approved by the FDA in 1997 and 2000, respectively 
(Krentz & Bailey, 2005).  These meglitinides are indicated to be used alone to treat 
type II diabetes or they can be used in combination with an agent such as Metformin 
or thiazolidinedione (TZD).  Those patients whose blood sugars have a tendency to 
spike after meals or those who have a history of experiencing hypoglycemic episodes 
may benefit from this type of therapy (McCann, 2007).  According to McCann 
(2007) blood sugars that are “too low” are known as hypoglycemic episodes and they 
can be dangerous. 
     The mechanism of action of Repaglinide stimulates rapid, short-lived pancreatic 
secretion of insulin.  This mechanism of action allows the individual to “treat when 
he eats”.  Due to the fact it binds to a different site on pancreatic beta cells and for a 
shorter time than do SUs there are less chances of hypoglycemic episodes (Krentz 
and Bailey, 2005,  p.395).  Repaglinide is glucose-dependent which means it will 
assist the pancreas to release insulin only when there is a ‘glucose load’ noted in the 
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body – such as during mealtime.  Therefore, Repaglinide is prescribed to be taken 
before meals.  It generates a relatively short effect of about 180 minutes.  This 
coincides with the amount of time it takes food to digest in the human body (Krentz 
and Bailey, 2005).    
     There are some advantages and limitations of Repaglinide therapy.   A clear 
advantage is the fact that it is thoroughly absorbed from the gastrointestinal (GI) 
tract. This medication actually peaks in about 60 minutes after dosing and secreted 
primarily in the feces.  This is an advantage because often times the person diagnosed 
with type II diabetes has a number of other medications on board affecting the renal 
system (Krentz and Bailey, 2005).  Due to the fact that it is processed via the hepatic 
system, an increase in the half-life of the medication may occur if the liver function is 
poor.  This may cause a hypoglycemic episode.  Repaglinide is not recommended for 
those patients in diabetic ketoacidosis nor is it recommended for the patient who has 
been diagnosed with type I diabetes. Older patients, those who are suffering from 
undernourishment or malnutrition, hepatic or renal disease should be monitored for 
low blood sugars - especially if Repaglinide is being used to treat type II diabetes in 
this population.  
Overall, the advantages of Repaglinide include its effectiveness, precipitous onset, 
and the limited amount of time that the medication is in the human body.  With this 
limited time that the medication is in the body, the probability of hypoglycemia is 
greatly reduced.  The A1C is expected to drop by 1.5 percentage points (Nathan, 
2006).  There are a few limitations to the product as well.  The limitations include the 
multiple dosing times, weight gain and the out of pocket cost.  The cost is usually 
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more expensive than the SU.  The patient should “treat when he/she eats”.  The 
regimen is usually three to four times per day, depending on the meal schedule of the 
patient.  The medication is taken zero to thirty minutes before the meal.  Taking 
multiple doses of medication can often lead to non-compliance (Nathan, 2006).     
     Nateglinide (Starlix) is in the meglitinide category and is chemically unrelated to 
SUs. This medication has a mechanism of action to secrete insulin in a similar 
manner as the aforementioned Repaglinide (Nathan, 2006).  
     Like repaglinide, the action of nateglinide also begins quickly when food has been 
ingested.   Again, one of the advantages of this type of medication is that it is glucose 
dependent and the duration of action in the human body is short-lived (Nathan, 
2006).  In fact, this is one of the major advantages of nateglinide - the rapid 
absorption.  The peak plasma concentration of this product is about 60 minutes and it 
has a half-life of about 1.5 hours.  A dose of nateglinide can be absorbed and 
stimulating insulin secretion from the pancreas within twenty minutes.  This is a 
positive attribute, especially if the person is not sure when the food will be served.  
According to Nathan (2006),  it is secreted primarily from the body in the urine; 
however, it is metabolized in the liver.  It should be prescribed with caution in the 
patient who has been diagnosed with moderate to severe liver disease.  It is not 
indicated to be used in patients with type I diabetes or those patients in a diabetic 
ketoacidosis state.  The leading advantage of nateglinide is the shortened duration of 
action.  The rate of hypoglycemic episodes is decreased when the duration of action 
of the medication is short.  There are some limitations to the nateglinide therapy.  The 
effectiveness, frequent dosing and cost are the limitations identified in the literature 
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(Nathan, 2006).  Compared to other agents in the marketplace, the overall A1C 
reduction of one percentage point is considered subpar (Nathan, 2006).  Compliance 
is an issue, as it has to be dosed several times during the day – with meals.  The 
nominal cost is also more expensive than the SU’s.   The ADA consensus guidelines 
do not endorse their use of meglitinides and the AACE guidelines recommend these 
agents as alternatives to SUs only in select patient populations (Nathan, 2006; AACE, 
2007).   
     In summary, the medications categorized as secretagogues stimulate the beta cells 
in the pancreas to create and secrete the life-saving hormone, insulin.  The 
pharmaceutical agents in this category include SUs, meglitinides and amino acid 
derivatives. They all have mechanisms of actions that involve connecting to the SUR 
(sulfonylurea receptors) on the pancreatic beta cells.   
     The sensitizer is another category of medication used to treat the patient with type 
II diabetes.  Unlike the aforementioned group of secretagogues, sensitizers do not 
increase insulin release from the pancreas - which may contribute to a condition 
known as “beta-cell burnout” (McCann, 2007).  The medications identified in the 
sensitizer OAD (oral anti-diabetic) class act by heightening the sensitivity of insulin 
in the peripheral tissues within the body (i.e., muscle and fat).  This class also 
improves insulin action in these tissues as well as process the glucose more 
efficiently at the cellular level.  The medications in this class include metformin and 
thiazolidinediones (TZDs). TZDs work more on the peripheral tissues whereas 
metformin acts more on the hepatic system (McCann, 2007). 
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     Metformin (Glucophage and Glucophage XR) is the only biguanide available for 
clinical use in the US. The FDA approved Glucophage in 1995 and Glucophage XR 
in 2000. As with all medication used to treat type II diabetes, metformin and 
extended-release metformin monotherapy are indicated to be used as an adjunct to 
low calorie meals and increased activity in an effort to improve blood sugars in 
persons who have been diagnosed with type II diabetes (Kooy et at., 2009).  
Metformin is indicated for patients 10 years old or older, and the extended-release 
metformin may be used in conjunction with a SU or insulin in patients 17 years old or 
older. The two agents may be prescribed with an SU or exogenous insulin in patients 
who are seventeen and older (McCann, 2007).  Both forms of Metformin are 
available in generic forms in the pharmacies across the United States.  In some 
pharmacies, this medication is free.   
     According to the ADA standards, metformin is the recommended first-line therapy 
for managing hyperglycemia in patients with type II diabetes, a position formerly 
held by SUs (Nathan, 2006).    This change in position occurred due to metformin’s 
effectiveness, low side effect profile, wide acceptance among the healthcare industry 
and the patients, and low cost (McCann, 2007).  According to McCann (2007, p. 
106), metformin is an ideal medication for the patient who has an elevated A1C, 
dyslipidemia, overweight or is insulin resistant.     
Metformin is indicated for treating patients with type II diabetes either as 
monotherapy or in combination with a SU, TZD, meglitinide, exenatide, acarbose. or 
insulin.   
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   Kooy et al (2009) reveal that the exact mechanism of action of a biguanide is 
unknown.  However, it appears that metformin can affect blood glucose control in a 
couple ways. First, it diminishes the volume of glucose that the liver creates by 
lessening the amount of blood glucose produced from adipose tissue and protein and 
by inhibiting the breakdown of glycogen to glucose. Through this mechanism of 
action, metformin can improve fasting blood glucose levels. Metformin also, to some 
level, improves cellular glucose uptake and utilization; that is, it helps the body to use 
its own endogenous insulin appropriately.  Unlike SUs, metformin does not have any 
impact on the amount of insulin secreted from the pancreas.  Therefore, the chance of 
experiencing hypoglycemia with the use of a biguanide as monotherapy is   
diminished.  
        According to Nathan et al. (2006), there are advantages and limitations 
associated with the class of medication called biguanides.  To begin with, metformin 
is a first line treatment of choice with patients diagnosed with type II diabetes 
(AACE, 2007).  Due to the mechanism of action, it is noted to be a highly effective 
agent with low rates of hypoglycemia.  The ADA and AACE consensus guidelines 
both support its first-line usage in addition to decreased calorie intake and increased 
activity in those patients, which are able to take this class of medication (Nathan et al. 
2006; AACE, 2007 p. 262-263).  The efficacy of this metformin as monotherapy is 
certainly remarkable.  This agent is known to create a reduction of the A1C by 1.5 
percentage points (Nathan et al., 2006).  According to Nathan et al. (2006), there is 
some noted weight loss associated with the class as well; however, it may be partially 
due to the gastrointestinal side effect, such as diarrhea.   
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Even though, metformin and extended-release metformin usually do not cause 
hypoglycemic episodes directly, this adverse event may occur when it is combined 
with other agents such as a SU or insulin (Nathan et al., 2006).  Studies also suggest 
reductions in microvascular complications associated with diabetes when metformin 
is used as treatment for the patient with type II diabetes (DeFronzo and Nauck, 1999 
p. 293) (Kooy et al., 2009).  Metformin also appears to have a favorable effect on 
serum lipids; some studies have found decreased LDL cholesterol and triglyceride 
levels, and slightly increased HDL cholesterol (Edwards et al., 2008). Extended-
release metformin has convenient, once-daily dosing, usually with the evening meal. 
The maximum dose should not exceed 2000 mg in adult patients. Plain metformin, on 
the other hand, is ordered to be administered two to three times a day, which can be 
inconvenient and may interfere with compliance.   Metformin, regardless if it is the 
extended release form or not, should be titrated slowly.  The titration process  is 
recommended in order to decrease any chances of gastrointestinal system adverse 
events (Kooy et al. 2009).   The dosing schedule of immediate release (IR) metformin 
varies, depending on the patient. The usual regimen involves dosing the medication 
along with the meal.  The maximum daily dose should not exceed 2550 mg in adults 
or 2000 mg in pediatric patients (Nathan et al., 2006).  
     There are some limitations associated with metformin dealing primarily with 
gastrointestinal adverse events.  According to Nathan et al. (2006), the most common 
adverse events associated with metformin therapy include gastrointestinal events 
such as diarrhea and nausea (53.2% vs 11.7% for placebo) and (12.5% vs 5,5% for 
placebo) respectively.  These adverse events are often ‘self-limiting’ with gradual 
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dose titration (Nathan et al., 2006).  According to Skidmore-Roth (2015), metformin 
carries a “black boxed warning” from the FDA for its association with lactic acidosis.  
Lactic acidosis is a rare condition that affects, on average, six cases per 100,000 
patient years of therapy; however, it is fatal fifty percent of the time (Skidmore-Roth, 
2015). Metformin is contraindicated in those patients with end stage renal disease due 
to their inability to metabolize and eliminate the medication from the body 
(Friedhoff, 2009; Skidmore-Roth, 2015).  To further explain, the hepatic system does 
not metabolize metformin, it is excreted from the body unaltered completely by the 
renal system.  If the renal system is impaired, the drug is not processed properly and 
acidosis is produced as the drug accumulates within the body.  Some people that have 
been diagnosed with type II diabetes, especially the elderly population, have 
diminished renal functioning and is often unable to take metformin due to this risk of 
acidosis (Mokdad et al., 2001).  Potential metformin users should have their renal 
function study tests completed before therapy is ordered and annually thereafter 
(Skidmore-Roth, 2015).  It is also recommended that when x-rays with contrast dyes 
are ordered, the patient on metformin therapy should discontinue the therapy before 
the test is initiated and therapy should only be restarted after kidney function has 
proven to be within normal limits (Skidmore-Roth, 2015).   Even though metformin 
is not processed through the hepatic system, it is not recommended for the patient 
with chronic liver disease or for those patients who are heavy drinkers of alcohol, due 
to the possibility of the accumulation of lactic acidosis (Skidmore-Roth, 2015).  
Metformin is also contraindicated in patients with the following conditions:  
congestive heart failure, low blood pressure or other disorders pertaining to a 
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reduction in tissue perfusion and metabolic acidosis (including diabetic ketoacidosis)  
(Skidmore-Roth, 2015).               
     Another class of medications used to treat type II diabetes is known as the 
thiazolidinediones, also known as TZD’s.  The medications in this group, also called 
glitazones, include rosiglitazone (Avandia) and pioglitazone (Actos).  These 
medications were approved by the FDA to treat type II diabetes in 1999 .  These 
agents treat type II diabetes by increasing insulin sensitivity within the body by 
acting on the patient’s muscles, fat and the liver through a process of binding 
(Skidmore-Roth, 2015).  By improving insulin sensitivity, the body is able to treat a 
stubborn condition known as insulin resistance via enhancing the body’s response to 
insulin by increasing the reuptake of glucose by the peripheral tissues and a reduction 
in hepatic glucose production (Skidmore-Roth, 2015).   In due course, the TZDs 
produce their glucose-lowering effects by increasing insulin sensitivity in the 
muscles, fat and liver rather than by stimulating insulin secretion and ultimately the 
TZD does not stimulate insulin production from the kidneys (Inzucchi, et al., 2012).  
Due to the mechanism of action, an episode of hypoglycemia is highly unlikely and 
the genetic changes within the cells of the targeted tissues may take several weeks in 
order to reveal efficacy (Skidmore-Roth, 2015).  These agents are indicated to be 
used in conjunction with a reduced caloric intake and increased physical activity 
along with a SU, metformin and or insulin therapy.  This category of medication can 
be implemented as second line therapy and is a viable option for patients who are 
diagnosed with insulin resistance or renal disease (Nathan, 2006; Inzucchi, et al., 
2012).      
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     The advantages of TZDs include their ability to decrease the A1C with a reduced 
risk of hypoglycemia.  There is also evidence of an improvement of the lipid profiles 
with a simplified dosing schedule.  To further explain, primary advantage of TZDs 
include their relative efficacy when compared to other agents in the market (A1C 
levels are reduced an average of 0.5% - 1.4%) and their low risk of hypoglycemia 
(e.g., 0.6% incidence in patients taking rosiglitazone vs 0.2% in patients taking 
placebo and  5.9% in patients taking SUs.) (Nathan et al, 2006).  As mentioned 
earlier, it may take several weeks for the efficacy of TZDs to be evident. TZDs also 
offer the advantage of controlling blood glucose without increasing circulating 
insulin levels and without inducing hypoglycemia when used as monotherapy 
(Powers, 2005; Nathan et al., 2006). Pioglitazone has a positive effect on lipid 
metabolism. To be precise, it decreased triglyceride levels by up to 26% and 
increased HDL cholesterol levels by up to 13% but did not increase LDL cholesterol 
in clinical trials (Edwards et al., 2008; Nathan et al, 2006). Consequently, 
pioglitazone may improve the LDL/HDL ratio (a predictor of cardiovascular risk). 
Nathan et al. (2006) contends that this improvement in lipid metabolism is not 
evident with rosiglitazone. 
     Rosiglitazone is administered every day or twice daily with a maximum daily dose 
of 8 mg. Pioglitazone is administered every day, with a maximum daily dose of 45 
mg. Both TZDs should be titrated gradually in an effort to monitor for adverse events 
related to fluid retention.  They can be administered with or without food (Skidmore-
Roth, 2015).    
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     There are some limitations to the TZD class as well.  Nathan et al. (2006) 
identifies these limitations as exacerbating cardiovascular issues, fluid build-up in the 
body (edema), increase in body weight, potential interaction with certain drugs and 
medication cost.   One of the most disturbing adverse events associated with TZDs 
include edema (fluid retention) and dose-dependent weight gain {ranging from two 
(2) to seven (7) pounds and two (2) to six (6) pounds} for rosiglitazone and 
pioglitazone, respectively (Powers, 2005).   The prescribing information for both 
TZD’s has boxed warnings emphasizing the increased risk of developing or 
worsening cardiovascular conditions.  These agents are contraindicated in patients 
with New York Heart Association Class III or IV heart failure, and TZDs can worsen 
heart failure regardless of severity. In addition, TZDs have been associated with the 
development of new onset heart failure in some patients (Skidmore-Roth, 2015). 
     Studies, in fact meta-analysis studies, reveal that there is an association of 
cardiovascular events and the use of rosiglitazone – especially as it pertains to heart 
attacks and other cardiovascular events when compared to other pharmacological 
treatments for type II diabetes ( Lincoff, 2007, p. 1185-1186).  Asnani et al. (2003) 
contends there are some slight differences in the two medications identified within 
the class of TZD.  Goldberg et al (2005) concurs as this comparison study reveals a 
difference in lipid profiles between these two agents. This comparison study of 
patients with type II diabetes and dyslipidemia (lipid imbalances) assessed the 
treatment with pioglitazone or rosiglitazone for 24 weeks. At the end of the study, 
triglyceride levels significantly decreased (-12.0%) in the group taking pioglitazone 
and increased (+14.9%) in the group taking rosiglitazone. Additionally, the group 
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taking pioglitazone experienced a more significant increase in HDL levels compared 
to the group taking rosiglitazone. Additionally, the group taking pioglitazone 
experienced a more significant increase in HDL levels compared to the group taking 
rosiglitazone (14.9% vs 7.8%, respectively; p<0.001) and a much smaller increase in 
LDL levels compared to the group taking rosiglitazone (15.7% vs 23.3%, 
respectively; p <0.001) (Goldberg et al., 2005).   
     Friedhoff (2009) identifies the rigorous process that the pharmaceutical company 
has to endure in order to bring an agent to market and the role the FDA takes to 
ensure the American public remains safe with these drugs on the market.  It is 
uncertain whether or not these differences on the lipid profiles influence the various 
cardiovascular outcomes observed between the two TZDs.  However, it should be 
noted that the FDA mandated a boxed warning stating the increasing CV concerns 
(including myocardial ischemia) with rosiglitazone (Skidmore-Roth, 2015).  Other 
warnings associated with TZDs include an increased risk of myocardial ischemia (as 
part of the rosiglitazone boxed warning) and, in female patients, bone fractures 
(Nathan et al., 2006; Skidmore-Roth, 2015).  Powers (2005) reveal that hepatic 
toxicity is another concern with this TZD class; therefore, their use in any patient 
with liver failure is contraindicated.  This concern was primarily with an earlier TZD, 
troglitazone.  Troglitazone was withdrawn from the American market in the year 
2000 due to its association with hepatic toxicities. Liver function studies should  be 
monitored with the current agents.  Monitoring lab values and the increased nominal 
cost of these agents can be costly to the patient who has been prescribed TZD 
therapy.   The current ADA consensus guidelines endorse the use of TZDs as a 
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second or third-line add-on therapy option for patients on metformin. The AACE 
guidelines endorse the use of TZDs as an option but they discuss the increased 
concern of CV risks with rosiglitazone (Nathan et al, 2006; AACE, 2007).   
     Alpha-glucosidase inhibitors (AGIs) are another group of oral antidiabetic agents 
that lower blood glucose levels by blocking the breakdown of carbohydrates in the 
small intestine, which in turn prolongs the absorption of blood glucose in the body. 
Acarbose (Precose) and miglitol (Glyset) are members of the AGI class of drugs.  
Acarbose received FDA approval in 1995, and miglitol received approval in 1996. 
AGI’s are indicated for monotherapy as an adjunct to a reduced calorie diet and 
exercise to lower blood glucose levels.  Acarbose has an indication to be prescribed 
with a SU, Glucophage (metformin) or insulin therapy.   Miglitol is indicated for use 
in combination with a SU (McCann, 2007).   Elevated postprandial glucose levels are 
often times a challenge for the type II diabetic patient.  AGI’s are particularly 
appealing to the patient who experiences elevated post-prandial glucose levels;   
however, the gastrointestinal adverse events make them a bit less attractive to the 
consumer (McCann, 2007).  The postprandial rise in blood glucose may be a 
significant problem for many patients with type II diabetes and monotherapy with 
acarbose or miglitol may be beneficial in these types of patients (McCann, 2007).   
     The mechanism of action of the AGI category of medication is established within 
the gastrointestinal tract.  Asnani et al. (2003) contends that these medications 
decrease the absorption of carbohydrates, which by the way is the source of dietary 
sugars, in the intestinal tract.  This process is mechanism of action begins when 
within thirty minutes of ingestion.  This medication binds and prevents the enzymes, 
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alpha-amylases and alpha-glucosidases, from breaking down carbohydrates in the 
small intestines.   Preventing this molecular process decreases the possibility elevated 
post-prandial glucose levels (McCann, 2007).  For maximum effect of this 
pharmaceutical agent, it must be ingested before the meal is consumed.   
     The main advantages of AGIs include that it is not associated with hypoglycemic 
episodes nor is it associated with an increase in body weight (McCann, 2007).  
As mentioned earlier, the mechanism of action of acarbose is in the GI 
(gastrointestinal) tract.  A small portion of acarbose, about two percent, is actually 
absorbed into the body via the bloodstream.  This is a favorable attribute of this class 
of medication because it also has a diminutive opportunity to interact with other 
pharmaceutical agents.  However, it is important to note that acarbose may affect the 
absorption of the popular medication, digoxin.  An increase dose of digoxin may be 
necessary, as it has been proven to affect the bioavailability of the drug (McCann, 
2007; Nathan, 2006).  Over fifty percent of the unabsorbed medication is excreted in 
the feces (Nathan, 2006).       On the other hand, a 25-mg dose of miglitol is entirely 
absorbed and over 50% of a 100-mg dose is absorbed, but there is no evidence of any 
therapeutic effect of miglitol outside the GI tract. This agent has an elimination half-
life of about 120 minutes and is processed entirely by the urinary tract.  Caution 
should be taken when prescribing these agents with medications such as glyburide, 
metformin, ranitidine, and propranolol.  Caution should be used because decreased 
peak plasma concentrations and drug absorption values are noted when they are taken 
concomitantly (Nathan, 2006).   
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     The limitations of this class of medication hinges on the poor efficacy rating, 
gastrointestinal disturbances, dosing and cost.  The expected A1C reduction is 0.5% 
to 0.8% and the most common side effects are gastrointestinal related such gas, 
bloating, diarrhea and abdominal discomfort (Nathan, 2006).   These gastrointestinal 
adverse events are usually self-limiting and the causative factor is related to the 
undigested carbohydrates remaining in the large intestines.  These carbohydrates 
combine with intestinal bacteria and the process of fermentation cause the 
gastrointestinal disturbances (Nathan et al., 2006).  The dosing of AGI’s can be a bit 
inconvenient, as they should be administered three times a day at mealtimes.  In fact, 
it is recommended that both agents be initiated at 75 mg/day (25 mg TID) and, if 
necessary, titrated to a maximum daily dose of 300 mg (100 mg TID). A gradual 
escalation schedule is recommended to decrease the chances of gastrointestinal 
disturbances.  As expected, with the type of mechanism of action of the AGIs, these 
agents are not indicated to be used as a treatment regimen for patients who have 
intestinal-related disorders dealing with the breakdown or the absorption of food 
particles.  These agents are also not indicated for patients diagnosed with diabetic 
ketoacidosis or end stage renal disease.  Interestingly, miglitol has not been reported 
to have issues with the hepatic system; however, acarbose is contraindicated with 
patients with hepatic disorders.  Nathan et al. (2006) reveals that elevated doses of 
acarbose in the body may cause an elevation of liver enzymes. In clinical trials of 
acarbose, 6% of patients had liver enzyme levels more than 1.8 times normal, as 
opposed to 2% in the placebo group, but these elevated levels created no symptoms 
and were not associated with any liver dysfunction (Fisher et al., 1998).  When 
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acarbose therapy is prescribed, liver enzyme levels should be monitored quarterly 
during the first year of therapy (Coniff  et al,.1995).  
In the event of a hypoglycemic episode during AGI therapy, Fisher et al (1998) 
recommend oral glucose tablets because sucrose will not be effective in raising the 
blood glucose level because its absorption would be blocked by the effects of AGI 
therapy.  
     The ADA consensus guidelines do not endorse the use of AGIs; however, the 
AACE guidelines endorse their use only as an option in patients with modest 
elevations in A1C (Nathan et al., 2006; AACE, 2007).   
     Incretin-based therapies target the incretin system in the body.  In incretin-based 
therapy, these pharmaceutical agents affect the incretin hormone, GLP-1 (glucagon-
like peptide-1).  GLP-1 is a hormone produced in the intestines and is responsible for 
the regulation of glucose following the digestion of food.     At the time of this study, 
two types of incretin-based therapies are currently available in the US, GLP-1 
analogues and DDP4 (dipeptidyl peptidase-4) inhibitors.   
     The GLP-1 receptor agonists are designed to treat type II diabetes by mimicking 
the endogenous GLP-1 profile. This class of medication reduces the A1C, on average 
by 0.8% to 1.6%. (Nathan et al., 2006; Skidmore-Roth, 2015).  GLP-1 therapy can be 
used in conjunction with metformin, SU’s, TZD’s or basal insulin (Skidmore-Roth, 
2015).        
     The mechanism of action for the GLP-1 class of agents is based on mimicking the 
effects of the endogenous GLP-1 profile.  Skidmore-Roth (2015) contends that this 
class of medication binds to the GLP-1 receptor site within the pancreatic beta and 
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stimulates insulin in a glucose-dependent manner.  It subdues glucagon production 
from the liver while delaying gastric emptying creating a sense of fullness 
(Skidmore-Roth, 2015; Nathan et al., 2006).  According to Wajchenberg (2007), this 
class of medication shows promising evidence of a possibility of preserving beta-cell 
function.  Data from studies involving rodent physiology suggest that in addition to 
normalizing the blood sugars, this category of medication may preserve the beta cells 
as well as increase their production.  The proliferation of beta cells is a key factor in 
maintaining a healthy pancreas for humans.  
     GLP-1 is a hormone that is naturally destroyed by the enzyme dipeptidyl 
peptidase-4 (DPP-4) and has a half-life of about 60-120 seconds.  A GLP-1 agonist is 
resilient and is not easily degraded by DPP4.  In fact, the half-life of manufactured 
GLP-1 is up to thirteen (13) hours as opposed to natural GLP-1, which is 1-2 minutes 
(Drucker, 2006; Campbell, 2007).             
     GLP-1 therapy is provided in a subcutaneous injection and is administered twice 
or once daily (exenatide and liraglutide, respectively).  When GLP-1 therapy is 
administered in conjunction with a SU, the manufacturer recommends decreasing or 
discontinuing the SU to lessen the chances of a patient experiencing an episode of 
hypoglycemia (Skidmore-Roth, 2015).    
There are advantages and limitations of GLP-1 therapy.  One advantage is GLP-1 
treatment is indicated to be used with other regimens in the marketplace to treat 
diabetes (Nathan, 2006; Amori et al., 2007; Skidmore-Roth, 2015).  Due to the 
mechanism of action, the incidences of hypoglycemic episodes are rare with this 
class of treatment.  Clinical trials have demonstrated the added benefit of weight loss 
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when GLP-1 therapy is implemented (Amori et. al, 2007; Powers, 2005; Skidmore-
Roth, 2015).  Studies reveal that type II diabetic patients are often challenged by the 
issue of weight gain and the effects of weight are of utmost importance when 
implementing a plan of action for treatment    (Unick et al., 2011; Heller, 2004; 
Mokdad et al., 2001).  The limitations of GLP-1 therapy include the adverse event 
profile, in particular, the gastrointestinal (GI) events.  These gastrointestinal events 
(nausea, vomiting, and diarrhea) are usually self-limiting especially when the titration 
dosing schedule is executed correctly (Amori et al., 2007).  Other limitations include 
the fact that it is an injection, associated with multiple endocrine neoplasia type II 
and medullary thyroid carcinoma (boxed warnings for the GLP-1 class of 
medications) and it is a costly regimen (Skidmore-Roth, 2015).            
     The DPP-4 (dipeptidyl peptidase-4) Inhibitor is a class of medication available in 
the United States to treat type II diabetes.  A DPP-4 inhibitor can be used as 
monotherapy or in combination with other agents such as metformin, TZD, SU, and/ 
or basal insulin (Campbell, 2007; Hollander et al., 2011).   
The mechanism of action for the DPP-4 inhibitor is to impede the actions of the 
enzyme DPP-4, which is designed to degrade the body’s endogenous GLP-1.  It is 
important to keep GLP-1 circulating because its natural job is to normalize blood 
glucose levels by preventing hyperglycemia (Hollander et al., 2011; AACE, 2007). 
Hermansen (2007) contends that there is evidence of this class of medication 
prolonging the activity of incretins and inadvertently naturally preserving beta-cell 
function. To further explain, when beta cells are preserved it allows the pancreas to 
continue to secrete the life- saving hormone, insulin. As the pancreas continues to 
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secrete its own insulin there is less chance of needing exogenous insulin due to 
pancreatic cell burnout.    
     The mechanism of action has revealed a unique method of regulating blood sugar 
levels that are independent of pancreatic stimulation; therefore patients with a history 
of hypoglycemic episodes or those who have challenges with weight should be 
considered for therapy with a DPP-4 inhibitor (Inzucchi et al., 2012).  According to 
Inzucchi et al,. (2012), national guidelines in the United States have recommend 
medications within the class of DPP-4 as second-line therapy for type II diabetes.  
The DPP-4 inhibitor class of medication can be administered with or without food 
and is dosed once a day.  The manufacturer recommends if the patient  has been 
diagnosed with renal insufficiency, the dosage of the medication should be altered to 
a reduced dose to prevent further renal insufficiencies (Inzucchi et al., 2012).     
There are advantages and limitations to DPP-4 therapy.  Studies reveal that A1C 
reduction is moderate when used as monotherapy.  The A1C is lowered by 0.7% to 
0.9% and the fasting plasma glucose as well as the post-prandial glucose levels is 
significantly lowered when compared to placebo (Inzucchi et al., 2012).  Comparison 
studies with the SU group reveal not only a decrease in the aforementioned 
parameters but there was a significant decrease in the body weight as well whereas 
the SU group identified a weight gain (Inzucchi et al., 2012).  With the once daily 
dosing of this oral medication, a weight neutrality status and a low side-effect profile 
(as it relates to GI disturbances and hypoglycemic episodes) makes this agent 
desirable for the type II diabetic who desires glycemic control (Skidmore-Roth, 
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2015).  The limitations of the DPP-4 class include the increased cost (as compared to 
older agents) and the increased incidences of pancreatitis (Inzucchi, et al., 2012).     
       Amylin-based therapy (Amylinomimetics) is identified as a treatment option for  
type I or type II diabetes.  Nathan et al. (2006), reveals the efficacy as being 
moderate.  When this agent is administered in conjunction with mealtime insulin 
therapy, the average A1C level is decreased by  0.5 to 0.7%.  Pramlintide (Symlin) is 
an injectable agent, has a mechanism of action that enhanced body’s own glucose 
metabolism and insulin sensitivity. It does this by mimicking the effects of the 
endogenous GI hormone, amylin.  Amylin is a hormone created by the beta cells in 
the pancreas.  These small peptide hormones are designed to normalize blood glucose 
production by decreasing gastric emptying, creating a sense of satiety and decreasing 
glucagon production  (Skidmore-Roth, 2015).  This is a key factor in not only 
controlling the post-prandial glucose levels but suppressing the appetite as well. 
 According to Skidmore-Roth (2015), in comparison to other blood-glucose lowering 
agent, pramlintide demonstrates more of a correlation to the steadiness of the post-
prandial glucose levels as well as the amount of insulin circulating within the body.  
This is important because the amount of this circulating hormone, insulin, in the body 
has a direct correlation to increased incidences of weight gain (Heller, 2004).  In fact, 
due to this diminished requirement for insulin therapy, this class of medication is 
associated with weight loss.  There are higher incidences of hypoglycemia when the 
medication is administered with insulin therapy.  Many patients are unwilling to 
adhere to the therapy due to the two separate injections required to maximize therapy.  
The product is prescribed to be administered simultaneously with injectable insulin 
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therapy.  If administered before meals, their insulin dosage must be reduced by fifty 
percent to decrease the chances of a hypoglycemic episode (Skidmore-Roth, 2015).  
Compliance is often an issue as this medication due to timing.  This medication 
should not be administered after the meal has been ingested.  The dosing regimen is 
escalated at intervals of a week to two weeks.  The duration is individualized to the 
patient – either the patient meets the goal of good glycemic control or unable to 
tolerate the therapy due to gastrointestinal adverse events, such as nausea.  The 
prescribing information instructs the patient to omit the dose in the event that the 
patient “forgot”.  The medication should be postponed until the following day of 
therapy.  Type I diabetic patients generally are prescribed more of this category of 
medication than the type II diabetic patient.  The administration site is a concern as 
well.  The subcutaneous tissue in the thigh or abdominal area is permissible however 
the posterior area of the upper arm is not recommended due to insufficient blood 
stream absorption (Skidmore-Roth, 2015).  The prescribing information for 
Pramlintide suggests never mixing insulin in the same syringe because of the 
decrease predictability of the product when mixed.  It is also recommended to 
administer the medication within two (2) inches of the insulin site of injection 
(Skidmore-Roth, 2015).  The ADA (2017) guidelines do not recommend Pramlintide 
as a therapeutic agent for the treatment of type II diabetes.  In fact, AACE guidelines 
recommend this as a therapeutic agent only as an addition to insulin users who seek a 
“moderate” reduction in their A1C (Nathan et al., 2006).       
     There are some advantages and limitations associated with this class of 
medication.  The advantages include potential weight loss and (possible) reduction in 
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their total daily dose of insulin (Nathan et al., 2006).  The limitations include the 
following: injectable therapy, limited effectiveness of the agent, complicated dosing 
with multiple injections required, costly and there is a high incidence of 
gastrointestinal disturbances (Inzucchi, et al., 2012). 
     In summary, this doctoral thesis identifies six categories of medication to treat 
type II diabetes.  The healthcare providers have an armamentarium of treatment 
regimens for this chronic disease, diabetes. These available choices allow the 
provider to choose the regimen most appropriate for the patient albeit, efficacy, safety 
or cost.  Creating a knowing organization allows all stakeholders involved in caring 
for patient with a chronic disease, such as diabetes, to be aware of every component 
surrounding the treatment regimen (Choo, 2006).  This added knowledge equates for 
a more informed decision. 
 
2.4   Theoretical Framework    
     The theoretical framework implemented for this action – learning based research 
can be identified as a blend of two theories.  The initial theory is a blend of 
organizational theory and information science. This theory is identified as Choo’s 
knowing organization.  The framework of  Choo’s knowing organization  (Choo, 
2006) postulates that advancing education and critical thinking through “sense 
making, knowledge creation and decision-making” can be accomplished with 
collaborative efforts and shared visions among stakeholders within the organization  
(Choo & Johnson, 2003).  The second theory is identified as Simon’s bounded 
rationality theory.  This decision-making theory is based on economic science. 
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     To begin with, in order to address the cost crisis within the organizational 
healthcare arena, stakeholders within the industry must have evidenced-based data in 
order to formulate cost-effective decisions.  Stakeholders must be able to make sense 
of the environment within the healthcare system, create knowledge through evidenced 
based data and make sound decisions through this information gathering process 
(Choo, 2002).  Within this action learning process, this can be accomplished due to 
the authenticity involved in the political dynamics of this workplace problem.  Each 
of the components identified as sense-making, knowledge creation and decision-
making has its own distinct value as it pertains to organizational management.  
However, Choo (1998) contends that it is the interconnection of these components 
that create a true ‘knowing organization’.  According to Thorpe and Holt (2008), 
sense-making can be defined simply as making something sensible.  The concepts 
involved in the sense-making experience deals with individuals reviewing various 
conditions while simultaneously making sense of the experience.  These communal 
thoughts of the stakeholders are  linked together to structure the purpose of the 
organization and to actually frame the problem(s) identified within the organization 
(Choo, 2002).  When workplace problems are discovered, they often become a 
platform to create knowledge in order to make sound decisions.  In the healthcare 
arena, there are three types of knowledge: implied knowledge that is often implanted 
through years of experience; formal knowledge formulated through education, rules 
and regulation; and cultural knowledge communicated via one’s own personal 
traditions, principles and standards.  In order to create new knowledge there has to be 
an interconnection of conversion, collaboration and amalgamation of all forms of 
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organizational knowledge (Choo & Johnson, 2003).  The overall goal of knowledge 
creation is to generate innovative ideas in order to expand an organization’s level of 
capability.  These ideas create sensible interventions that often set forth a plan of 
action with new alternatives.  Choo (1998) contends that these new action plans will 
often times create well-orchestrated successes; however, there may also be hidden 
challenges as the plan unfolds. Albeit a challenge or a success, when the interventions 
are implemented a decision is forth-coming.   To further explain, when these 
innovative ideas are presented with evidence-based data, the interventions are 
implemented and a decision is created.  Through this decision-making process, an 
organization is able to give birth to new beginnings (Choo, 2002).   Decision-making 
can be defined as a component within organizational management that is goal-driven 
and structured by the preferred rules and regulations of the organization (Thorpe & 
Holt, 2008).    The organization has an ability to grow and allow others to learn from 
not only the successes but the challenges as well.   
      Sense making, knowledge creation and decision-making are indeed key 
components to constructing a “knowing organization” (Choo, 1998; Choo, 2006).  
This theoretical framework was selected for this action – learning based research 
because its implementation creates an authentic educational evaluation of 
organizational management.  It also illustrates an insightful and collaborative 
approach for the stakeholders involved in the process of action  learning  (Herr & 
Anderson, 2005).  This type of framework is ideal when addressing America’s 
complex healthcare crisis (Choo, 2002).        
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2.4.1  Sense Making 
     Weick (1979) uses sense making as a descriptive term to identify how individuals 
within an organization perform in an environment by linking their experiences using 
critical thinking to generate knowledge.  Sense making is often triggered by a 
challenge in the organization that has caused some sort of disruption or concern to the 
stakeholders within the organization (Weick, 1995).  These disruptions or concerns 
offer opportunities within the organization to create new knowledge.  Weick (1995) 
contends that there is a formula used to identify these disruptions and concerns – 
discovery, choice and retaining.  In the discovery phase, the stakeholders review the 
disruptions or concerns and try to “make sense” of these issues.  This selection 
process is usually based on the “cause and effect” methodology.  This type of 
explanation is clear with meaning for the stakeholders.  The data collected is 
reviewed and a choice is made by using past or present interventions that have been 
successful.  If using past or present interventions are not effective, new ideas are 
generated.  A selection is then made from these choices and the solution is retained 
and implemented.  Upon further evaluation, the solution is captured as a success or 
perhaps a “challenge” for further study.   
     Organizational sense making as it relates to healthcare is primarily maneuvered by 
the political beliefs and / or actions of the stakeholders within industry (Austvoll – 
Dahlgren et al., 2008).  When a political driven belief is an intricate part of the 
equation, data driven evidence is beneficial to create a more plausible structure to the 
process.  Stakeholders may implement their political beliefs as a method to direct 
their choices of the various interpretations concerning choices identified in America’s 
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costly healthcare dilemma.  In an action driven process, the stakeholder may review 
the past and present actions within the healthcare environment to give meaning to 
their structure of sense-making.  In this sense-making process of healthcare, the 
stakeholders develop grounds of significance in order to validate the choices in which 
they have committed themselves – especially when billions of dollars are at stake 
(Poisal et al., 2007; Kahn & Anderson, 2009).   
 
2.4.2  Knowledge Creation 
According to Choo (1998), knowledge creating is often ignited by a detectable void 
within the current knowledge of an organization.  When these voids in knowledge are 
not properly addressed, they often impede solutions to work place problems and will 
hinder the opportunity for organizational growth (Choo, 1998; Choo, 2002).   The 
literature reveals that there are three categories of knowledge (Choo & Johnson, 
2003; Choo, 2002).  To begin with, implied knowledge  is naturally developed after 
years of experience and tutelage – this pertains to an individual or group.  Secondly,  
formal knowledge is formulated through education, organizational rules and 
regulations, policies and procedures, etc.  Finally, cultural knowledge is 
communicated via one’s own personal traditions, principles and/or standards.  It is 
through time filled teachable moments that implied, formal and cultural knowledge 
amalgamate in order to form organizational core competencies.  Organizational core 
competencies provide the organizations with unique structure and are often attached 
to the values and norms of the stakeholders  (Choo, 1998).    
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    It is important that organizational core competencies remain refreshed with new 
ideas to prevent stagnation (Choo, 1998).  To further reiterate  this point, Leonard 
(1995) reveals four behaviors associated with successful organizations.  These 
behaviors are  identified as follows: shared best practices and thought provoking 
ideas, utilizing integrated technologies and tools to enhance these new ideas, 
implementing these new ideas while thoroughly documenting the challenges as well 
as the successes.  It is dutifully noted that these behaviors were implemented while 
collaboratively seeking the guidance of those stakeholders who share an interest 
outside of the organization.  When stakeholders from outside of the organization are 
invited to be involved in the problem-solving efforts, new perspectives are often 
generated.  Even though innovative solutions can be formulated, tension may also 
arise (Leonard, 1995).  In this case when implementing the new methods, it is crucial 
that the new practices are adaptable to the existing organization.  Implementing the 
new solution into the workplace is the responsibility of all stakeholders involved in 
the process (Leonard, 1995).   
     When new ideas concerning the American public healthcare system are being 
implemented, there are a couple of behaviors that are vital to the success of the 
execution of this process (Leonard, 1995).  To begin with, the healthcare system is 
formulated with governmental rules, regulations and standards.   The stakeholders 
must be receptive to the new ideas as they incorporate their level of expertise in 
various areas of the process.  Secondly, since stakeholders are identified from various 
departments within the system i.e. healthcare providers, managed care divisions, 
pharmaceutical companies, insurers, consumers, pharmacies, etc., it is imperative that 
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all disciplines be properly informed of the objectives within the process.  To be 
certain that this behavior is executed Leonard (1995) highlights the importance of 
constant collaboration.  When the objectives are revealed and all of the stakeholders 
are in agreeance, these innovative ideas build knowledge and are capable of 
facilitating learning within appropriate healthcare organizations.   
 
2.4.3 Decision Making 
     The decision making process in organizational management is designed to 
discover various courses of action for the purpose of goal-attainment (Easterby – 
Smith et al., 2008).  In this stage of creating a “knowing” organization, the challenge 
is often surrounded by issues of ambiguity when faced with choosing appropriate 
interventions to solve the problem.  Decision making in the dynamics of 
organizational management involve two features: clearly defined goals and clearly 
defined interventions (March & Simon, 1993).  When the stakeholders understand the 
goals as well as the interventions, the decision making process is usually guided by 
the decision principles and practices within the organization.  Having this sense of 
clarity defines the criteria to be reviewed, as well as the interventions to be 
considered.  Relevant information is easily detected among the stakeholders, as they 
are familiar with the components within the selection process.  According to March 
and Simon (1993), choosing the appropriate interventions is simplified with episodes 
of familiarity and single goal – attainment.  On the other hand, when goals are clear 
and the interventions are not clear, there is a course of action necessary in order to 
create success.  Mintzberg, Raisinghani and Theoret (1976) have identified a course 
88 
 
of action that entails three components in order to create success in this decision - 
making process.  They are as follows:  identification, development and selection.  The 
course of action involving identification allows the stakeholders to accept the fact that 
there is indeed a problem and understand the need to address the issue.  The course of 
action involving development allows the stakeholders to review viable options and 
create a solution.  The course of action involving selection concentrates on choosing 
the intervention(s) with the least path of resistance and the greatest potential for 
stakeholder commitment.   
     In the event that there are large groups of stakeholders and the decision making 
process involves conflicting goals yet everyone is clear on the preferred interventions 
– the organization must behave as a coalition (Cohen, March & Olsen, 1972).  In 
other words, alliances are formed in order to endorse preferred interventions.  Large 
organizations encountering confusion concerning goal-attainment will often adhere to 
the rules and regulations of the organization (Starkey et al., 2009). The stakeholders 
involved will often create discussion groups and formal procedures that permit 
everyone with a vested interest identify their concerns, make inquiries, validate points 
and reach a sustainable conclusion.  This decision-making process creates a 
conclusion that is sustainable because it has been properly formulated through 
negotiating and compromising (Cohen, March & Olsen, 1972).       
     In situations whereas there is little clarity on both goal attainment and 
interventions, Cohen, March and Olsen (1972) have identified an approach known as 
the “garbage can” approach.  With this approach, brainstorming is implemented in 
order to identify organizational challenges, viable solutions, stakeholder involvement 
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as well as evaluation tactics.  During this process, the challenges are identified and 
viable solutions are paired with them.  The availability of stakeholders is then 
reviewed in order to identify who has the time, energy and effort to commit to 
execute the plan of action.  
     When creating a “knowing” organization, many of the aforementioned  
decision- making methods are implemented contingent on circumstance (Choo, 
2002).  When a group of stakeholders within an organization has been equipped with 
the information necessary to identify goals and interventions to create practical 
solutions, this is often noted as a well-structured situation (March & Simon, 1993).  
In the event that the goals are not clear and the interventions are not, the phased 
process of searches with rules and regulations being the foundation of the search has 
proven to be effective – especially in large groups (Cohen, March & Olsen, 1972).  
Positioning the rules and regulations of the organization as the foundation 
acknowledges acceptable interventions without parochialism or uncertainty.  Finally, 
in situations where total perplexity has been identified, brainstorming is a practical 
process.  Brainstorming allows the group to identify challenges, seek solutions and 
assign a plan of action to the most qualified stakeholder who has the time, energy and 
effort to complete the task (Cohen, March & Olsen, 1972).   
 
2.4.4  The Knowing Organization 
     When creating a “knowing” organization, a constant exchange of relative 
information is imperative for growth and opportunity (Choo, 2002).  In fact, the 
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organization should be designed to allow a continuous flow of information through 
the links of sense-making, knowledge creating and decision making.   
     Choo (2002) contends that during the process of sense making, a void within the 
organization is often discovered.  When the void has been identified, its origin and its 
impact should be sought out immediately.  The end-product of sense making is the 
stakeholder’s view of the void and the suspected impact that this void has on the 
organization.  Through various collaboration efforts goals are set and the 
interventions are created to propel the organization in the desired direction of change 
(Leonard, 1995).  As this plan of action is developed and the interventions are set 
forth, this shared purposeful data allows the stakeholders within the organization to 
detect the workplace problems and seek the opportunity to create modifications 
within the system (Choo, 2002).  In the event that the stakeholders are unable to 
pinpoint the origin of the challenges crippling the origination, this is considered a 
void in the knowledge level of the company.  When a void is discovered new 
knowledge must be created to address this issue; hence the term knowledge creation.  
In the case that stakeholders are familiar the challenge, the organization can proceed 
with the courses of action to rectify the problem(s) and or challenge(s) (Choo, 2002).  
This is known as a void in the decision making process.  The ultimate end-result of 
the concept of knowledge creation is advancement of organizational opportunities 
through innovative ideas.  Developing new ideas through the decision making process 
certainly has the capability of valuable progress; however, there is also the possibility 
of uncertainty and failure (Leonard, 1995).  Uncertainties and failures are an intricate 
part of risk-taking of the decision making process, especially in endeavors dealing 
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with management (Reynolds, 1999; Rigg & Trehan, 2008).  When the stakeholders 
create a plan of action, a commitment to the implementation process leads to a goal-
directed evaluation (Choo, 2002).  Curtin et al. (2006) proclaims that some of the 
most effective decisions in healthcare have been identified as short-term, goal 
oriented and attainable.  In this case, a prompt evaluation of the return on investment 
(ROI)  can be dutifully noted (Curtin et al., 2006).  A swift evaluation allows 
challenges during the process to be addressed and adaptive long-term goals may then 
be initiated through new cycles of sense making, knowledge creation and decision  
making (Choo, 1998).   
 
2.4.5  Herbert Simon’s Bounded Rationality Theory   
     Herbert Simon’s Bounded Rationality Theory is a behavioral theory approach to 
decision-making (Simon, 1990).  To further explain, this behavioral theory approach 
is based on a philosophy of behaviorism.  In the philosophy of behaviorism, 
administration is considered a science, a social science to be exact.  Behavior science 
subjects actually deal with the behavior of people and is based on the assumption that 
there is value in the decision-making process (Simon, 1990; Kalantari, 2010).  
     Herbert Simon’s Bounded Rationality Theory takes behavior science a step further.  
This social science foundation has been grounded within a concept of economic 
science and in turn it is directly associated with human behavior in the administrative 
setting (Barros, 2010).  This decision-making theory is ideal for the workplace 
problem identified in this doctoral dissertation.  It is ideal because according to Simon 
(1990) stakeholders within an industry can be rational in their decision-making only 
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within the boundary of the resources available.  These resources may include, but not 
limited to, personal experiences, written materials of reference and the knowledge of 
the present action plan.  The investigative process of data collection, analyzing factors 
associated with cost and implementing resources may be available yet time-
consuming and expensive (Barros, 2010).  Executive leaders within the company may 
view this as an arduous task in an effort to reach a viable decision for a solution to a 
company-wide problem.  Kalantari (2010) argues that instead of taking the time to 
complete a thorough investigation, human nature forces those in an organizational 
management position to take “short cuts”.  These “short cuts” often transition to what 
is known as “trial and error” type procedures.  This type of problem solving often 
results in a limited pool of options.  Ultimately, this may result in a  knowledge 
deficit with the decision-making processes and objectives cannot be fully 
accomplished.  As a result, the organization embarks upon a concept viewed as 
“satisficing”.  Velupillai (2010) explains this concept was created by Simon in the 
1950’s as a means to achieve the first satisfactory outcome with the available 
resources at the time of the decision-making process.  This process is identified as an 
ongoing evaluation process.  It is known as an ongoing evaluation process because as 
the steps are implemented and challenges are incurred then the procedure is modified 
in an effort to promote growth.  According to Simon (1990) when there are limited 
resources, the human brain is prompted to process available resources through what is 
known as bureaucratic procedures executed in previous situations similar to the 
present problem.  In organizational management, stakeholders have a tendency to 
collaborate in order to create action plans, policies and procedures to develop a 
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template for continuity (Stacey, 2011).  This template, when structured properly can 
expedite a decision-making process that is acceptable within the organization.  
Simon’s (1990) Bounded Rationality Theory explains the process of this decision-
making tactic in three stages.  The first stage of this process is that of an intelligence 
activity.  In this stage, an authenticated problem must be identified.  In this stage, it is 
crucial to recognize that the problem must not be presumptuous or perceived – as this 
could result in an erroneous perception of the actual query.  When the problem has 
been authenticated, the next step in the process is the design activity.  In this activity, 
all available alternatives are reviewed in its entirety.  Areas of interest within the 
organization as it relates to these alternatives may include cost, accessibility, 
practicality as well as data to support the choice(s).  The final stage is to select the 
best alternative(s).  This decision-making process does not always result in one 
hundred percent (100%) rationality (Barros, 2010; Simon, 1990; Kalantari, 2010).  
However, the outcomes of the process can create a valuable document through the 
creation of a template.  When structured properly, through an ongoing evaluation 
process, this template can expedite a decision that is not only acceptable but can be 
implemented and altered as changes within the organization are detected.  An 
ongoing evaluation is often chosen by administration because it allows the company 
to be strengthened through the challenges (Carmeli & Schaubroeck, 2008; Simon, 
1990).  To clarify, when a challenge is discovered, a new solution is researched and 
the template is changed.  Ultimately, this type of evaluation creates an organization 
that can be improved through challenges.  Simon’s theory of bounded rationality   has 
been implemented to create actionable knowledge for the workplace problem 
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identified within this study,  In this conceptual framework, a standard pattern of 
behavior can be adopted, analyzed and verified by not only an organization but an 
industry as well (Barros, 2010).   
     Simon’s Bounded Rationality Theory applies well to aid in problem-solving 
through algorithmic procedures (Barros, 2010).  This method of strategizing in the 
arena of decision-making is beneficial because it involves researching the problem, 
creating valuable objectives (known as criteria) as well as a thorough review of 
valuable options for a satisfactory outcome (Kalantari, 2010).  This theory examines 
economic constraints and reviews the complexity in its entirety.  In the 
pharmaceutical industry, this is important because such recognition aids in not only 
the ability to handle the problem at an organizational level but transition it to a frame 
of reference for an industry problem as well. Case in point, this investigation within 
this pharmaceutical industry has revealed limited outcomes based data concerning the 
cost associated with branded products used to treat of type II diabetes.  Simon’s 
Bounded Rationality Theory allows one to deal with factual data to derive at an 
acceptable algorithm to address a work-place problem that is actually an industry 
wide dilemma (Simon, 1990; Velupillai, 2010).  Simon’s Bounded Rationality Theory 
was implemented to create an algorithm that can be used as a template to identify 
interventions acceptable to treat type II diabetes and prevent long term (costly) 
complications associated with the chronic disease, such as cardiovascular disease.                                      
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2.5  Diabetes management goal development 
     In the United States, guidelines for treating diabetes are produced by ADA 
(American Diabetes Association), AACE (American Association of Clinical 
Endocrinologist) and AAFP (American Academy of Family Physicians).  The ADA 
is an organization of scientists, consumers, and healthcare professionals (ADA, 
2008).  The guidelines for this organization recommend an A1C goal of less than 7% 
with an ultimate goal of reaching this target without experiencing hypoglycemia.  
They also recommend keeping the fasting plasma glucose between 70mg/dl and 130 
mg/dl and post prandial plasma glucose less than 180mg/dl.  The AACE membership 
is usually composed of clinical endocrinologist (AACE, 2007).  The recommended 
guidelines are more stringent in efforts of obtaining better blood sugar control.  The 
A1C goals are less than 6.5%.  The fasting plasma glucose level has a goal of less 
than or equal to 110mg/dl and the postprandial plasma glucose goal is less than or 
equal to 140 mg/dl.  The AAFP consists of family practice physicians.  This group 
does not necessarily set blood glucose goals; however, they encourage individualized 
treatment planning for the patient (AAFP, 2008).  
     There are actually two studies that are considered to be the gold standards in terms 
of diabetes management and goal development in the United States (Brownlee et al, 
2016).  These two studies include the Diabetes Control and Complications Trial 
(DCCT) Research Group and the UK Prospective Diabetes Study (UKPDS) Group 
(Brownlee et al., 2016).  In the DCCT (1993) trial a comparison study was completed 
using an intensive insulin regimen versus conventional therapy in type I diabetics.  It 
concluded that patients managed intensively reduced their risk for microvascular 
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complications by 35 - 70%.  Benefits of blood sugar control occurred via evidence of 
the reduced A1C concluding that this reduction was indeed beneficial.  However, the 
study does indicate that intensive control does lead to more incidents of 
hypoglycemia and weight gain.  The UKDPS (1998) trial was a large trial using type 
II diabetes patients as subjects.  In the study, patients were selected randomly for 
either the conventional or intensive therapy group.   The intensively treated group 
reduced their A1C to an average of 7.0% compared to 7.9% in the conventional 
therapy group.  This led to decreased microvascular complications and a trend 
towards a reduction in heart attacks.  In addition, implementing stringent guidelines 
for blood pressure control created a reduction in both micro and macro vascular 
complications.  Once again, as the A1C was lowered incidences of hypoglycemia 
increased.     
  
2.5.1  Diabetes Management and Cost Effectiveness 
     Being in the pharmaceutical industry, one must recognize the correlation of 
scientific investigations and quantifiable measures to support clinical judgment.  In 
this industry, the stakeholders are often scrutinized as this (costly) science is 
transformed into applications of clinical knowledge.  Without this clinical 
knowledge, the ability of the healthcare providers to decode facts and identify the 
best treatment for the patient would be non-existent.  Making such informed 
decisions depend on their levels of clinical expertise and ability to apply this 
knowledge to the most important stakeholder, the patient.  Education is a key factor 
in the decision-making process especially as it is related to cost-effectiveness.  This 
study demonstrates that there are a number of valid investigations that support the 
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idea of the link between education and cost-effectiveness especially as it relates to 
chronic illnesses such as diabetes.    
     Balamurugan et al. (2006) conducted a study of 56 weeks with the implementation 
of a diabetes education program to diabetic patients who were of low income.  In this 
study, a continuous quality improvement (CQI) type course of action was initiated to 
evaluate the quantifiable measures and the cost effectiveness of the program.   The 
participants within the program had a decrease in their A1C on average of 0.45% and 
the recidivism rate for readmissions to the healthcare facilities decreased as well.  
This study revealed that within a three (3) year period the estimated cost savings of 
diabetes – related expenses would be four hundred fifteen dollars ($415.00) per 
person who completed the program.  Over a decade, completers of the program were 
estimated to have a reduction in cardiovascular disease as well as microvascular 
disorders by twelve (12%) and fifteen (15%) percent – respectively.  The utilization 
of this educational program decreased the use of funds used within this Medicaid 
program as well.   
     Christensen et al. (2004) performed a cost analysis of the effectiveness of a 
diabetes education program.  The three month study involved the implementation of a 
diabetes education course.  This assessment included diabetes knowledge regarding 
various aspects of nutrition and its relationship to a reduction in A1C.  This study 
revealed that as the participants’ education level increased , the A1C level decreased 
by 0.73%, the body mass index (BMI) decreased by 8.82 kg/m2 (P=.000), waist 
circumference decreased by 1.27in (P=000), hip circumference decreased by 0.6in 
(P=.000) and waist-to-hip ratio decreased 0.01 (P=.000) .  This training on 
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nourishment and blood sugar control were calculated to reduce the medical costs 
associated with hospitalizations by ninety four thousand ten dollars ($94.010).  
     Cranor et al. (2003) conducted a study to evaluate the sustainability of the results 
after the community-based pharmaceutical care services had been implemented.  
There were 136 diabetic, self-insured participants who were enrolled in this study.  
The goal was to determine the results of lab values measuring blood glucose and 
cholesterol levels after the initiation of a communal program designed to implement 
pharmaceutical care assistance – five years ago.  The education was provided by 
certified diabetes educators.  The lab values were measured after the initiation of this 
long-term communal program with identified patients.  The patients involved in the 
program were self-insured by a variety of managed care plans.  The blood glucose 
findings revealed a reduction in the A1C as well as the lipid levels in more than 50% 
of the patients in the study.  In fact, the study revealed that the more elevated the 
A1C at baseline – the more likelihood of improvement was noted.  There was a direct 
correlation between the cost of caring for this study group of patients and the 
education / knowledge level.  It seems that the more educated the patient – the less it 
cost to care him/her.  The study revealed that the average cost to care for these 
patients decreased by $1200 to $1872 per patient annually (Cranor et al., 2003).  For 
four years (1997-2001), documented days for leave decreased and productivity 
increased at an estimated $18,000 per year.  According to Cranor et al (2003), the 
employers were convinced that educating workers who have a chronic disorder such 
as diabetes has a profound effect on direct and indirect medical cost associated with 
diabetes, sick leave, as well as productivity rates. 
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     Fries and McShane (1998) conducted a comparison study in order to identify the 
cost-effectiveness of the health education courses in high-risk patients as compared to 
other patients who were not identified as high risk.  The 2586 participants were 
randomly selected and provided with an assessment form, a letter of consent and 
educational materials based on the identified high risk disorders identified during the 
assessment i.e. musculo-skeletal disorders such as arthritis, cardiovascular issues 
such as elevated blood pressure and endocrine disorders such as diabetes.  The 
assessment also captured whether or not the patient indulged in activities such as 
smoking.  The direct and total cost of the program was assessed to determine the 
return on investment (ROI).  After 180 days, the direct costs for those identified in 
the high risk group were lessened by $304 versus $87 in the group who were not 
identified as high risk.  Overall the ROI was 6:1 in the high risk group vs 4:1 in the 
non-high risk group.  Implementing an educational program proved to be beneficial 
in the high risk patient population more so than those who were not identified as high 
risk.  
     Garrett and Bluml (2005) performed an analysis of the cost-effectiveness of a 
community health management program involving 256 diabetic patients.  The 
analysis consisted of an assessment of the clinical benefits, satisfaction and economic 
measures from the program implemented to these participants who were self-insured.  
Various levels of care were provided to the participants who were self-insured.  The 
pharmacists provided scheduled pharmaceutical-based discussions.  The health care 
providers performed physical assessments and screenings.  The care provided by 
these identified healthcare professionals included medication consultations, goal 
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setting, assessments and screenings. The participants reported an overall satisfaction 
rating of 95.7% of the pharmacists in the study.  There was an increase in the amount 
of screenings performed as well as improvements noted within the cardio-metabolic 
assessments.  The rate of patients accepting the flu vaccine escalated from 52% to 
72%.  There was in increase in patients completing their eye exams as well – 46% to 
82%.  The importance of the diabetic foot exam was conveyed which led to an 
increase of 38% to 80% for the podiatric assessments.  Through these educational 
efforts, the parameters concerning diabetic care improved from 57% to 87%.  The 
average A1C declined from 7.9% to 7.1%.  The average low-density lipoprotein 
cholesterol (LDL-C) declined by nine points (113.4 mg/dL to 104.5 mg/dL).   The 
average systolic blood pressure was reduced by five points (136.2 mm Hg to 131.4 
mm Hg).  The overall analysis revealed that the cost per patient was actually $918 
lower than the projected outcome at the beginning of the study.  
     Menzin et al (2001) implemented a study, which assessed the influence of  
adequate blood sugar regulations on diabetic complications (short term in duration) 
and the cost associated with these complications.  In this study, 3294 diabetic patients 
over the age of 18 were  assessed over a period of three years.  The study participants 
were selected and identified according to their hemoglobin  A1C  levels.  The 
categorized labels were as follows: good control (A1C less than 8%); fair control 
(A1C less 8%-10%) and poor control (A1C greater than 10%).  Nearly 10% of the 
2394 patients participating in the study were  hospitalized due to short-term 
complications associated with diabetes.  Over the three year period, the rates were as 
follow for inpatient treatment: good (13 per 100 patients), fair (16 per 100 patients) 
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and poor (31 per 100 patients).  The respective charges were identified as 970 dollars, 
1380 dollars and 3040 dollars.  The patients identified as being in poor glycemic 
control were more costly to the healthcare system.  Those patients identified as being 
in good glycemic control saved an average of 400 to 2000 dollars over a three- year 
period – when compared to the fair and poorly controlled groups.   
                 Rubin et al (1998) conducted a study to determine the cost-effectiveness of 
an intensive management program on a population of 7000 diabetic patients who 
were actively treated and monitored through seven managed health care plans.  The 
savings from the implementation of this intensive management program proved to be 
significant at a gross-adjusted reduction of fifty dollars per member.  In-patient 
admissions to the local healthcare facility decreased by an average of 20%.  The 
study revealed that patients actively enrolled in the program were more likely to 
follow-up with their healthcare providers for lab work (A1C and cholesterol levels), 
foot exams and annual eye exams. The overall conclusion reveals that the initiation of 
such a program leads to not only improvements in the cost associated with diabetes 
but the clinical outcomes for present and as well as future.  
                 Shetty et al. (2005) conducted a cost analysis assessing the variations in 
the expenses associated with the differences in the A1C levels of type II diabetic 
patients.  In this study, there were 3121 patients with an A1C targeted level less than 
or equal to seven percent and 3659 patients who had an A1C greater than or equal to 
seven percent.  Using data that met the criteria for this study, a retrospective database 
analysis was performed.  Managed care organizations across the country provided the 
laboratory results from its members.  Medical and pharmaceutical claims were also 
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reviewed for this study.  These type II diabetics were not provided with any particular 
interventions but were followed for 52 weeks to determine an analysis of diabetes 
related costs for the two groups of patients.  After the 52 week study was completed, 
the follow-up period revealed that the diabetes-related costs for the “above-target” 
group was $1540.00 per patient; whereas, the “at target” group was $1171.00 per 
patient.  The diabetes-related cost for the group of diabetics categorized in the above 
range group was thirty-two percent higher than the group at a targeted level of seven 
or less.   
                Sidorov et al. (2002) performed a retrospective study to determine if the 
diabetes disease management (DDM) program had any influence on the cost 
associated with the care of the diabetic patient.  The study participants were 
diagnosed diabetics chosen from the Health Plan Employer Data and Information Set 
(HEDIS).  Of these study participants, 3118 were assigned to the DDM program and 
3681 were not assigned to the program.  A retrospective-type study was completed 
comparing the submitted claims of the participants for two years.  The primary care 
visits per year were similar for those enrolled in the program and those not enrolled.  
The results were 8.4 visits per year vs. 7.8 visits per year patient.  The study 
participants were diagnosed diabetics  for the participants enrolled in the DDM 
program were less among the commercial group as well as the Medicare group.  The 
results were $302.19 (DDM) vs. $525.96 (non-DDM) for the commercial costs and 
$424.00 (DDM) and $500.37 (non-DDM) for the Medicare group.  For those patients 
enrolled in the DDM group versus the non-DDM group, the cost analysis  
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revealed a reduction of 21% for the commercial as well as the Medicare group.  The 
mean savings per person/year was $1294.32.  This is a statistically significant value 
and the patents enrolled in the DDM program achieved better measures in the key 
diabetes HEDIS review and the charges incurred for care was less than the group who 
were not enrolled in the program.   
                Testa and Simonson (1998) conducted a 12 week study including 569 
employees diagnosed with type II diabetes.  This study was designed to assess the 
loss earnings associated with these employees as it related to the therapeutic levels of 
their blood sugar ranges.  The blood sugar levels were monitored, symptoms were 
recorded, quality of life (QOL) assessments were conducted and levels on the job 
efficiency were assessed via journals and surveys.  The interventions used in the 
study included diet and a well - known sulfonylurea called Glipizide.  At 12 weeks, 
labwork (A1C and fasting blood sugar levels) was performed on the study 
participants.  Those employees enrolled in the study who participated in an exercise 
and sulfonylurea regimen had lower AIC scores, lower fasting blood sugar scores and 
better productivity ratings vs those who participated in exercise only.  Respectively 
the results are as follow:  A1C scores 7.5% vs 9.3%, fasting blood sugar scores 126 
vs 168 and productivity ratings 99% vs 87%.  These same employees also had less 
absenteeism, fewer sick days and fewer “light-duty” assignments.  Respectively the 
results are as follow:  absenteeism computed to $24 vs $115 per employee per 30 day 
period; sick days computed to $1539 vs $1843 per 1000 days of work; and   These 
same employees also had less episodes of absenteeism of $2660 vs $4275 per 1000 
days of work.  Overall absenteeism ratings decreased by one percent vs an increase of 
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eight percent for the employees whose blood glucose levels were not in therapeutic 
range.  This study concluded that there is certainly a co-relation of good glycemic 
control and employee level of productivity.   
     Type II diabetes is a complex disorder.  Recognizing the pathophysiology, 
epidemiological cost factors, FDA approved pharmacological treatments and proper 
management of the disease process is interconnected to an overall accurate cost of 
treatment.  Linking these factors to workplace relativity within this action learning 
research is crucial in order to investigate the cost savings and health benefits of 
medications used to treat type II diabetes in Georgia, United States (Morrell, 2008).        
     The literature reveals that workplace relativity is of extreme importance in the 
implementation of action learning based research (Pedler, 2008; Newbold, 1982).  
This latter section of the literature review reveals workplace relativity, action learner 
relevance with an overview of the researchers profile and an overall evaluation of the 
process as it pertains to scientific thinking via the investigator as well as the 
stakeholder. 
 
2.5.2  Evaluating the process via scientific thinking for the stakeholder 
     As the new healthcare reform has begun, a variety of changes are occurring in the 
United States.  One of the major changes that have developed is the creation of value-
based purchasing.  There are three concepts surrounding the framework associated 
with value-based purchasing and they are as follow:  quality care measures, open and 
honest reporting with clarity, and fair reimbursement recognition (Damberg et al., 
2010).  To begin with, the concept of quality care measures with proper recognition is 
unable to be executed without proper performance evaluation.  According to Cheng 
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et al. (2013) quality care measures can be assessed amongst various stakeholders 
within the healthcare industry such as managed care participants, healthcare 
institutions, healthcare providers as well as manufacturers within the pharmaceutical 
industry.  The concept of quality measures is a patient centered concept that has been 
designed to create a ‘check and balance’ type analogy that would support 
standardized care to individuals in the United States.  Creating this ‘check and 
balance’ type system encourages accountability within a circle of excellence as it 
relates to the stakeholders involved in the care of the patient.  When this circle of 
excellence is expected in the patient- centered strategy, everyone recognizes that the 
care provided will be assessed, measured and the outcomes revealed (Young et al., 
2007).  Secondly, this level of accountability and transparency is important as the 
outcomes are publicly distributed and are pertinent in creating the plan of care to the 
most important individual in this equation, the consumer.  According to Doherty 
(2013)  this heightened level of accountability is actually considered a motivating 
factor to provide quality care to the consumer.  When the healthcare provider is 
publicly “graded” on the quality of care provided, managed care organizations and 
employers are able to access this data.  Employers and managed care companies 
desire the providers who have demonstrated an acceptable quality care performance 
(Doherty, 2013; Rosenthal et al., 2008).  Needless to say, employers and managed 
care companies (especially Medicare) should have a vested interest in keeping their 
consumers healthy.  Healthy consumers are less costly (direct and indirect) in terms 
of provider office visit, urgent care visits, labs, missed days of work, medications, 
procedures, etc. (King et al., 1998).  Thirdly, pay-for-performance is a concept that 
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has been implemented into the healthcare reform.  In the United States, this pay-for-
performance (also revealed in the literature as fee-for-service reimbursement) can be 
defined as a concept whereas practitioners are incentivized for keeping their patient 
healthy instead of ordering various services.  Traditionally our healthcare system was 
designed to “take care of the sick” instead of focusing on a methodology that would 
encourage health and wellness – especially as it relates to chronic diseases such as 
high blood pressure and diabetes (King et al., 1998).  Lastly, the consumer, as the 
primary stakeholder, has to be accountable if any of the initiatives identified in the 
healthcare reform is to be successful.  When requesting the consumer to make more 
informed decisions about lifestyle changes, adherence to a regimen, coaching and 
guiding, one must consider the motivating factors.  Some of these factors may 
include lower insurance rates for the non-smoker with lab values that are within 
normal range (Young et al., 2007).  As the stakeholders are recognizing the changes 
that are occurring within our nation due to the cost of healthcare, plans are being 
implemented across the country designed to decrease the deficit.  According to 
Damberg et al. (2010), value-based purchasing will be a standard used by healthcare 
providers to quantify, report and get compensated for quality care provided to their 
patients.  Value-based purchasing involves stakeholders such as providers, managed 
care companies, consumers and the pharmaceutical industries to address the rising 
costs of healthcare.  When quality care is provided on a routine basis by excellent 
providers, the practice will be rewarded with maximum reimbursement rates within 
the managed care plan.  According to Young et al. (2007), value based purchasing 
can be used as an effective influence for the healthcare providers as well as the other 
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stakeholders.  There are 26 quality control entities used to measure this value-based 
purchasing (Rosenthal et al., 2008).  These quality control entities included twelve 
clinically relevant categories that are processed.  For example, whether diabetic 
patients receive quarterly hemoglobin A1C checks); eight clinically coordinated 
support efforts (such as documented communications between physician, lab staff, 
nurse or social services); five summaries identifying the patient’s outcomes (this 
entity will consist of 30-day death rates for related conditions that are  cardiovascular 
or respiratory in nature); and one cost-benefit analysis for each payee.  When the 
healthcare providers submit the claims, the reimbursement rates are  based on the 
rankings.  This methodology is a novel strategy and even though the system has not 
been perfect, Young et al. (2007) reports that the quality incentive program is 
designed to decrease the cost of treatment by rewarding excellent healthcare 
practices.  The governing bodies of healthcare policy has condoned this method of 
promoting quality care; however, as a stakeholder within the pharmaceutical industry, 
who has an insight on true cost-benefit analysis of diabetic medications I urge the 
evaluators of the system to be certain that the outcomes truly reflect quality care.  
Simply measuring cost does not address the complexity associated with the full 
ramifications of the disease process and the adverse events associated with the 
pharmacologic agents.  This is especially evident in the review of long-term 
outcomes associated with various treatment modalities (Damberg et al., 2010; Curtin 
et al., 2006; Luce, 2005). 
     As mentioned, value-based purchasing is certainly one method of addressing the 
escalating cost of healthcare in the United States.  It is especially helpful when 
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addressing at least two of the components associated with these issues.  These 
components include health and wellness tactics as well as short-term savings tactics 
(Doherty, 2013).   According to Cheng et al. (2013) the components dealing with 
health and wellness are designed to encourage preventive medicine.  These often 
surround programs such as healthy eating, smoking cessation, weight loss, or 
substance abuse counseling.   Implementing preventive measures have been 
associated with creating and maintaining healthy habits, which impacts the health 
status of individuals.  Studies show that when the consumer is healthy, the quality of 
life improves and ultimately the workforce is maintained and chronic conditions are 
improved (King et al., 1998).  Allowing these value-based purchasing programs to be 
implemented has positive effects.  It will allow employers to offer these health and 
wellness programs in an effort to increase job productivity, promote a company’s 
mission statement as well as the triple bottom line as it relates to strengthening all 
stakeholders involved in the creating an optimal level of wellness  (Rosenthal et al., 
2008).  The other component deals with the short-term savings, which stems from 
getting compensated for quality service delivered to a population of people who 
genuinely need care – especially those who have chronic illness (Rosenthal et al., 
2008).  Rosenthal et al. (2008) contends that healthcare providers focusing on 
tripartite aspects of care such as quality service, excellent treatment and fair 
reimbursement viewed by others in the healthcare field as catalysts to promote a true 
value-based system.  
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2.5.3  Evaluating our actions through Health Impact Assessments 
     In the healthcare sector of business, conducting a health impact assessment (HIA) 
is one method of determining if a certain decision has been effective.   These 
assessments have been conducted on an international level for decades (Harris-
Roxas, Villani, Bond, Cave, Divall, Furu, et al., 2012).  These reports are thorough as 
they depict the discoveries, impacts, goal attainments and short-comings of our 
present plans of care.   
     In fact, many of these health impact assessments reveal evidence-based data to 
support the use of certain medications to reduce the risk of many of the cardio-
metabolic risk factors that are contributing to the cost associated with chronic 
disorders such as type II diabetes.  These studies reveal the value associated with 
medications such as SGLT2 inhibitors and GLP1 agonists.  These medications have 
proven to be not only safe but efficacious as it decreases the adverse events often 
associated with medications used to lower the blood glucose level.  As of this date, 
there are two large health impact studies addressing cardiovascular outcomes as it  
relates to SGLT2 therapy.  The first trial is known as the EMPA-REG OUTCOME 
(Empagliflozin Cardiovascular Outcome Event Trial in Type II Diabetes Patients-
Remove Excess Glucose).   According to Kosiborod et al. (2017) there were 7,020 
patients enrolled in the study and a significant reduction in the number of  major 
cardiovascular events (MACE) categorized as nonfatal myocardial infarction (MI), 
nonfatal stroke or cardiovascular (CV) mortality in patients who received the SGLT2 
inhibitor as opposed to the placebo.   The data gathered for this assessment was on 
adjudicated claims, electronic medical records and data from national registries.  
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These type II diabetic patients were randomly selected and a medication regimen of 
empagliflozin  (10mg or 25mg daily) was ordered as a treatment.  Compared to 
placebo, the patients in the empagliflozin group encountered a 14%  decrease in the 
primary (composite) end points of the study, which were identified as cardiovascular 
death, myocardial infarction or stroke as well as a 32% decrease in the overall 
mortality rate.  These factors also contributed to the 38% decrease in the amount of 
cardiovascular related deaths noted as well.  A secondary endpoint of heart failure 
hospitalizations was dutifully noted with a decreased by 35%.  It is important to 
recognize that empagliflozin is the only SGLT2 inhibitor that is recognized and 
approved by the FDA (Food and Drug Administration) to reduce the risk of CV death 
in adults with type II diabetes and established cardiovascular disease. 
   The second health impact assessment, known as the CANVAS (Canagliflozin 
Cardiovascular Assessment Program) programs actually enrolled 10,142 patients of 
whom 72% had established atherosclerotic cardiovascular disease (ASCVD).   The 
patients were prescribed either a placebo or canagliflozin (100 or 300 mg tablets). 
The first CANVAS program consisted of 4,330 patients and the second CANVAS-R 
program consisted of 5,812 patients.  The analysis of the two trials revealed a 14%  
decrease in the primary endpoint of MACE (major cardiovascular events) which 
consisted of a composite of nonfatal myocardial infarction, nonfatal stroke and 
cardiovascular death.  The results from the CANVAS program revealed a significant 
33% decrease in the secondary endpoint of hospitalizations for heart failure.   
     Kidney disease, as mentioned previously in the literature review, is yet another 
major concern for those patients who have been diagnosed with the chronic disorder, 
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type II diabetes.  Empagliflozin and canagliflozin are both considered suitable 
clinical choices as treatment regimens for type II diabetes patients.  Studies reveal 
that not only do the SGLT2 inhibitors slow the progression of kidney disease but it 
also improved the eGFR (estimated glomerular filtration rate) by at least 40% 
(Cherney et al., 2017;  Neil et al., 2017;  Wanner et al., 2016).  As mentioned earlier 
in the section entitled classes of medication used to treat type II diabetes, the SGLT2 
inhibitor has a mechanism of action that allows glucose to be excreted via the urine in 
order to lower the blood glucose level.  Vallon and Thomson (2017) contend that this 
diuretic effect not only rids the body of excess glucose but it promotes weight loss 
and lowers the systolic blood pressure as well.    
     The GLP1 receptor agonist is the second category of medication used to treat type 
II diabetes that has shown benefits for those patients at risk for CV (cardiovascular) 
events.  Those health assessment impact studies measuring cardiovascular outcome 
usually measure a three (3) point MACE outcome of CV death, nonfatal myocardial 
infarction (MI) or nonfatal stroke and the LEADER (Liraglutide Effect and Action in 
Diabetes: Evaluation of Cardiovascular Outcome Results) trial is no exception.  In 
the LEADER trial 9,340 type II diabetic patients who were clinically diagnosed with 
ASCVD ( 81% of the overall total) or patients over the age of 65 who were at risk for 
ASCVD  (19% of the total) were randomly assigned to either the Liraglutide group or 
the placebo group.  The three point MACE outcome of CV death, nonfatal 
myocardial infarction and nonfatal stroke were decreased by 13% with Liraglutide 
when compared to placebo.  In fact, all of the components of the MACE composite 
revealed a reduction.  Marso et al. (2016) suggest that this may be due to the 
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reduction in the overall CV deaths within the Liraglutide group.  There were no 
reductions in the heart failure events noted in the LEADER trial.  According to the 
American Diabetes Association (2018),  Liraglutide is the only GLP1 that has been 
approved by the FDA to reduce the risk of  MACE in adults with type II diabetes and 
established cardiovascular disease.    
     As mentioned earlier, kidney disease is a major concern as it relates to type II 
diabetes.  Liraglutide is in the GLP1 receptor agonist category and the LEADER trial 
reveals some renal benefits.  In fact, the LEADER trial reveals a 26% decrease in the 
risk of macro-albuminuria.  Similar to the SGLT2 inhibitor category, Liraglutide use 
shows a reduction in the weight, systolic and diastolic blood pressure, waist 
circumference as well as the total cholesterol panel (le Roux et al. 2017). This 
reduction in weight and improvement in cardio-metabolic risk factors exemplifies 
value to the treatment regimen.                                    
     Health impact assessments are not only completed in the clinical arena.  They are 
conducted  in the communities as well.  In fact, Davenport, Mathers and Parry (2006) 
conducted one of the larger studies in the United Kingdom (primarily in Europe) 
concerning health impact assessments.  This study was implemented through the 
University of Birmingham and was expanded for eight years.  In fact, eighty-eight 
health impact assessments were  reviewed.  The decisions created from these 
assessments impacted not only local level but a regional and national level decisions  
as well.  Health impact assessments, in this case, dealt with public transportation, 
housing, health and wellness, ecosystems and local industries.  The review methods 
included case studies and surveys.  The outcomes of this study indicated that 
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examining the implementation of policy was crucial to identifying whether the plan 
of action was successful.  Davenport et al. (2006) revealed that communicating with 
the persons who are responsible for making decisions on an individual basis, instead 
of in a public forum, was important.  Communicating with these decision-makers in 
private discourages the possibility of group-think.  These health impact assessments 
are most beneficial when they are incorporated into the plan of action upon project 
initiation (Davenport et al., 2006).  Davenport et al. (2006) revealed a number of 
successes with the decision-makers, policy-developers, timing, methodology 
implementation tactics as well as reportage capabilities.  Decision-makers and 
stakeholders (both external and internal) communicated well.  Sufficient 
communication allowed the researcher to establish credibility early in the process.  
Upon reviewing this policy-making process a clear commitment to the collaborative 
efforts involved in legislature, intervention implementation consistency, evaluations 
and modifications were obvious.  Various levels of supportive areas were  discovered 
by the evidence-based data.  With this data, political drivers were revealed resulting 
in recommendations for the planning process.  These recommendations for the 
planning process were  implemented in an “on-going” delivery for advancement.  
The proper timing of these assessments was another area revealed through this 
evaluation process.  Whether or not the health impact assessment is a success or a 
failure could really depend upon the timing of the assessment and if it is conducive to 
the policies and procedures of the company.  The methodological aspect the 
assessment was consistent.  A variety of factors were discovered that proved to be 
impactful.  Due to the consistency and adequate communication efforts, the 
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awareness of organizational concerns and urgencies could be used to as action based 
solutions to work-place problems.  There were a number of negative aspects such as 
unforeseen staffing issues, timeless and availability of resources.   
     Wismar, Blau, Ernst and Figueras (2007) conducted a study in Brussels, Belgium 
at an organization identified as the European Observatory on Health Systems and 
Policies.  Expanding over a four- year period (2002-2006), one hundred fifty eight 
health impact assessments were performed to determine policy - efficacy in nineteen 
countries in Europe.  The results affected ten local and six national decision-making 
bodies within various sectors including public transportation, environmental 
planning, farming communities, factories, building structures as well as food and 
nutrition.  Interviews were conducted  with those responsible for making decisions in 
order to determine the effectiveness of the present policy and procedure(s).  There 
were numerous health impact assessments conducted and the complexity of each 
project varied.  However, it is important to note that there were no cancelations of 
any health impact assessment due to complexity.  The level of efficacy was defined 
via a four-framework model.  The four categories of framework chosen to identify 
effectiveness included a straightforward framework defined as one that leads to an 
abrupt change in decision-making.  An unspecified framework defined as something 
that creates a heightened level of awareness; however, a modification of policy is not 
justified with this choice.  Thirdly, an opportunity based framework defined as one 
that would have resulted in a policy change anyway – if rules and regulations were 
properly enforced.  Finally, ineffectual identifies the framework that results in a 
health impact assessment being completely disregard in the decision-making process. 
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Wismar et al. (2007) revealed a number of factors indicating goal attainment.  To 
begin with, discoveries revealed on how to effectively deal with stressors 
encountered within the community.  Factors regarding the amount of time to 
complete decision-making processes in the community were revealed.  The 
stakeholders who were crucial in the decision-making process within the organization 
were uncovered.  This was a crucial point because it enhanced not only the support of 
the community but leadership as well.  Streamlining the process allowed those 
important to the decision-making process to be accountable early in the development 
of the proposal.  Effective healthcare systems and the costs associated with them 
were discovered.  Wismar et al. (2007) suggested that efficacy be computed via the 
assessment of three components.  These components included health and wellness 
efficacy, populace efficacy and societal efficacy.   The components of health and 
wellness included those that encouraged the positive and reject those that proposed a 
challenge.  The component of populace included a thorough assessment of the impact 
noted on the most vulnerable section of the study population.  Societal efficacy 
integrated the health related concerns in the decision-making process.  There were 
some challenges identified in the study.  These included communication efforts with 
the decision-makers across the country.  There were differences of opinions noted 
especially pertaining to the objectives of the various sectors identified in the study 
used to measure efficacy.     
     Bourcier, Charbonneau, Cahill and Dannenberg (2015) conducted a study based in 
Seattle Washington with an organization called the Group Health Research Institute.   
The researchers compiled a total of twenty-three  U.S. based Health Impact 
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Assessments, completed during the years 2005-2013, with the sole purpose of 
measuring the efficacy of the changes implemented within the community.  Various 
segments were assessed including ecosystems, city transport, energy as well as 
healthcare.   The levels of impact were considered to be on a regional and state level.  
When the Health Impact Assessment reports were reviewed,  various disciplines were 
interviewed including key policy makers, stakeholders and actual HIA team 
members.  A total of one hundred sixty six interviews and one hundred forty four 
surveys were completed.  Forty-eight percent of the policy makers indicated that the 
HIA’s were crucial in their decision making process.  These recommended changes 
were incorporated directly into the action plan.  These plans of action affected both 
policies and community programs.  In fact, some of the results revealed that 
outcomes were beneficial far beyond the outcome date.  The results revealed that the 
working relationships became stronger by the knowledge gained in the process.  The 
collaborative efforts allowed the policy makers and stakeholders to identify 
commonalities between the health and non-related health entities.  Recognizing these 
differences allowed the stakeholders to participate in the conflict-resolution process 
with ease.  When conflict-resolution is simplified, complex problem solving among 
the group is not such a tedious task (Gase, Pennotti and Smith, 2013).  As the 
efficacy of these changes within these HIA’s were assessed,  Bourcier et al. (2015) 
identify a number of successful attributes.  The process allows collaboration between 
the policy makers and stakeholders.  With this type of engagement, key personnel 
required for each dimension of the process is expedited and a plan of action can be 
more readily developed with full recommendations.  Implementing these 
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recommendations with the right individuals and at the right time is crucial to program 
success.  Bourcier et al. (2015) identified challenges within this process as well.  
Reportedly, the researchers miscalculated the amount of time, energy and effort 
required for a project of this magnitude.  Accessibility of the data was more of an 
arduous task than anticipated.  Finally, even though proper collaboration ignited the 
success of the study, facilitating the engagement between the stakeholders and policy 
makers required countless hours of strategic planning.     
     As America undergoes drastic changes in healthcare, Rhodus, Fulk, Autrey, 
O’Shea and Roth (2013) suggest that the stakeholders and policy-makers evaluate the 
established strategies in order to determine efficacy.  Stakeholders and policy makers 
are often responsible for the changes and a proper evaluation of plan is needed in 
order to promote productivity.  In the healthcare industry this includes identifying 
plans of action, screening the present process, identifying productive and non-
productive choices, assessing the consequences of continuing poor practices, creating 
recommendations and reporting those recommendations to pertinent stakeholders and 
policy makers (Rhodus et al., 2013).   
     This action based learning research within the pharmaceutical industry provides an 
opportunity to “break new ground” in a setting that traditionally has been accused of 
being the culprit in matters concerning the escalating cost of healthcare in the United 
States (Kantarjian et al., 2013).  With this extensive literature review, evaluating  
healthcare cost and the present interventions seem to be an ideal method to determine 
if the present plan of action is effective.  This action based learning research allows 
an authentic view of such assessment.  With the data presented regarding this 
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workplace problem, the stakeholders and policy-makers shall grasp a deeper level of 
understanding of the health benefits and cost savings of diabetes medications used to 
treat type II diabetes in the state of Georgia (Herr and Anderson, 2005; Pearson and 
Clair, 1998).  
 
2.6  Summary 
     The literature review reveals that type II diabetes is a costly and chronic disorder.  
In fact, the ADA (2013) reveals a total economic cost of diabetes as being 
approximately $245 billion.  Needless to say,  this disease is costly not only in 
monetary expenditure but quality of life for the consumer as well.  The medications in 
the marketplace used to treat diabetes are primarily for adults; however, studies show 
that children are being diagnosed with type II diabetes at an alarming rate (Boyle et 
al., 2010).  As type II diabetes strikes our youth, so does the complications associated 
with this chronic disorder.  Creating an action plan to address the risk factors that 
contribute to this disorder is crucial in order to effectively deal with issues (ADA, 
2015).  One of those risk factors includes weight gain (Carlson & Campbell, 1993).  
According to Hodgson and Kizior (2014), many of the treatment modalities 
developed to treat type II diabetes involve weight gain.  Nearly eighty percent of the 
persons diagnosed with type II diabetes are overweight (ADA, 2015).  In order to 
create a viable plan of action to address this problem, the industry must take an 
extensive close examination into all aspects of pathophysiology of the disease 
process, epidemiological cost factors as well as the pharmacological agents.   
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     Identifying the true indirect and direct cost of the various medications used in the 
market to treat type II is a crucial step in diabetes management (Caro et al., 2002).  
Revealing the cost savings and health benefits of the medications being prescribed 
allows the stakeholders to have a sense of clarity for the pharmaceutical agents 
ordered.  The consequences of not understanding the causative factors associated with 
this chronic disorder, type II diabetes, is dangerously expensive (Boyle et al., 2010).   
     Cost effectiveness of treatments for type II diabetes and other chronic disorders is 
a major concern for America’s economy.  According to ADA (2018), the total cost of 
diabetes continues to escalate regardless of the new treatment modalities.  Having a 
sense of clarity in terms of the indirect and direct cost of the treatment modalities for 
type II diabetes allows the stakeholders to make more informed choices  (Bolen et al., 
2007).   
     The emergence of the hypotheses identified in this study stemmed from the high 
cost of prescription medications to the American public, government, employers and 
health insurance companies.  When viewed in isolation, the direct cost of prescription 
medications can seem quite expensive. However, a broader view of the cost of 
medications, which include: 
• Cost of complications avoided due to the use of specific medications 
• Hospitalization cost avoided due to the use of specific medications 
• Emergency Department visits avoided due to the use of specific medications 
• Prevention of complications due to the use of specific medications 
 
120 
 
can provide greater clarity concerning data based evidence in the assessment of the 
true cost of medication therapy (Herman, 2011).  This doctoral thesis examined the 
direct and indirect cost of medications used to treat type II diabetes using a broader 
view of the actual cost of these medications.  The aforementioned studies demonstrate 
the importance of health impact assessments on implementing change within an 
industry.  
 
2.7  Hypotheses 
     The general null hypothesis for this action learning based study was created 
through the processes identified in the theoretical framework of creating  a ”knowing 
organization”  via the links of sense making, knowledge creating and decision 
making.  The null hypothesis was there is not a correlation between health benefits 
and cost savings of diabetes medications used to treat type II diabetes in the state of 
Georgia, United States of America.  The data gathered from this action learning based 
study was to assess the following hypotheses:   
         1.  There are no more cardiovascular events resulting in cardiovascular 
rehabilitation in type II diabetic persons in Georgia prescribed combination generic 
medications for type II diabetes than persons prescribed monotherapy generic agents 
and non-generic agents for type II diabetes. 
 2.   There are no more renal insufficiency episodes resulting in dialysis 
treatments in type II diabetic persons in Georgia prescribed generic medications (both 
monotherapy and combination) for type II diabetes than persons prescribed non-
generic medications for type II diabetes. 
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 3.  There are no more amputations experienced in type II diabetic persons in 
Georgia prescribed generic medications (both monotherapy and combination) for type 
II diabetes than persons prescribed non-generic agents for type II diabetes. 
 4.  There are no more cancer episodes experienced in type II diabetic persons 
in Georgia prescribed generic (combination) medications and DPP4 inhibitors for 
Type II diabetes than persons prescribed (monotherapy) non-generic agents.    
 5.  There are no differences in the absenteeism rate of type II diabetic persons 
in the work force in Georgia; regardless, of the pharmacological treatments prescribed 
for type II diabetes.  
 6.  There are no differences in weight gain in type II diabetic persons in 
Georgia; regardless, of the pharmacological treatment prescribed  
 7.  There are no differences in the overall level of satisfaction of prescribed 
treatment of choice for type II diabetic persons in Georgia.   
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CHAPTER 3:  METHODOLOGY 
      
3.1  Introduction 
Chapter 3 consists of information gathered to characterize the type II diabetes 
population in Georgia, USA.  It involves a description of the subject population and 
research sampling, research setting, ethical considerateness and research design.  The 
research instrument utilized in the study, techniques concerning the data collection, 
data recordings and an analysis have been explained.   
     The purpose of the research study was to compare the health benefits and cost 
savings of diabetes medications used to treat type II diabetes in the state of Georgia, 
United States of America.  A questionnaire implemented in this study was developed 
to determine the health benefits and cost savings of diabetes medications used to treat 
type II diabetes.   
 
3.2  Research Setting 
     The setting for the study was various diabetes support groups in Georgia.  These 
diabetes support groups are managed by clinic directors.  The clinic directors granted 
permission to obtain consent and distribute the instrument to the study participants.  
The economy of these various research settings cities in Georgia were mainly 
agricultural business and manufacturing.  
 
3.3  Population and Sampling  
     The population for this action learning based research was comprised of persons 
over the age of 18 with a diagnosis of type II diabetes and was presently prescribed at 
least one FDA approved medication for diabetes.  The study participants’ revealed 
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their information voluntarily.  Those study participants, who met the criteria, were 
provided with a copy of their rights and the consent forms were signed accordingly. 
This research population was considered a purposive controlled sample used to 
identify the overall fiduciary impact of the pharmaceutical choices used to treat type 
II diabetes in the state of Georgia (Easterby-Smith et al., 2008 p. 218).  The 
participants were chosen from those persons diagnosed with type II diabetes who 
attended diabetes support group meetings in Georgia, United States.  The following 
indicators were specific criteria for subject selection:  adult over the age of 18;  able 
to  read, write and comprehend the English language;  have a diagnosis of type II 
diabetes; presently have a prescribed treatment regimen of at least one FDA approved 
medication for type II diabetes; not be hearing impaired and able to remain seated for 
at least 15 minutes. 
     Three hundred and one subjects meet the criteria for this action learning based 
research study.  Three hundred and one subjects participated in the research study 
primarily because of the purposive controlled sample group and the fact that the 
clinic directors had provided permission for the investigator’s presence in the facility 
(Leedy & Ormrod, 2005).   
 
3.4  Ethical Considerateness 
     Permission to conduct the study was acquired from the Committee on Research 
Ethics (Health and Human Subjects Committee) of the University of Liverpool.  The 
clinic directors of identified diabetes treatment centers participating in the study 
provided written consent as well (Appendix A).   The participants, who met identified 
criteria for inclusion in the study,  were provided information about the study 
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(Appendix B).  These individuals were requested to authorize consent to participate 
in the study by signing an actual consent form (Appendix C).   
 
3.5  Research Design 
     This action learning based research implemented a simple ex post facto design.  
This design was chosen to be assured that a complete and factual comparison of the 
health benefits and cost savings of diabetes medications used to treat type II diabetes 
in the state of Georgia, United States of America.  The independent variable, 
medications used to treat type II diabetes, was present prior to this study; therefore, 
this study is considered a simple ex post facto design (Leedy & Ormrod, 2005).  The 
study participants were not randomly assigned to a treatment condition because all 
participants were indeed diagnosed type II diabetic subjects.  However, the 
investigator did manipulate the categorization of the responses as it related to the 
independent variable identified by the study participant.  This manipulation of the 
categorization of the independent variable(s) allowed the researcher to determine the 
relevant response as it relates to the dependent variables, which have been identified 
as cost and health benefits of the medications used to treat type II diabetes.  The 
responses were examined by the investigator.  A comparison of the health benefits 
and cost savings of diabetes medications used to treat type II diabetes in the state of 
Georgia, United States of America was then determined via statistical analysis.   
 
3.6  Research Instrument 
     The demographic questionnaire and investigative questions were created based 
upon the guiding inquiries of the study and the literature reviewed.  The investigator 
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explored various healthcare journals, managed care journals, interviews imploring 
mixed methodologies and data analysis techniques (Herr & Anderson, 2005; Boyd, 
2002; Raelin, 2003; Leedy & Ormrod, 2005; Choo, 2006).  Using the concepts 
identified in the theoretical framework of the Knowing Organization (Choo, 2006), 
the questions were created.  According to Choo (2006 p. 230), in sense-making when 
attempting to access information during the process of information needs, clarity is 
crucial.  Conflicting interpretations and meanings should be avoided.  In the process 
of information seeking, accessing the channels of communication may influence the 
information seeking behavior.  In the process of information use, information can be 
shaped by cognitive schemas of the various stakeholders – including the investigator.   
The data driven instrument used to collect the data was established (Appendix D).  
The first three questions of the study dealt with the demographics of the study 
participants.  The fourth question dealt with the duration in which the study 
participant had been diagnosed with type II diabetes.  The fifth question revealed the 
identification of the type of medications that were being prescribed for the type II 
diabetic study participants.  The sixth question revealed whether or not the study 
participants actually experienced any long term complications associated with type II 
diabetes.  The seventh question revealed whether or not the study participant had 
gained any weight since he/she had been prescribed medications for type II diabetes.  
The eighth question revealed whether or not the study participant remained in the 
workplace and if so, an absenteeism rate was established.  The ninth question 
revealed if the study participant had experienced any cancer episodes since he/she 
had been diagnosed and treated for type II diabetes.  The tenth question revealed 
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whether or not the study participant was satisfied with his/her treatment regimen for 
type II diabetes.   
     The questionnaire was submitted to the dissertation committee and interview 
questions were revised as recommended.  The questions were modified until they 
were easily comprehensible and capable of obtaining the participants’ experience 
concerning their diabetes treatment regimen.   
 
3.7  Theoretical based data collection and recording  
     The following approach was used to collect and record data for this action 
learning research based study:  The investigator reviewed the interview process with 
the participants before the actual interview was conducted.  This step was 
implemented in order to minimize disruptions and to reassure the research 
participants of the confidentiality of the information provided during the interviews.  
Full consent was obtained from each participant prior to the actual interview.  The 
participants were notified that each questionnaire was coded in an effort to maintain 
confidentiality.  The alpha / numerical coding allowed the investigator to be the only 
person able to identify the study participant(s).  With the implementation of this 
coding process, the participants’ given names were not identified on the 
questionnaires or any meeting notes written by the investigator.  The participant(s) 
was only referred to by the codes assigned by the investigator.  Prior to the interview, 
each participant was provided with a copy of their rights as study participants.  
Leaving a copy with the study participant, the investigator obtained a signed copy of 
these rights from the participant(s) in an effort to verify participant comprehension.   
All research recorded notes as well as completed questionnaires remains properly 
127 
 
protected, secured and maintained by the investigator.  The data for this investigative 
study was obtained through a semi-structured interview process of the chosen 
participants from the various diabetes support group meetings throughout the state of 
Georgia.  The technique of semi-structured interviews was implemented in order to 
allow the investigator the liberty to elaborate on any of the participant responses if 
needed.  The investigator referenced an interview guide from which the questions 
were properly structured (Boyd, 2002).  Meeting notes were written per the 
investigator during the interview.  The researcher adhered to the announced estimated 
time for each interview, which was 10-15 minutes.  There were three hundred one 
(301) interviews conducted during the time frame of November, 2014 through 
January, 2015.    Upon the completion of the interview process, the information was 
reviewed with the participant(s).  The purpose of reviewing the information with the 
study participant is due to the fact that the implementation of the interview process is 
a part of knowledge sharing (Choo, 2006 p. 308).  Choo (2006) identifies knowledge 
sharing as a norm that is reinforced through trust and reciprocity.  Reviewing the 
gathered information for accuracy is a worthwhile gesture to reiterate the importance 
of this information concerning personal experiences and practices.  
 
3.8  Data Analysis 
     In the action learning based research study, micro-costing was utilized to obtain 
information regarding direct medical costs (medication regimen, healthcare visits, 
long term complications associated with diabetes) as well as indirect medical costs 
(absenteeism rates) .  Respectively, GoodRx, Inc. and CostHelper, Inc., were 
implemented to authenticate pricing used for medication(s) and healthcare services / 
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procedures.  A statistical analysis was performed on the assembled data.  The data 
was computed by using both inferential and descriptive statistics.  Descriptive 
statistics were used as a method to calculate distributions of frequency and various 
numerical values.  Inferential statistics were implemented for the chi-square test, 
which was applied to the 6x4 contingency table.  The chi-square test was applied to 
the contingency table in order to assess the significance of the various outcomes 
identified within the study.  The calculation of the chi-square statistic performed a 
comparison of frequencies.  These frequencies can be identified as those observed 
during the data collection process and the expected outcomes if there was a null 
relationship between the variables.  The identified outcomes 
were identified in the rows and columns of the contingency table.   
     A summarization of the calculated differences between the observed and expected 
frequencies for each section within the table was identified and documented.  For this 
action learning based research study, a 6x4 contingency table was utilized.   
According to Leedy and Ormrod (2005 p. 274), chi-square is used to determine how 
closely observed frequencies and probabilities complement the expected frequencies 
or outcomes.  Using chi-square as a nonparametric statistic, which is appropriate to 
compute this nominal data.  The calculation of the degrees of freedom (dƒ), is 
implemented to determine whether the null hypothesis can be rejected or not.  It is 
based on the variables and the outcomes identified in the calculated data.  According 
to Leedy and Ormrod (2005), P-value can be defined as a calculated probability.  To 
further explain, it is determining the probability of a variate that would assume a 
value greater than or equal to the observed value strictly by chance.  
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3.9  Summary 
     Chapter 3 is a descriptive chapter used to identify the procedures for selecting the 
population for this study.  The study participants were provided with information 
sheets explaining the purpose of the research and the importance of confidentiality.  
Before the questionnaires were distributed, written consent was obtained from each 
study participant.    
     This is an action learning based research study.  The design used is known as a 
simple ex post facto design.  The study participants (N=301) were adult persons 
diagnosed with type II diabetes who were presently on a treatment regimen of at least 
one FDA approved medication used to treat type II diabetes.  The settings used for 
this study were various diabetes support group meetings across the state of Georgia, 
United States during the months of  November, 2014 through January, 2015.   
     The instrument, consisting of ten (10) questions, was created from concepts 
derived the theoretical framework of the Knowing Organization (Choo, 2006).   This 
instrument was administered by the investigator of the study.  The responses from the 
instrument was used to compare the cost savings and health benefits of medications 
used to treat type II diabetes in the state of Georgia, United States.   The instruments 
identified for collecting subject data and recording responses have been described in 
Chapter 3.  
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CHAPTER 4:  DEMOGRAPHICS AND SENSE-MAKING OF THE RESULTS 
 
4.1  Introduction      
This study represented a demographical and geographical diverse population of type 
II diabetics in Georgia, United States.   Inferences were made about the health 
benefits and cost savings of diabetes medications used to treat type II diabetes in the 
state of Georgia, United States of America.  Chapter 4 represents an analysis of the 
overall results by identifying the demographics of the population of the study 
participants and the results of the data gathered from the participants.  The 
aforementioned data has been respectively positioned at Section 1( Demographics of 
Sample Population) and Section 2 (Group Results) of Chapter 4.    
 
4.2  Demographics of Sample Population  
 How old are you?  Upon reviewing the ages of the study participants, the ages 
ranged from thirty seven to seventy eight.  The categorization of the age ranges is 
identified in Table 1.  See Table 1.   
AGE FREQUENCY PERCENTAGE 
30-39 28 9.30% 
40-49 37 12.29% 
50-59 112 37.20% 
60-69 101 33.55% 
70-79 23 7.64% 
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TOTAL 301 100% 
 
TABLE 1:  Age Ranges   N = 301  
Are you male or female?   Eighty percent of the study participants who responded 
were female and twenty percent of the study participants were male.  The gender 
proportions are shown in Table 2.  See Table 2.   
GENDER FREQUENCY PERCENTAGE 
MALE 61 20% 
FEMALE 240 80% 
TOTAL 301 100% 
 
TABLE 2:  Gender   N = 301 
 
What is your race?   The study participants revealed a mixture of various races 
throughout the state of Georgia.  The racial demographics are identified in Table 
3. See Table 3.   
RACE FREQUENCY PERCENTAGE 
Caucasian 153 50.83% 
African American 94 31.23% 
Hispanic 44 14.61% 
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Indian 10 10% 
Total 301 100% 
 
TABLE 3:  Racial Demographics  N = 301 
 
4.3  Group Results 
     A Comparison Study of the Health Benefits and Cost Savings of Diabetes 
Medications Used to Treat Type II Diabetes in the State of Georgia, United States of 
America.  The questionnaires were hand distributed and one hundred percent of the 
questionnaires were returned.   
How long have you had type II diabetes?  The duration in which the study 
participants had been diagnosed with type II diabetes varied a great deal – ranging 
from newly diagnosed (less than 6 months) to over twenty years.   Table 4 indicates 
the duration in which the participants had been diagnosed with type II diabetes.  See 
Table 4.     
DURATION OF 
DIAGNOSIS  (YRS) 
FREQUENCY PERCENTAGE 
0-5 84 27.90% 
6-10 97 32.22% 
11-15 02 0.66% 
16-20 104 34.55% 
➢ 20 14 4.65% 
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TOTAL 301 100% 
 
TABLE 4:  Duration of diagnosis (years) N = 301 
Please list the current medications you are presently taking for diabetes.  Upon 
gathering the data, the researcher coded the medications identified via using an 
alpha-numerical coding system signifying the medication class.  The classes of 
medications identified in this study were as follows: secretagogues {sulfonylureas 
(SU)}, sensitizers {bigunides and thiazolidinediones (TZD)}, dipeptidyl peptidase-
4 inhibitors (DPP4) and glucagon-like peptide receptor agonists (GLP-1).  Many of 
these agents were prescribed in monotherapy as well as combination therapy.  A 
categorization of the medication findings has been identified in Table 5. 
See Table 5.   
MEDICATION FREQUENCY PERCENTAGE 
MONOTHERAPY   
Biguanide 25 8.3% 
TZD 23 7.64% 
DPP4 Inhibitor 74 24.58% 
GLP1 54 17.94% 
COMBINATION   
SU + Biguanide 102 33.88% 
TZD +Biguanide 23 16.61% 
TOTAL 301 100% 
 
TABLE 5:  Medications identified in the study   N = 301 
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Have you experienced any of the following?  The following conditions were 
listed in question six:  stroke, heart attack, blindness, dialysis and amputation.  
The date of occurrence was identified to reveal if the condition was diagnosed 
before or after the diagnosis of type II diabetes.  The findings regarding these 
complications associated with diabetes were identified in Table 6. See Table 6.   
 
COMPLICATION FREQUENCY PERCENTAGE 
Stroke  3.65% 
Before diagnosis 0  
After diagnosis 11  
Heart Attack  8.97% 
Before diagnosis 2  
After diagnosis 25  
Blindness 0 0% 
Dialysis  2.65% 
Before diagnosis 0  
After diagnosis 8  
Amputation  1.32% 
Before diagnosis 1  
After diagnosis 3  
Non-Applicable 251 83.38% 
Total 301 100% 
 
TABLE 6:  Complications associated with type II diabetes N = 301 
 
Have you gained any weight since you have been taking medication(s) for 
diabetes?  If so, how much have you gained?   For simplicity, the responses to 
this question were integrated with the responses to the question regarding 
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medication identification.  If applicable, the average weight gain for each 
category has been computed and indicated in the table.  The findings to this 
question 7 can be identified in Table 7.  See Table 7.    
 
Meds & Weight Inquiry FREQUENCY PERCENTAGE 
Monotherapy   
Biguanide 25  
   Weight gain  NO 22 88% 
  Weight gain YES 3 12% 
  How much gain? 8#  
TZD 23  
  Weight gain NO 4 17.39% 
  Weight gain YES 19 82.60% 
  How much gain? 22#  
DPP4 74  
  Weight gain NO 68 91.89% 
  Weight gain YES 6 8.10% 
  How much gain? 7#  
GLP1 54  
Weight gain  NO 50 92.59% 
 Weight gain  YES 4 7.40% 
How much gain? 6#  
Combination     
SU + Biguanide 102  
  Weight gain  NO  3 2.94% 
  Weight gain YES 99 97.05% 
  How much gain? 25#  
TZD + Biguanide  23  
  Weight gain  NO 2 8.69% 
  Weight gain YES 21 91.30% 
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  How much gain? 25#  
TOTAL 301  
 
TABLE 7:  Weight gain in conjunction with treatment N = 301 
 
Are you still active in the work force?  If so, how many days have you had to 
“call in sick” due to your diabetes?  This question pertains to the absenteeism 
rates relating to type II diabetes.  Table 8a and 8b reveal the findings of the study 
participants’ employment status and their rates of absenteeism (categorized via 
age) respectively.  See Tables 8a and 8b.   
Employment Status FREQUENCY PERCENTAGE 
Unemployed 53 17.60% 
Employed 248 82.39% 
   Days Absent 150  
Total 301 100% 
TABLE 8A:  Employment Status with overall absenteeism rating  N = 301 
 
 
Absenteeism Rates FREQUENCY 
Age:  30-39 28 
   unemployed 0 
   employed 28 
 Absent from work   12 days (average) 
Age:  40-49  37 
  unemployed 0 
  employed 24 
 Absent from work 24 days (average) 
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Age: 50-59 112 
  unemployed  0 
  employed 112 
 Absent from work 54 days (average) 
Age:  60-69 101 
  unemployed 29 
  employed 72 
Absent from work 60 days (average) 
Age 70-79 23 
  unemployed 23 
  employed  0 
Absent from work N/A 
Total N = 301 
 
TABLE 8B: Employment Status with absenteeism rating according to age N=301 
  
Have you been diagnosed with cancer since you have been diagnosed with 
diabetes?  If so, where was the cancer and when was the date of occurrence?   
The findings revealed four percent (4%) of the study participants had been diagnosed 
with (various) cancers.  Seventy five percent (75%) of these cancer diagnoses 
occurred after the patient had been diagnosed with type II diabetes.  Table 9 depicts 
these findings.  See Table 9.   
Cancer Diagnosis FREQUENCY PERCENTAGE 
No 289 96.01% 
Yes 12 3.98% 
Types of Cancer   
Breast 2  
Before diagnosis 0  
After diagnosis 2  
Colon 4  
Before diagnosis 0  
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After diagnosis 4  
Liver 3  
Before diagnosis 1  
After diagnosis 2  
Pancreas 3  
Before diagnosis 0  
After diagnosis 3  
Total N = 301 100% 
 
TABLE 9:  Categorized cancer diagnosis   N = 301 
 
Are you satisfied with your present treatment regimen for diabetes?  The 
findings of this question identifies whether or not the study subjects are satisfied with 
their present treatment for diabetes management.  These findings are reflected in 
Table 10. See Table 10. 
Response FREQUENCY PERCENTAGE 
Yes 187 62.12% 
No 114 37.87 
Total 301 100% 
 
TABLE 10:  Treatment regimen satisfaction  N = 301 
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CHAPTER 5:  EVALUATION OF OUTCOMES 
      
5.1  Introduction 
     The collected data related to the direct and indirect cost of diabetes were 
statistically analyzed using inferential and descriptive statistics.  Inferential statistics 
used the chi-square test which was applied to the 6 x 4 contingency table.  Descriptive 
statistics employed were response rates, frequency distributions, numerical values 
identifying calculated responses pertaining to the pharmaceutical agents and 
comorbidities (relating to diabetes) identified in the interview process.  The 
qualitative analysis portion of the study demonstrated that the responses of the 
research subjects were multifaceted and complex.  The responses to the 
questionnaires were analyzed using the chi-square test within a 6 x 4 contingency 
table to compute the significance of the comparison.  This analysis also indicated that 
there are strong correlations relating to the disease process of diabetes and certain 
long term complications as it is related to cost.  The similar themes that materialized 
throughout these responses reiterated the challenges that individuals who have been 
diagnosed with type II diabetes struggle with in regards to their well-being on a daily 
basis (Gray et al., 2000).   
 
5.2  Research Question Outcomes 
     The first three questions of this study dealt with demographics.  The first question 
revealed that within this study group of participants the ages ranged from thirty seven 
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to seventy eight years of age.  The majority of the participants were of female (80%) 
and Caucasian (50.83%).   
     The fourth question dealt with the duration of which the participant had been 
diagnosed with type II diabetes.  The durations varied with this study group.  In this 
action learning process, recognizing the duration of the illness was beneficial as it 
corresponds with the pharmacological therapies provided and the overall cost of 
treatment.  The participants ranged from being newly diagnosed to a time of diagnosis 
of over twenty years.  The duration of diagnosis group in the 16-20 year range was 
identified as the most prominent group with a rate of 34.55%; whereas, the group 
ranging from 11-15 years was least represented at 0.66%.   
     The fifth question revealed the identification of the type of medications that were 
being prescribed for these type II diabetic participants.  Upon cross-referencing the 
data, this investigator discovered that there was a correlation in the types of 
medications being prescribed to certain age groups of study participants.  This study 
revealed that those study participants who were eligible for Medicare Part D, age 65 
and older, were being prescribed medications in three primary categories – 
sulfonylureas, thiazolidinediones and biguanides.  These medications were either 
ordered as monotherapy or in combination therapy with each other.  Those 
participants who were under the age of 65 and who remained in the workforce with 
commercial insurance were prescribed medications in three primary categories as 
well – biguanides, DPP4-inhibitors and GLP1 receptor agonists.  Either the DPP4 
inhibitor or GLP1 receptor agonist would be ordered as monotherapy or in 
conjunction with a biguanide.   
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     The sixth question revealed whether or not the study participants experienced any 
long-term complications associated with diabetes such as stroke, heart attack, 
blindness, (end stage renal disease resulting in) dialysis or amputation.  The date of 
occurrence was identified to determine if the participant experienced the incident 
before or after the type II diabetes diagnosis.  This study revealed that 16.62% of the 
participants experienced complications identified in the questionnaire.  Of this 
16.62%, 94% of these participants experienced these complications after they had 
been diagnosed with type II diabetes.  Two of the participants experienced heart 
attacks before they were diagnosed.  One of the participants experienced a ‘blood 
clot’ after a surgical procedure, which resulted in a heart attack.  The other participant 
was diagnosed with coronary heart disease and had a heart attack two years before 
being diagnosed with type II diabetes.  The participant that revealed the BKA (below 
the amputation) which occurred before the type II diabetes diagnosis disclosed that 
this amputation was due to trauma (car accident).   
     The seventh question revealed whether or not the participants have gained weight 
since he/she has been taking medication(s) for type II diabetes.  The study results 
substantiated information noted within the literature regarding the medications used 
for diabetes and their association with weight gain. The participants taking agents 
within the categories of sulfonylureas and thiazolidinediones revealed the most 
weight gain albeit in monotherapy or combination therapy.  The Medicare eligible 
age group of 65 and older as previously mentioned is being prescribed this category 
of agents more often than other age groups within this study.   
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     The eighth question dealt with whether or not the study participant remained in the 
workforce and if so had he/she ever had to “call in sick” (within the past year) due to 
a clinical complication associated with type II diabetes.  The information regarding 
absenteeism and age was cross-referenced.  The study revealed that after the age of 
fifty the rates of absenteeism actually more than doubled for those participants who 
remained in the workforce.   
     The ninth question revealed whether or not the study participant had been 
diagnosed with cancer of any kind and if so, did the diagnosis occur before or after 
the diagnosis of type II diabetes.  Four (4) percent of the study population had indeed 
been diagnosed with (various) cancers.  Of this four (4) percent, one of the 
participants revealed being diagnosed with liver cancer before he was diagnosed with 
type II diabetes.  The participant revealed that the liver cancer was detected after 
many years of being diagnosed with Hepatitis C.  This was (an undetermined amount 
of years) before the type II diabetes diagnosis.  On the other hand, seventy five (75) 
percent of the participants were indeed diagnosed with various cancers – after the 
type II diabetes diagnosis.  The cancers identified in this study were as follow: breast, 
colon, liver and pancreas.   
     The tenth question revealed whether or not the study participants were satisfied 
with their present treatment for diabetes management.  The majority (62.12%) of the 
participants were satisfied with their present treatment regimen.  During the interview 
process, many of the participants admitted to experiencing side effects from the 
medication; however, still revealed that they were satisfied with the present regimen 
due to affordability of the treatment.   
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5.3   Discussion of the cost savings and health benefits of these findings 
     Micro-costing was used as a method to determine the cost savings and health 
benefits of the reported findings.  Micro-costing can be defined as a cost estimation 
method, which permits a detailed assessment of reported healthcare costs, albeit 
direct or indirect (Frick, 2009; Smith, 2003).  GoodRx, Inc., a private company not 
sponsored or affiliated with any pharmaceutical company, was implemented to 
identify pricing of medications reported by study participants.  CostHelper, Inc. a 
privately owned company not affiliated with any particular healthcare company was 
used to provide information regarding the cost of the various healthcare services and 
procedures reported by study participants.  These unitary costs for the medications, 
healthcare services and procedures were estimated utilizing this micro-costing 
technique.  The computed nominal figure was then divided by the number of 
participants according to the category of medication identified on the instrument, 
generic or non-generic.  Participants in the generic medication  group were 
identified as those prescribed a biguanide (Metformin), thiazolidinedione (TZD), 
TZD + Met combo (combination of thiazolidinedione and Metformin), SU + Met 
(combination of sulfonylurea and Metformin) because these medications were listed 
as generic by the FDA at the time of this study (Hodgson & Kizior, 2014) .  
Participants in the non-generic mediation group were identified as those prescribed a 
DPP4 inhibitor or a GLP1 agonist because these medications were considered non-
generic, according to the FDA, at the time of this study (Hodgson & Kizior, 2014).  
     The mean annual costs of the pharmaceutical treatments, healthcare services / 
procedures as well as absenteeism rates identified in this study are outlined in detailed 
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with a summation to follow.  The tabulated costs of the overall treatment, direct and 
indirect, were divided by the number of study participants in each category of 
treatment. The cost savings and health benefits of the study participants prescribed 
generic versus non-generic were computed and identified.  The total, direct and 
indirect, cost of the group taking generic medications was $149,382.23.  The total, 
direct and indirect, cost of the group taking non-generic medications was $25,070. 54.  
A summation of the findings can be reviewed in Table 11.      
 
5.4  Pharmacological Treatment:  MET (Monotherapy treatment of Metformin) 
 In this study, twenty five participants had been prescribed Metformin 
(monotherapy) as the treatment of choice for type II diabetes.  This medication is in 
the biguanide category.   The average annual cost of healthcare provider services for 
this group of patients was $2,047.00 per person.  This medication, generic at the 
implementation of this study, carried a nominal value of $96.00 per year (per person).  
There were no reported cardiovascular events resulting in cardiac rehabilitation for 
this group of study participants.  There was one reported case of an amputation.  The 
average cost to this amputation was $50,000.  There were three reported cases of 
hemodialysis, commonly known as kidney dialysis, which had an average cost of 
$72,000 per episode.  There were no cancer treatments reported in this group.  The 
absenteeism rate for the Metformin group of participants computed an annual average 
of $654.00 per person.  The monotherapy group of Metformin participants reported 
less weight gain than when used in combination therapy with other oral agents.  
Eighty-eight percent of the patients denied gaining weight with this therapy.  Of the 
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twelve percent of the patients who admitted to gaining weight, the average weight 
gain was approximately eight pounds within a year.     
Within this group of participants, the cost associated with the treatment of 
(monotherapy) Metformin is as follows:   
• Quarterly physician appointments with the healthcare provider (2027 x 
25) $51,175.   
• Cost of medication used to treat type II diabetes (96x25) $2400.  
• Cardiac Rehabilitation  (0) 
• Dialysis ($72,000 x 3) $216,000 
• Amputation ($50,000 x 1) $50,000 
• Cancer Treatments (0) 
• Absenteeism  Rate ($654 x25)  $16,350.00 
The total annual amount for the treatment of this (monotherapy) 
Metformin group of participants was $335,925.  
          
5.4.1  Pharmacological Treatment:  TZD (Monotherapy treatment of 
Thiazolidinedione) 
 In this study, twenty three participants had been prescribed a class of 
medication called Thiazolidinedione as a treatment of choice for type II diabetes.  The 
average annual cost of healthcare provider services for this group of patients was 
$18,434.00 per person.  This medication, generic at the implementation of this study, 
carried a nominal value of $624.00 per year (per person).  There were three reported 
cardiovascular events resulting in cardiac rehabilitation for this group of study 
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participants.  Each event averaged $89,676.00.  There were no reported cases of an 
amputation in this group.  There were two reported cases of hemodialysis, which had 
an average cost of $72,000 per episode.  There was not any cancer treatments 
reported in this group.  The absenteeism rate for the Thiazolidinedione group of 
participants computed an annual average of $1960.00 per person.  This monotherapy 
group of the Thiazolidinedione participants reported a significant amount weight 
gain.  In fact, 82.60% reported gaining an average of twenty-two pounds within a 
year.     
Within this group of participants, the cost associated with the treatment of 
(monotherapy) Thiazolidinedione is as follows:   
• Quarterly physician appointments with the healthcare provider (18,434 
x 23)  $423,982.   
• Cost of medication used to treat type II diabetes (624 x 23) $14,352   
• Cardiac Rehabilitation  (89,767x3) $269,301 
• Dialysis ($72,000 x 2) $144,000 
• Amputation (0)  
• Cancer Treatments (0) 
• Absenteeism  Rate ($1960 x 23)  $45,080.00 
The total annual amount for the treatment of this (monotherapy) group of 
Thiazolidinedione participants was $896,715.  
 
 
 
147 
 
5.4.2  Pharmacological Treatment:  DPP4 (Dipeptidyl  peptidase-4 inhibitor class) 
 In this study, seventy four participants had been prescribed a class of 
medication belonging to the dipeptidyl  peptidase - 4 inhibitor class as a treatment of 
choice for type II diabetes.  The average annual cost of healthcare provider services 
for this group of patients was $7409.00 per person.  This medication, non-generic at 
the implementation of this study, carried a nominal value of $4147.00 per year (per 
person).  There were two reported cardiovascular events resulting in cardiac 
rehabilitation for this group of study participants.  Each event averaged $19,552.00.  
There were no reported cases of an amputation or dialysis in this group.  There were 
four cases of cancers resulting in treatments for this group.  The average cost of these 
treatments was $23,090 per person.   The absenteeism rate for the DPP4 group of 
participants computed an annual average of $967.00 per person.  The majority of the 
DPP4 group of participants did not report weight gain with their therapy.  In fact, 
91.89% denied gaining weight while on the medication.  Only 8.10% of the 
participants admitted to gaining weight – averaging approximately seven pounds in a 
year.      
Within this group of participants, the cost associated with the treatment of the 
DPP4 group is as follows:   
• Quarterly physician appointments with the healthcare provider (7409 x 
74)  $548,266   
• Cost of medication used to treat type II diabetes (4147 x74) $306,878   
• Cardiac Rehabilitation  (19,552 x 2) $39,104 
• Dialysis (0) 
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• Amputation (0)  
• Cancer Treatments (23,090 x 4) 92,360 
• Absenteeism  Rate ($967 x 74)  $71,558.00 
The total annual amount for the treatment of this group of DPP4 
participants was $1,058,166.  
 
5.4.3  Pharmacological Treatment:  TZD + MET (combination treatment of 
thiazolidinedione + metformin)  
 In this study, twenty – three participants had been prescribed a combination 
medication with the ingredients of a thiazolidinedione and metformin for type II 
diabetes.  The average annual cost of healthcare provider services for this group of 
patients was $12,044.00 per person.  This medication, non-generic at the 
implementation of this study, carried a nominal value of $1626.00 per year (per 
person).  There were ten reported cardiovascular events resulting in cardiac 
rehabilitation for this group of study participants.  Each event averaged $81,934.00.  
There were two reported cases of an amputation in this group, which averaged 
$50,000 each.  There were no reported cases of hemodialysis nor amputations within 
this group of participants.   There were ten reported cases of cancer treatments 
reported in this group.  These cancer treatments averaged $52,327.00 per episode.   
The absenteeism rate for this combination therapy of TZD /Metformin group of 
participants computed an annual average of $2300.00 per person.  This group of 
participants reported a significant amount weight gain.  In fact, 91.30% reported 
gaining an average of twenty-five pounds within a year.     
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Within this group of participants, the cost associated with the treatment of the 
thiazolidinedione + metformin combination therapy is as follows:   
• Quarterly physician appointments with the healthcare provider (12,044 
x 23)  $277,012   
• Cost of medication used to treat type II diabetes (1626 x 23) $37,398   
• Cardiac Rehabilitation  (81,934 x 10) $819,340 
• Dialysis (0) 
• Amputation (0) 
• Cancer Treatments (52,327 x 10) $523,270 
• Absenteeism  Rate ($2300 x 23) $52,900 
The total annual amount for the treatment of this combination therapy of 
thiazolidinedione + metformin was $1,711,920 
 
5.4.4  Pharmacological Treatment:  SU + MET (combination treatment of 
sulfonylurea + metformin)  
 In this study, one hundred two participants had been prescribed a combination 
medication with the ingredients of a sulfonylurea and metformin for type II diabetes.  
The average annual cost of healthcare provider services for this group of patients was 
$9302.00 per person.  This medication, generic at the implementation of this study, 
carried a nominal value of $185.00 per year (per person).  There were ten reported 
cardiovascular events resulting in cardiac rehabilitation for this group of study 
participants.  Each event averaged $67,089.00.  There were two reported cases of an 
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amputation in this group, which averaged $50,000 each.  There were three reported 
cases of hemodialysis, which had an average cost of $72,000 per episode.  There were 
four reported cases of cancer treatments reported in this group.  These cancer 
treatments averaged $33,480 per episode.   The absenteeism rate for this 
SU/Metformin group of participants computed an annual average of $2047.00 per 
person.  This group of participants reported a significant amount weight gain.  In fact, 
97.05% reported gaining an average of twenty-five pounds within a year.     
Within this group of participants, the cost associated with the treatment of the 
Metformin/sulfonylurea combination therapy is as follows:   
• Quarterly physician appointments with the healthcare provider (9307 x 
102)  $949,314   
• Cost of medication used to treat type II diabetes (185 x 102) $18,870   
• Cardiac Rehabilitation  (67,089 x 10) $670,890 
• Dialysis ($72,000 x 3) $216,,000 
• Amputation (50,000 x 2) $100,000 
• Cancer Treatments (33,480 x 4) $133,920 
• Absenteeism  Rate ($2047 x 102) $208,794.00 
The total annual amount for the treatment of this combination therapy of  
sulfonylurea +metformin participants was $2,297,686  
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5.4.5  Pharmacological Treatment:  GLP1 (Glucagon  like peptide -1 receptor 
agonist) 
 In this study, twenty seven participants had been prescribed a class of 
medication called Glucagon - like peptide -1 receptor agonists as a treatment of 
choice for type II diabetes.  The average annual cost of healthcare provider services 
for this group of patients was $3,458.00 per person.  This medication, non-generic at 
the implementation of this study, carried a nominal value of $6223.00 per year (per 
person).  There were not any reported dialysis treatments, amputations, cancer nor 
cardiovascular events resulting in cardiac rehabilitation for this group of study 
participants.   The absenteeism rate for the Glucagon – like peptide -1 receptor 
agonist group of participants computed an annual average of $1090.00 per person.  
This group of the Glucagon – like peptide -1 receptor agonist participants did not 
report a significant amount weight gain.  In fact, 92.59% reported that they had not 
gained any weight while on this treatment.       
Within this group of participants, the cost associated with the treatment of 
(monotherapy)  glucagon – like peptide -1 receptor agonist is as follows:   
• Quarterly physician appointments with the healthcare provider (3,458 
x 54) $186,732.00   
• Cost of medication used to treat type II diabetes (6223 x 54) 
$336,042.00   
• Cardiac Rehabilitation  (0) 
• Dialysis (0) 
• Amputation (0)  
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• Cancer Treatments (0) 
• Absenteeism  Rate (1090 x 54)  $58,860.00 
The total annual amount for the treatment of this group of Glucagon – like 
peptide -1 receptor agonist participants was $581,634.00. 
 
5.5 Summation of direct and indirect cost 
Medication 
Category 
Annual  Costs Direct & 
Indirect 
Number of study subjects Average Cost 
Generic    
Metformin $335,925.00 25 $13,437.00 
TZD $896,715.00 23 $38,987.60 
TZD + MET $1,711,920.00 23 $74,431.30 
SU + MET $2,297,686.00 102 $22,526.33 
Non-Generic    
DPP4 $1,058,166.00 74 $14,299.54 
GLP1 $581,634.00 54 $10,771.00 
Total $6,882,046.00 301 $579,577.00 
Table 11: Summation of direct and indirect costs N = 301 
 
5.5.1  Formula implemented 
 
The formula implemented to define the chi-square was  
Χ² = Σ¡ (O¡ - E¡)²  
                E¡ 
 
Where O¡ is the observed number of cases within the study who has a 
difference in the cost savings / health benefit whereas E¡ is the expected  
number of cases to have a difference in the cost savings / health benefit.  
This chi square has been calculated by finding the variance between the 
observed versus the expected tabulated cases.  The calculated variance is 
squared and divided by E¡ within the equation.  The value was tabulated 
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and this has been referred to as the chi-square value.   This test of 
independence was instrumental in creating a greater level of accuracy in 
the cross classification summation.  In the event that the null hypothesis is 
true, the observed and expected frequencies should be similar.  In the 
event that the null hypothesis is not true, the observed and expected 
frequencies will not be similar.  This sum is an indication to a greater 
observed frequency.  This total was subtracted from the squared frequency 
of the expected value.  In the event that the chi-square value is of a higher 
numerical value – then this serves as statistical evidence that the null 
hypothesis of independence should be rejected. 
 
5.6  Tests of the Hypothesis 
The hypotheses has been the base on which the statistical analysis has 
been presented.  The following information presents each hypothesis with 
an independent analysis for each factor indicated in the data.  Maximum 
acceptable significance level was ɑ = .05 
 
Hypothesis 1:   There are no more cardiovascular events resulting in cardiovascular 
rehabilitation in type II diabetic persons in Georgia who were prescribed combination 
generic medications for type II diabetes than persons prescribed monotherapy generic 
agents and non-generic agents for type II diabetes. 
 Oneway ANOVA (Table 12) reveals no significant difference in the number of 
cardiovascular events (strokes and heart attacks) experienced by persons in Georgia 
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between who were prescribed generic agents versus non-generic agents.  Therefore, 
this null hypothesis cannot be rejected.  This is interpreted to mean that the number of 
cardiovascular events (i.e., strokes and heart attacks) among persons taking generic 
medications for type II diabetes was statistically similar to the number of 
cardiovascular events among those taking non-generic medications for diabetes.      
Table 12 
One-way ANOVA of Cardiovascular Events 
Source df SS MS F p 
      
Prescribed 
Generic 
1.00 3.30 3.30 10.29 .185 
Error 18.00 5.60 0.31 - - 
Total 19.00 8.80 - - - 
 
    
Hypothesis 2:  There are no more renal insufficiency episodes resulting in dialysis 
treatments in type II diabetic persons in Georgia who were prescribed generic 
medications (both monotherapy and combination) for type II diabetes than persons 
prescribed non-generic medications for type II diabetes. 
 Oneway ANOVA  reveals no significant difference in the number of renal 
insufficiencies resulting in dialysis experienced by persons in Georgia who were 
prescribed generic medications versus non-generic medications for type II diabetes.  
Therefore, this null hypothesis cannot be rejected.  This is interpreted to mean that the 
number of renal insufficiencies, which resulted in dialysis amongst persons taking 
generic medications for type II diabetes, was statistically similar to those prescribed 
non-generic medications for type II diabetes. 
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Table 13 
One-Way ANOVA of Renal Insufficiencies Resulting in Dialysis 
Source df SS MS F p 
      
Prescribed 
Generic 
1.00 2.25 2.25 18.00 .160 
Error 14.00 1.75 0.13 - - 
Total 15.00 4.00 - - - 
 
   
Hypothesis 3:  There are no more amputations experienced in type II diabetic persons 
in Georgia who were prescribed generic medications (both monotherapy and 
combination) for type II diabetes than persons prescribed non-generic agents for Type 
II diabetes. 
Oneway ANOVA reveals no significant difference in the number of amputations 
experienced by persons in Georgia who were prescribed generic medications versus 
non-generic medications for type II diabetes.  Therefore, this null hypothesis cannot 
be rejected.  This is interpreted to mean that the number of amputations experienced 
by persons taking generic medications for type II diabetes was statistically similar to 
the number of amputations experienced by those prescribed non-generic medications 
for type II diabetes. 
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Table 14 
One-Way ANOVA of Amputations 
Source df SS MS F p 
      
Prescribed 
Generic 
1.00 0.50 0.50 0.00 .40 
Error 4.00 2.00 0.10 - - 
Total 5.00 2.50 - - - 
Hypothesis 4:  There are no more cancer episodes experienced in type II diabetic 
persons in Georgia who were prescribed generic (combination) medications and 
DPP4 inhibitors for type II diabetes than persons prescribed (monotherapy) generic 
agents.  
Oneway ANOVA reveals no significant difference in the number of cancer episodes 
experienced by persons in Georgia who were prescribed generic medications versus 
non-generic medications for type II diabetes.  Therefore, this null hypothesis cannot 
be rejected.  This is interpreted to mean that the number of episodes of cancer 
experienced by persons taking generic medications in combination therapy for type II 
diabetes and DPP4 was statistically similar to the number of episodes of cancer by 
those prescribed other non-generic medications, such as GLP1, for type II diabetes. 
Table 15 
One-Way ANOVA of Cancer Episodes 
Source df SS MS F p 
      
Prescribed 
Generic 
1.00 5.00 5.00 50.00 .167 
Error 18.00 1.80 0.10 - - 
Total 19.00 6.80 - - - 
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Hypothesis 5:  There are no differences in the rate absenteeism of type II diabetics in 
the work force in Georgia regardless of the pharmacological treatments. 
Oneway ANOVA reveals no significant difference in the absenteeism rate of type II 
diabetics in the work force in Georgia who were prescribed generic medications 
versus non-generic medications for type II diabetes.  Therefore, this null hypothesis 
cannot be rejected.  This is interpreted to mean that the absenteeism rate for persons 
taking generic medications type II diabetes was statistically similar to the absenteeism 
rate for those prescribed non-generic medications for type II diabetes. 
Table 16 
One-Way ANOVA of Absenteeism Rates 
Source df SS MS F p 
      
Prescribed 
Generic 
1.00 2131.60 213160 9.55 .173 
Error 8.00 1786.00 1786.00 - - 
Total 9.00 3917.6 - - - 
 
 
Hypothesis 6:   There are no differences in weight gain in type II diabetics in Georgia 
regardless of the pharmacological treatment prescribed. 
One-way ANOVA reveals no significant difference in episodes of weight gain 
experienced by persons in Georgia who were prescribed generic medications versus 
non-generic medications for type II diabetes.  Therefore, this null hypothesis cannot 
be rejected.  This is interpreted to mean that persons taking generic medications in 
type II diabetes experienced a similar amount of weight gain when compared to those 
prescribed non-generic medications. 
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Table 17 
One-Way ANOVA of Weight Gain 
Source df SS MS F p 
      
Prescribed 
Generic 
1.00 1244.57 1244.57 1.92 .524 
Error 12.00 7761.14 646.76 - - 
Total 13.00 9005.71 - - - 
 
Hypothesis 7:   There are no differences in the level of satisfaction with the 
prescribed treatment of choice for type II diabetes in Georgia regardless of the 
treatment regimen prescribed. 
Oneway ANOVA reveals no significant difference in overall satisfaction level 
between prescribed treatment regimens for type II diabetic persons in Georgia.  
Therefore, this null hypothesis is not rejected.  This is interpreted to mean that type II 
diabetic persons in Georgia taking generic medications and non-generic medications 
reported similar levels of satisfaction with their prescribed treatment regimen.   
Table 18 
One-Way ANOVA of Satisfaction Level of Treatment 
Source df SS MS F p 
      
Prescribed 
Generic 
1.00 1332.25 1332.25 0.11 .562 
Error 2.00 25314.75 11991.25 - - 
Total 3.00 26647.00 - - - 
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5.6.1  NULL HYPOTHESIS 
The null hypothesis was that there is not a correlation between health benefits and 
cost savings of diabetic medications used to treat type II diabetics in the state of 
Georgia, United States. 
 The results of this analysis were not statistically significant, 𝜒2(15) = 35.10, p > 05. 
There is not a statistical significant relationship between health benefits and cost 
savings of diabetic medications used to treat type II diabetics in Georgia. Therefore, 
the null hypothesis cannot be rejected.  Although an examination of the cross -
classification matrix identified that more study participants prescribed non-generic 
medications experienced less direct and indirect cost to treat type II diabetes in 
Georgia, United States, the results were not statistically significant.   
 
5.7  Summary  
     Chapter 5 represented a well-defined view of the demographics of this diverse 
population of participants in the study.  The study participants’ (N=301) responses 
from the research instrument revealed various themes concerning cost savings and 
health benefits of medications used to treat type II diabetic persons in Georgia, United 
States.  The responses were statistically analyzed.  The compiled data was analyzed to 
specifically test the null hypothesis identified in this study.  Χ² = 35.1.  The null 
hypothesis was not rejected.   
     The findings of this action learning based research study revealed that when 
compared there was not a statistical significance in the difference in the cost savings 
and health benefits of medications used in Georgia to treat diabetes.   
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CHAPTER 6:  CONCLUSIONS, REFLECTIONS AND IMPLICATIONS 
 
6.1  Introduction      
     The five preceding chapters of this action learning based study comprised of the 
aim of the study, a thorough review of the workplace problem, relevance and 
relativity components, hypothesis’, literature review, theoretical framework specifics, 
procedural statistical and data analysis.  Chapter 6 includes a conclusion and an 
overall summation of this action learning study.      
 
6.2  Conclusion      
     This action learning based study was a purposive controlled study.  The study 
participants included adult persons diagnosed with type II diabetes who were 
currently prescribed at least one FDA approved medication to treat type II diabetes.  
The aim of the study was to compare the cost savings to the health benefits of 
medications used to treat type II diabetes in Georgia, United States.   
      Consent was granted from the University of Liverpool’s committee on research 
ethics, the clinic directors and the study participants.  A questionnaire was distributed 
to each study participant who met criteria for inclusion into the study.   The sample 
size of this study was three hundred one (n=301).  Of the three hundred one 
questionnaires distributed, three hundred one were returned for a 100% response rate.  
The fact that this writer had obtained permission from the clinic directors in advance 
and consent for study participation was thoroughly reviewed before the 
questionnaires were personally distributed resulted in an enhanced response rate 
161 
 
(Boyd, 2002).  The research instrument implemented to compare the cost savings and 
health benefits of medications used to treat type II diabetes in Georgia, United States 
was developed by the investigator. 
     A simple ex post facto design was used for this study.  This type of design is often 
used in healthcare related research when a current therapy is already in place and one 
desires to investigate possible causal factors (Leedy and Ormond, 2005).  This design 
was structured  to compare the cost savings and health benefits of medications used to 
treat type II diabetes in Georgia, United States. The investigator manipulated the 
categorization of the independent variable(s) in order to properly determine the 
relevant responses as it related to the dependent variables, which have been identified 
as cost and health benefits of the medications used to treat type II diabetes.  In an 
effort to summarize the differences amongst the observed and expected frequencies a 
chi-square test was implemented.  When the data was analyzed, the results did not 
reveal a statistically significant difference in the cost savings and health benefits of 
medications used to treat type II diabetes in Georgia, United States.   
 It was hypothesized that there would be no difference at the .005 level of significance 
in the cost savings or health benefits of study participants regardless of the type of 
FDA approved medication(s) prescribed to treat type II diabetes.  The level of 
significance criteria for the study was not surpassed.  The null hypothesis was 
accepted.  The null hypothesis revealed that, when compared, there was not a 
statistically significant difference in the cost savings and health benefits of FDA 
approved medication(s) prescribed to treat type II diabetes.  The .050 level of 
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significance can be interpreted as a probability of five out of one hundred chances 
that the probability of this result may perhaps have occurred by random chance. 
 
6.3  Summation     
     Data obtained from the study participants of this action learning based research did 
not reveal a statistical significance in the difference in the cost savings and health 
benefits of medications prescribed to treat type II diabetes in the state of Georgia, 
United States.  The study subjects were active participants in various diabetes support 
group meetings in Georgia, therefore findings are not generalized.  The findings of 
this action learning based research does however support previous literary works 
cited concerning the advancements of newly manufactured pharmaceutical agents 
used to treat type II diabetes.  This data driven study is indicative that the newer 
pharmaceutical agents, also referred to as non-generic medications, created through 
research and development to treat type II diabetes are indeed more costly at their base 
prices; however, health benefits outweigh the cost of the adverse events as compared 
to the generic medications (Skidmore-Roth, 2015).   The generic medications 
designed to treat type II diabetes are actually less expensive; however, there are 
hidden costs such as weight gain (Skidmore-Roth, 2015).   
      When this “hidden cost” of weight gain transitions into obesity, studies indicate a 
number of weight-related comorbid conditions that affect the cardiovascular system 
as well as the overall quality of life for the consumer (Apovian, 2013).  Stakeholders 
within the industry, i.e. healthcare providers, managed care officials and 
pharmaceutical companies, have a common interest as it relates to therapeutic 
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regimen for type II diabetes.  This common interest is cost.  Creating a knowing 
organization has allowed this writer to appeal to the stakeholders as it relates to a 
treatment regimen.  Treatment regimens chosen to treat type II diabetes that decreases 
the chances of weight gain and weight related comorbid conditions are available.  
Efficacy and cost-effectiveness are two of the most sought after components when 
choosing therapeutic agents to treat type II diabetes.  To the healthcare provider, it is 
important because in the aspect of value-based medicine, the healthcare provider is 
often incentivized to treat the patient with the most economical treatment regimen 
available in order to “save money”.   The managed care officials within the insurance 
industry recognize that there are a number of treatment regimens available and profit 
is determined by contract acquisition.    The pharmaceutical industry considers this 
important as well.  This is proven with the value demonstrated as the research and 
development department of the pharmaceutical industry brings these products to 
market.      
     As these treatment regimens for type II diabetes are implemented in the patient’s 
plan of care, the literature reflects that the stakeholders should be held accountable 
(Kerr and Hayward, 2013).  The implementation of value-based medicine seems to 
hold all entities responsible as it links the reimbursement rates of the pharmaceutical 
company to the results associated with the therapy received.  A contract is created and 
presented to the managed care providers (insurance companies) as well as the 
pharmaceutical company as a detailed proposal as to instructions on they will be 
reimbursed as it relates to patient outcomes-based data.  The pharmaceutical 
company, such as  NovoNordisk, Inc. would be required to present evidenced-based 
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data to illustrate that the expected hemoglobin A1C is in line with the standards of 
care presented by the American Diabetes Association.  If such goals are not reached  
as indicated in the contract as outlined, the pharmaceutical company would be 
required to pay a “rebate” to the managed care company.  According to the American 
Diabetes Association (2019), type II diabetes is a chronic illness that is creating a 
financial burden within the healthcare system in America.  Due to the economic 
burden that this disease is inflicting on America, value-based contracting would be a 
fitting business-related approach to address the issue.                              
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CHAPTER 7:  IMPLICATION FOR KNOWLEDGE AND PRACTICE 
 
                   7.1  Relating the findings to knowledge and practice   
          The findings of this action learning based research study indicate that 
stakeholders within the pharmaceutical industry can collaborate across company 
lines in order to create a knowing organization – through sense making, 
knowledge creation and decision making.  One that recognizes the importance of 
full disclosure as it relates to treatment regimens for the type II diabetic persons is 
of utmost importance.  Adverse events, such as weight gain, associated with older 
treatment regimens used to treat diabetes is a key factor in the overall cost of this 
chronic disorder.   Diabetes, primarily type II diabetes, is costing North America 
millions of dollars each year (Rowley & Bezold, 2012; American Diabetes 
Association, 2019).  In fact, Rowley and Bezold (2012) reveal that the statistics 
demonstrate an increase by 64% within the next decade.  Discovering the impact 
of diabetes and the complications associated with this disease is a core defense in 
creating a viable solution to the dilemma.  Americans are at an increased risk of 
developing this disease due to an aging population of people, familial history, 
smoking, lack of exercise and poor eating habits (Kim, 2007).  The literature 
reveals that obesity is often identified as a common denominator in complications 
associated with diabetes such as cardiovascular disease, renal insufficiency, 
damaged eye vessels and nerve ending abnormalities (Brown et al., 1999; Caro et 
al., 2002).  In fact, Fitch et al. (2017) reveals that those persons diagnosed with 
type II diabetes (compared to the non-diabetic population) are two to four times 
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more likely to have their cardiovascular systems compromised resulting in 
myocardial infarctions (heart attacks) and cardiovascular accidents (strokes).  
Statistics reveal that the population of type II diabetic persons also have an 
admission rate nine times higher for heart failure and five times higher for 
coronary revascularization procedures (Fitch et al., 2017).   According to the 
Georgia based organization, Centers for Disease Control and Prevention (2012; 
2017), these complications are creating a cumbersome burden on the economy in 
Georgia.  The literature lacks evidence concerning the health benefits and cost 
savings of medications used to treat type II diabetes in Georgia.  This action 
learning based research has revealed evidence to support that even though more 
sophisticated pharmacological agents have been developed through research and 
development, older treatment regimens continue to dominate the industry.  
Certain treatment options, namely generic pharmacologic treatments, are less 
expensive at the counter.  This study reveals that the adverse events associated 
with these agents create a number of long-term expenses.  The findings in this 
study indicated that these expenses were not proven to be statistically significant; 
however, numerous studies in the literature review reveal these clinically related 
long term expenses are significant not only to the patient but the healthcare 
industry as a whole (Lincoff, 2007; Powers, 2005; Skidmore-Roth, 2015; Wanner, 
et al., 2016) .  According to Leedy and Ormrod (2005), the small sample size of 
this writer’s study could have been a determining factor in the computed data 
resulting in a statistical insignificant finding.  
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          With the exception of Metformin, weight gain has proven to be an adverse 
event of generic agents used in this study.  Using the Tree Age Pro Software 
(Williamstown, Massachusetts), the Markov Model was implemented to identify a 
true comparison of the health benefits and cost savings of diabetes medications 
used to treat type II diabetes in the state of Georgia, United States of America.  
Upon completion of this local comparison study, this writer was able to recognize 
the need to address the health benefits and cost savings of the higher priced 
prescription drugs used to treat type II diabetes by implementing the Choo’s 
knowing organization.   Through the components of Choo’s knowing organization 
(sense-making, knowledge creation and decision-making) and the decision-
making theory of Herbert Simon, Bounded Rationality Theory, this writer has 
been able to create actionable knowledge as follows:  
• “ make sense” of our current healthcare crisis 
•  create knowledge from data driven evidence in the form of an algorithm and 
value-based contract formation for the healthcare industry 
• decision- making via recommending an avenue in which to compute the 
findings to assess the true value of the prescription therapy used to treat this 
chronic disease, type II diabetes.      
 
7.1.2 Actionable Knowledge  ~ Sense-making  
Over eighty percent of the type II diabetic population in America are over –
weight (Jacob et al., 2007).  As this over-weight status transitions into obesity, a 
various number of health related risks emerge in the human body.  Statistics 
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indicate that a modest decrease in weight, even five to ten percent, is associated 
with not only improved blood sugar levels but other weight related comorbidities 
as well (Cawley and Mayerhoefer, 2012).  In particular, those disorders associated 
with cardiovascular conditions such as non-HDL cholesterol, systolic and 
diastolic blood pressure and triglycerides are improved.  The treatment options for 
type II diabetes that are weight neutral (or may even promote weight loss) and 
will not pose an increase in major cardiovascular events (MACE) are considered 
desirable therapies according to the American College of Cardiology (ACC) 
(Fitch et al., 2017).  To further explain, the treatment of diabetes was centered 
around normalizing blood glucose levels for many years.  As the treatments for 
type II diabetes have evolved, a number of discoveries have been revealed 
throughout the years.  Discoveries such as weight gain, weight-related comorbid 
conditions and overall effects associated with these discoveries.  The research and 
development departments within the pharmaceutical companies, namely 
Boehringer Ingelheim and NovoNordisk have created a couple of classes of 
medications used to treat type II diabetes that have been statistically proven to 
reduce the risk of cardiovascular deaths.  These recent developments in treatment, 
SGLT2 inhibitors and GLP1 receptor agonists (Empagliflozin and Liraglutide 
respectively), demonstrate not only glucose lowering properties but improved 
cardiovascular effects as well (Das et al., 2018).  As mentioned in Chapter 2, there 
are meticulously organized clinical trials by both Boehringer Ingleheim and 
NovoNordisk that have proven to decrease the rates of myocardial infarctions, 
cardiovascular accidents and cardiovascular related deaths.  In some instances, 
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patients undergoing treatment of SGLT2 inhibitors, there have been reductions 
noted in heart failure hospitalizations of those persons diagnosed with type II 
diabetes.  It is important to note that these advantages were not related to the 
blood glucose levels.   
 
7.1.3 Actionable Knowledge ~ Knowledge Creation ~ Algorithm 
The American College of Cardiology recommends Empagliflozin or Liraglutide 
as first line treatment regimen in those type II diabetic patients who have been 
diagnosed with cardio-metabolic risk factors.  Implementing the techniques of 
Simon’s Bounded Rationality Theory, this writer has developed an algorithm that 
can be implemented by healthcare providers when considering treatment for type 
II diabetic patients who have been diagnosed with other cardio-metabolic risk 
factors  (See Appendix E).  This algorithm identifies an evidence-based approach 
to manage this particular population of type II diabetes in patients.  To begin with, 
after being properly diagnosed, the patient is evaluated for either SGLT2 inhibitor 
or GLP1 receptor agonist therapy.  There are three routes to consider.  The first 
route examines the approach of a SGLT2 inhibitor.  If the patient has experienced 
an allergic reaction to Empagliflozin, has severe renal impairment, end-stage renal 
disease or is presently undergoing dialysis, then this treatment is considered 
inappropriate.  The second route examines the approach of a GLP1 receptor 
agonist.  If the patient has a personal or familial history of Medullary Thyroid 
Carcinoma or Multiple Endocrine Neoplasia II, is pregnant or if the person has 
experienced an allergic reaction to the components of  liraglutide then this 
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treatment is considered inappropriate.  In both cases, if the therapy is prescribed 
and the patient is on another agent for diabetes, the dosage may need to be 
adjusted such as insulin or sulfonylurea.  The adjustment may be necessary to 
prevent episodes of hypoglycemia.  The third option is if the patient refuses 
treatment.  If this is the case, the healthcare provider should counsel the patient on 
the consequences of not adhering to therapy and document accordingly.   
     This aforementioned algorithm may be used as a set of instructions created to 
guide the healthcare provider in aiding the type II diabetic patient to an optimal 
level of wellness.   When the healthcare provider decides on the appropriate 
prescription medication, the second step is to create the value-based contract to 
make certain that the pharmaceutical company recognizes they will be held 
accountable for the claims concerning “better outcomes” than the older/cheaper  
medications used to treat type II diabetes.      
     
7.1.4 Actionable Knowledge ~ Knowledge Creation ~ Value Based Contract 
 The purpose of creating a template for a value based contract is to allow the 
stakeholders within the healthcare industry (healthcare providers, managed care 
companies and pharmaceutical companies) to focus on a  patient centric analysis 
of cost and benefit of the treatment regimen(s) chosen to treat type II diabetes.  
This template will allow the stakeholders to analyze the total cost of care for those 
type II diabetic persons who have been prescribed Liraglutide as opposed to those 
who have not been prescribed Liraglutide.  Analyzing this data is critical because 
cardiovascular disease is the primary causative factor in not only disability but 
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death as well in the type II diabetic population.  Creating value based contracts 
from this template allows managed care companies to negotiate with 
pharmaceutical companies in order to facilitate payment for quality care. The 
following is a template for the pharmaceutical company (namely NovoNordisk, 
Inc.) to create a value-based contract.  This contract shall be created to improve 
the lives of those type II diabetic patients who have a risk of elevated blood 
sugars as well as an increased risk of cardiovascular disease.   The following 
information serves as template for a value-based contract for the GLP1 receptor 
agonist, Liraglutide: 
I.  Develop a value-based medicine team to coordinate this venture.  The 
team should consist of 6-8 participants with the following skill sets: 
Administrative staff with decision-making abilities shall be integrated to 
coordinate the efforts of others. 
Field staff that are able to communicate with the managed care companies 
and healthcare providers shall be integrated to be certain pertinent 
information is gathered appropriately. 
Staff from the department of commercial execution shall be integrated to 
analyze data appropriately.  This portion of the team will be a part of the 
“checks and balance” portion of the process. 
II. Create a value-based measurement plan that is congruent with the clinical 
studies outlined in the prescribed information.   
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 Within 56 weeks of Liraglutide therapy, HbA1c will decrease by at least 1 
– 1.5 points when compared to generic medications used to treat type II 
diabetes   
Within 16 weeks of Liraglutide therapy, body weight will decrease by at 
least 4% when compared to generic medications used to treat type II 
diabetes    
Within 56 weeks of Liraglutide therapy, statistical data will reveal less 
occurrences of cardiovascular deaths, nonfatal myocardial infarctions and 
nonfatal cardiovascular accidents when compared to generic medications 
used to treat type II diabetes   
III. Upon completion of the value-based measurement plan of action, it is the 
recommendation of this writer that the committee shall present the 
proposal to the executive corporate team, including the CEO and CFO of  
NovoNordisk, Inc.  Upon approval of the plan, it is recommended that the 
proposal shall be presented to the managed care companies who have 
decided to partner with NovoNordisk, Inc. Upon acceptance of this 
partnership, it is recommended that the desired outcomes derived from this 
partnership shall be communicated to the field staff.  This proposal then 
recommends that the field staff communicate the partnership of this value-
based medicine contract to the healthcare providers.  Finally, this proposal 
recommends that a concerted effort shall be made to meet with those 
providers who are in network to provide care to the members with such 
contracted managed care plan.      
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7.1.5 Actionable Knowledge ~ Decision-making  ~ Outcome measurements 
This proposal of actionable knowledge shall be used to create a partnership with a 
value-based medicine committee within NovoNordisk and the managed care 
company.  It is recommended that these stakeholders shall agree upon a third 
party corporation to gather the information with a definitive time frame to 
measure the outcomes.  It is the recommendation of this writer that the company 
must be able to conduct thematic research implementing cloud computing in 
healthcare.  It is recommended that the in order to capitalize on the ROI (return of 
investment)  proper interpretation of the data is needed.  If the goals are met, then 
the managed care company will be charged the full amount of the price of the 
GLP1 receptor agonist, Liraglutide.  However, if the goals are not met,  
NovoNordisk shall provide a rebate, amount to be to be negotiated prior to 
contract development, to the managed care company.      
     Implementing Choo’s Knowing Organization has allowed this writer to make 
sense of this work-place problem, create knowledge by developing an algorithm 
for type II diabetic patients who have been diagnosed with cardio-metabolic 
issues and a template for value-based medicine contract formation.  Last but not 
least, the decision-making component has allowed this writer to implement a 
method of evaluation within outcome measurements.     
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7.2  Limitations 
     This data driven study has proven to be valuable and the research objectives were 
achieved; however, the following five (5) limitations are acknowledged and present 
the opportunity for further research as featured in section 7.3 below:   
1. Primary dependence on the limited viewpoints of study participants:  The study 
participants in this research consisted of a self-selected sample of type II 
diabetics in the state of Georgia from various diabetes support groups; 
therefore, the responses of these participants may not represent those of all 
individuals who have been diagnosed with type II diabetes in the state of 
Georgia.  Generalization is limited.   Sample size and diversity are both 
influential factors in research outcomes (Altman and Anderson, 2009; Leedy 
and Ormrod, 2005).        
2. Limited knowledge of the variables associated with environmental, financial 
and social aspects of the study participants lives.  Cranor et al, (2003) reveal a 
correlation between the environment, financial status and social variables as it 
relates to diabetes management.   
3. The reliability and validity of the instrument was not tested :  According to 
Coghlan and Brannick (2010) there are four areas in action research that are 
crucial in its success.  These areas include participation, real life problems, 
joint meaning construction and workable outcomes.  The information gathered 
is important to in order to capture components associated with the action 
learning process.  According to Leedy and Ormrod (2005), an instrument tested 
for reliability and validity maximizes the chances of a more superior study.     
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4. Limited literature on developing tools to address issues within a restricted 
managed market.  Herr and Anderson (2006) reveal the importance of being 
able to gather data to create knowledge albeit through concepts, personal 
experience, research or even intuition.  Gathering the data is crucial in order to 
link it to theory development.         
5. Attitudes of the professional personnel within in the diabetes treatment centers 
were not integrated as a variable.  Attitudes of the personnel may influence the 
participants’ responses.  Keegan (2009) reveals that attitudes as well as 
knowledge created from experience can affect the approach, which in turn may 
affect the responses provided by the participants.      
 
7.3  Recommendations for further research  
     Upon reflection of this action learning based research, recommendations are noted.  
These recommendations are as follows: 
1. Diversify:  This study should be extended to include the following: all types 
of diabetes i.e, type I diabetes, type II diabetes, gestational diabetes, and drug 
induced diabetes as well as diabetes 1.5, all FDA approved medications for 
type II diabetes (including insulin therapies)  
2. Larger sample size:  This study should be extended with a larger sample size 
in other facilities and other geographical locations as well  
3.  Cost Utility analysis tool:  This study should be extended using another cost – 
utility analysis such as the Swedish Institute for Health Economics Cohort 
Model.  According to Sonnenberg and Beck (1993), this model has been used 
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in other studies dealing with diabetes related issues and it also involves the 
use of a double Markov chain.  This is important because a number of diabetic 
patients suffer with complications associated with obesity -which further 
complicates the health status of the participant.   
4. Theoretical Framework:  This study should be extended to include a different 
theoretical framework.  These factors would alter the theoretical basis for this 
investigative study, which would make it an even more valuable source to the 
stakeholders in the industry (Van de Ven and Johnson, 2006).        
5. Implementation of the newly developed Pay for Performance tool:  This study 
should be extended implementing the outcomes data derived from the value-
based medicine template developed by this researcher in order to determine 
the value of a particular medication used to treat diabetes.  
 
7.4    My reflections on what I have learned: 
     I have learned that pharmaceutical agents being evaluated by the U.S. Food and 
Drug Administration (FDA) for treatment of type II diabetes are not only being 
evaluated for blood glucose regulation but cardiovascular safety as well (Smith, 
Goldfine and Hiatt, 2016).  With this targeted approach, value-based medicine is 
becoming an essential component as managed care companies decide which 
medications to add to the formulary as a treatment regimen.  Stakeholder 
involvement, albeit the managed care companies, healthcare providers or the 
pharmaceutical companies, will  often identify pricing as a leading factor in the 
identification of the treatment regimen chosen for not only type II diabetes but other 
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chronic conditions as well (Fitch et al., 2017; Smith et al., 2016).  This is impactful 
when viewed via a managerial perspective primarily due to the tremendous 
investment that the United States of America has in its healthcare system.  The 
aforementioned stakeholders are searching for data – driven documentation in order 
to aid in excellent, cost-effective decision - making practices (Fitch et al., 2017; Sultz 
and Young, 2004).  I have learned that this is crucial because outcomes - based data, 
as demonstrated in this doctoral dissertation, reveal authentic findings.  These 
authentic findings uncover not only efficacy but safety of treatments implemented for 
chronic illnesses (Sultz and Young, 2004).  As the healthcare industry evolves, 
identifying the health benefits as it relates to long term cost effectiveness improves 
the lives of those affected by chronic diseases by changing the behaviors of those 
creating the guidelines implemented to treat these chronic diseases such as type II 
diabetes and its culprit, cardiovascular disease (Kahn et al., 2008; Luce, 2005; 
Rosenthal et al, 2008).                  
     Needless to say, the contents of this doctoral dissertation should be reviewed by all 
stakeholders within the healthcare industry.  This information is especially crucial to 
those stakeholders who aim to seek a greater understanding in terms of the return on 
investment for pharmacological treatments used in diabetes management.  There are a 
variety of stakeholders with whom I collaborate on a daily basis, such as employers, 
third party payers, healthcare professionals, consumers, managed care representatives, 
pharmacists, as well as other pharmaceutical sales professionals that will certainly 
find that this information is not only beneficial to patient care but a key component to 
managing the healthcare costs in America.    
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     In practicality, if this study were to be reviewed by the stakeholders identified in 
healthcare such as healthcare professionals, managed care, pharmaceutical industries 
as well as the consumer – a profound impact on America’s economy would be 
imminent.  In addition, type II diabetes is a chronic disease that has been deemed 
treatable, not curable, at this point.  After all, the greatest value of any data-driven 
study is determined by its ability to implement the model into the healthcare decision-
making process  (Edejer et al., 2003).   Ultimately, altering the thought processes and 
behaviors of those making clinical decisions within the healthcare community is the 
key component to effective change.  Yagudina et al., 2017 contends that stakeholders 
within the healthcare community are in need of data driven evidence, as indicated in 
this dissertation, in order to create a viable plan of care for the type II diabetic.  This 
writer has created an algorithm and a template for generating a value-based medicine 
contract for the type II diabetic with a history of cardio-metabolic risk factors.  These 
tools shall serve as a part of a solution to addressing the escalating cost associated 
with the treatment of the type II diabetic person living in the United States of 
America.  As action learners, we must continue to create knowing organizations 
through sense making, knowledge creation and decision making in order to improve 
the lives of our fellow Americans.  Due to the cost of healthcare in America, patient 
outcomes have become a profound influence on choices identified within the 
treatment regimen of those affected with a chronic disease, such as type II diabetes 
(Fagan et al., 2010).  The stakeholders involved in caring for the American patient 
must realize that accountability is becoming more and more prominent in healthcare.  
Payers (managed care industry) and pharmaceutical companies must become partners 
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in order to address the escalating cost of healthcare in America.  As a pharmaceutical 
sales consultant, I have implemented Choo’s Knowing Organization and Simon’s 
Bounded Rationality Theory to address my workplace problem by conducting this 
comparison study to aid in making sense of the problem, creating the algorithm and 
the template for creating a value-based contract and a method of evaluation of this 
contract.  As a researcher, medical professional and consultant, I can honestly 
verbalize that I am a part of the solution to addressing one of the most complex 
problems in America, effectively treating the type II diabetic patient in America.           
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APPENDICES 
 
Appendix A 
 
 
 
Mr. Sample Jones      01 November 2014 
Clinical Director 
Any Hospital 
Any Address 
Any Zip code 
  
Re: Request for approval to distribute questionnaires to consumers within your 
facility  
Dear Sir (or madam): 
     I have been actively pursuing my Doctorate of Business Administration degree from 
the University of Liverpool (United Kingdom) since Summer, 2010.  The program 
requires a completion of nine (9) modules and a doctoral development plan in order to 
prepare one for the doctoral thesis.  With the assistance of my supervisor, Dr. Joanna 
Poon, I have prepared a doctoral thesis proposal.  This proposal was submitted in 
conjunction with the ethics application.  I must obtain approval from you to interview 
participants from your facility in order to complete this investigative process.  Please 
allow me to provide a brief overview of my intentions for the study.  The title of my 
study is as follows:  A comparison study of the health benefits and cost savings of 
diabetes medications used to treat type II diabetes in the state of Georgia, United States 
of America.  The overall purpose of this study is to explore the health benefits and cost 
effectiveness of various medications used to treat type II diabetes in the state of 
Georgia, United States of America.  A mixed methodology will be implemented in 
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order to complete this study.  This mixed methodology will consist of both qualitative 
and a quantitative components.  In the qualitative component of the study, an 
investigative tool in the form of a questionnaire will be implemented with the 
participants.  In the quantitative component of the study, a clinical and cost analysis 
shall be conducted to determine the healthcare benefits and cost savings of the 
pharmaceutical agents used to treat diabetes in Georgia.  
 
     I have chosen to conduct this survey to those participants attending diabetes support 
group meetings because the meetings are pre-arranged, the audience is the appropriate 
population for this study and the meeting times are convenient for both the investigator 
and the participants.  I need permission from you to administer the surveys in an effort 
to complete the qualitative portion of this methodology.  The surveys will be hand 
delivered to the participants at your facility at an appointed group session time.  In an 
event that the participant is not able to attend the scheduled meeting time, then the 
survey will be either emailed or faxed.  Please note that the emails received are 
password protected and the fax machine is in a locked room in which only the 
investigator has a key to both methods of communication.  These surveys shall be 
administered and collected within the months of November and December, 2014.  Each 
survey will take approximately 10-15 minutes.  These questions will be designed to 
gather information about the treatment regimen of diabetes, complications associated 
with this disorder and the cost analysis of the treatment regimen as it relates to the 
diabetes process.                  
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     I am presently employed as an executive diabetes care specialist with one of the 
largest manufacturers of diabetes products in the world.  At this critical time of 
healthcare reform in the United States of America, it is of utmost importance to identify 
cost-effectiveness of agents for not only the patient but the national economy as well.  
The results of this study shall be beneficial for the consumer, healthcare providers as 
well as those decision-makers in the managed care markets.   
 
Please contact me via the following method(s) of communication to either confirm or 
deny my request to implement this study with your facility:  mobile (call or text 
messages accepted) 478.501.9253 or sonja.jenkins@onlineliverpool.ac.uk 
Thanking you,  
Sonja Jenkins 
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Appendix B 
 
Committee on Research Ethics 
 
Participant Information Sheet  
 
 
You are being invited to participate in a comparative investigative study in Georgia.  
This study deals with the diabetes and the costs associated with this disorder.  Your 
input is vital to the outcome of this study and your voluntary participation would be 
much appreciated.  Please read this letter carefully and ask questions if needed.  Your 
participation in this study is voluntary and your confidentiality is of utmost 
importance.  You may withdraw from this study for any reason and at any time 
without fear of retaliation.            
  
 
 
Title of Study:  A comparison study of the health benefits and cost savings of diabetes 
medications used to treat type II diabetes in the state of Georgia, United States of 
America 
 
Version Number and Date:  30 October 2014 
 
Invitation:  You are being invited to participate in a comparative investigative study 
in Georgia.  This study deals with various treatments for diabetes and the costs 
associated with this disorder.  Your input is vital to the outcome of this study and your 
voluntary participation would be much appreciated.  Please read this letter carefully 
and ask any questions if needed.  Your participation in this study is voluntary and your 
confidentiality is of utmost importance.  You may withdraw from this study at any time.  
 
What is the purpose of the study?  The overall purpose of this investigative study is 
to discover and recognize the health benefits and cost savings of various medications 
used to treat type II diabetes in the state of Georgia.  Due to the present epidemic status 
of diabetes in the United States, the information gathered will be of significance to the 
healthcare community within the state of Georgia as it relates to the creation of 
treatment protocols and policies for those consumers who have been diagnosed with 
type II diabetes. 
. 
Why have I been chosen to take part?  You have been chosen to take part in this 
comparative investigative study because you are a type II diabetic who resides in 
Georgia, is over the age of 18, attends a support group for diabetes and is presently 
being treated with at least one medication indicated for use in type II diabetes.   
 
Do I have to take part?  Your participation in the study is voluntary and no, you do 
not have to take part in this investigative process.  In fact, if you decide to participate 
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and later decide to withdraw – you may do so for any reason and at any time without 
fear of retaliation.  
  
 
What will happen if I take part in the study?  If you should decide to participate in 
this comparative investigative study, you will be provided with a questionnaire with a 
series of questions pertaining to your health and treatment modalities prescribed to treat 
your disorder (diabetes).  This questionnaire is designed to gather information which 
will determine the overall cost of the disease process as it relates to medical treatment. 
The questionnaire shall take approximately 10-15 minutes to complete and shall be 
returned immediately upon completion to the student investigator, who shall be present 
at the support group meeting.  If the questionnaire is electronically administered or 
faxed, the expected return time shall be within forty-eight (48) hours.         
 
 
 
Expenses and / or payments:  There will be no expense, compensation, gift(s) or 
payment to the participants of this study.        
 
 
Are there any risks in taking part:  There are not any physiological or financial risks 
associated in taking part in this investigative study.  However, there is a minimal risk 
of one experiencing anxiety or a certain level of frustration/shame when revealing their 
health status and the prescribed treatment modalities for diabetes.  This category of risk 
is considered psychological and has been anticipated to be minimal.          
l  
Are there any benefits in taking part?  There are benefits to you as a participant in 
this investigative process.  The benefits include being a key player in generating 
knowledge regarding diabetes treatment and overall cost of therapy.  This learning 
process is very important as it will provides information to be considered as managed 
care companies create policies for the upcoming healthcare reform.    
  
  
What if I am unhappy or if there is a problem?  In the event that a participant is 
unhappy and or there is a problem encountered within this investigative process, I can 
be notified immediately via telephone (4785019253) or email 
(sonja.jenkins@online.liverpool.ac.uk.  If by chance the participant is not comfortable 
in contacting me then the Research Governance Officer can be contacted directly via 
the telephone at 1.612.312.1210 via email at liverpoolethics@ohecampus.com.   If you 
choose to notified the University please provide the following information: title of 
study, researcher involved and the specifics of the complaint.  As the researcher, I shall 
attempt to promptly rectify the problem to the best of my ability.      
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Will my participation be kept confidential? Yes.  All documents shall be password 
protected via the computer and or locked securely in a cabinet whereas only the 
investigator has access.   
 
  
What will happen to the results of the study? The results of this study shall be made 
available to further the education regarding diabetes and cost outcomes to anyone who 
has a desire to inquire. 
 
 
What will happen if I want to stop taking part?  Participants shall be allowed to 
withdraw for any reason and at any time without fear of retaliation.   
 
 
Who can I contact if I have further questions?  Please contact Sonja Jenkins at 
4785019253 or sonja.jenkins@online.liverpool.ac.uk for further information.  
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Appendix C 
Committee on Research Ethics 
 
 
PARTICIPANT CONSENT FORM 
 
Title of Research Project:  A comparison study of the health benefits and cost savings 
of diabetes medications used to treat type II diabetes in the state of Georgia, United 
States of America 
 
Researcher(s):  Sonja Jenkins 
 
The information you have submitted will be published as a report; please indicate 
whether you would like to receive a copy. 
 
 
I understand that confidentiality and anonymity will be maintained and it will not 
be possible to identify me in any publications  
 
 
 
I agree for the data collected from me to be used in future research and understand 
that any such use of identifiable data would be reviewed and approved by a 
research ethics committee.   
 
 
 
 
I understand that I must not take part if I am deaf and not able to read 
the English language 
 
 
 
I agree for the data collected from me to be used in relevant future research. 
 
 
 
 
I understand that my responses will be kept strictly confidential. I give permission 
for members of the research team to have access to my anonymized responses. I 
understand that my alpha - numeric identifiers will not be linked with the research 
materials, and I will not be identified or identifiable in the report or reports that 
result from the research. 
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I understand and agree that once I submit my data it will become anonymized and 
I will therefore no longer be able to withdraw my data. 
 
 
 
 
 
 
          
               Participant Name                           Date                    Signature 
  
 
 
                 
      Name of Person taking consent                                Date                   Signature 
 
 
Sonja Jenkins 
       
       Researcher                                                     Date                               
Signature 
 
Student Researcher: 
Name:  Sonja Jenkins 
Work Address: Locust Grove, Ga 30248 
Work Telephone: 4783659062 
Work Email: Sonja.jenkins@ohecampus.com 
 
Version 2.1 
July 15, 2013 
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Appendix D 
 
Questionnaire 
 
 
 
Alpha / Numeric Identifier: __________________  (to be completed by investigator) 
1. How old are you?  __________________________________________ 
2. Are you male or female? _____________________________________ 
3. What is your race?  __________________________________________ 
4. How long have you had type II diabetes?  ________________________ 
5.  Please list the current medications you are presently taking for diabetes: 
 __________________________________________________________ 
  __________________________________________________________ 
 __________________________________________________________ 
 __________________________________________________________ 
 __________________________________________________________ 
6. Have you experienced any of the following? If so, please circle and 
identify a date of the occurrence.   
Stroke     date of occurrence:___________________________ 
Heart Attack   date of occurrence:_______________________ 
Blindness   date of occurrence:__________________________ 
Dialysis   date of occurrence:____________________________ 
Amputation  date of occurrence:_________________________ 
 
7. Have you gained any weight since you have been taking medication(s) for 
diabetes?  _________   If so, how much have you gained?  
______________ 
8. Are you still active in the work force?  ______________If so, how many 
days have you had to “call in sick” due to your 
diabetes?__________________________ 
9. Have you been diagnosed with cancer since you have been diagnosed with 
diabetes?  If so, where was the cancer ____________________  when was 
the date of occurrence?___________________   
10.   Are you satisfied with your present treatment regimen for diabetes? 
________ 
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Appendix  E  :  Approach to managing type II diabetic patients with cardiometabolic risk factors 
 
Is the patient an adult 
with type II diabetes with 
cardiometabolic risk 
factors
Yes.  Evaluate patient 
for SGLT2 therapy
Currently Empagliflozin 
is recommended 
*if necessary adjust any 
other medications used 
to treat diabetes to 
prevent hypoglycemia 
Yes.  Evaluate patient 
for GLP1 therapy
Currently Liraglutide is 
recommended
*if necessary adjust any 
other medications used to 
treat diabetes to prevent 
hypoglycemia
Yes. However patient 
refuses treatment. 
Discuss and document 
consequences of non-
compliance
